November 2024
In July 2024 the Food and Drug Administration approved donanemab (KISUNLA) to treat Alzheimer’s disease in patients with mild cognitive impairment or who were in the mild stages of the disease. Public Citizen’s Health Research Group has classified donanemab as a Do Not Use drug because it has minimal benefit and substantial health risks, including brain swelling and bleeding.
November 2024
Created in August 2013 as part of the Affordable Care Act, the Open Payments database archives industry payments to U.S. physicians, non-physician practitioners and teaching hospitals. Data for 2023 cover an astounding 15.64 million records of payments with a total value of $12.75 billion. The editor’s column discusses why the public availability of payment data has done little to curb industry influence over physicians.
November 2024
In 2023, Public Citizen’s Health Research Group petitioned the FDA to strengthen safety warnings for BOTOX and related drugs. Learn about a Centers for Disease Control and Prevention (CDC) investigation of adverse effects in clusters of people related to what the agency characterized as “counterfeit or mishandled botulinum toxin injections.” Public Citizen has urged the CDC to be more transparent about all the cases it has investigated and to disclose whether any of the patients received recommended doses of Food and Drug Administration-approved botulinum toxin products.
November 2024
In July 2024 the FDA approved a blood test (SHIELD) to detect colorectal cancer or precancer in patients with average risk of such cancer. Learn about the new test and why it is not as good as colonoscopy. Stool- or blood-based screening for colorectal cancer should not be relied upon as a replacement for regular colonoscopy at the recommended intervals.
November 2024
The oral drugs valproic acid (generics only) and divalproex (DEPAKOTE and generics) are used to treat certain kinds of seizures. Children born to mothers who took valproate drugs during pregnancy have higher risks of reduced intelligence and birth defects. A new post-marketing study suggests an increased risk of neurodevelopmental disorders (mental or developmental disorders that begin in early childhood) in children of fathers treated with valproate drugs during the three months prior to conception.
October 2024
In 2023 the Food and Drug Administration (FDA) approved daprodustat (JESDUVROQ), an oral drug for anemia due to chronic kidney disease. Daprodustat is only approved for chronic kidney disease patients who have been receiving dialysis for at least four months. Public Citizen’s Health Research Group has designated daprodustat as Do Not Use for seven years because the drug has no truly unique benefits over erythropoiesis-stimulating agents and not enough is known about its potential long-term risks.
October 2024
In June 2024 the FDA expanded its earlier approval of delandistrogene moxeparvovec-rokl (ELEVIDYS), a gene therapy for patients with Duchenne muscular dystrophy. The editor’s column discusses the problems with the decision and why the FDA should not have granted the gene therapy accelerated approval in 2023, nor full approval in 2024.
October 2024
Learn about sexual problems (dysfunction) that can occur during treatment with drugs in two commonly used antidepressant drug classes — selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors — and why Public Citizen has sued the FDA to compel a decision on a 2018 petition requesting the addition of boxed warnings, the most prominent warnings that the FDA can require.
October 2024
Two recent observational studies add to the evidence that the use of stimulant medications to treat attention deficit hyperactivity disorder (ADHD) increases the risk of cardiovascular disease, a risk that may persist even after patients discontinue the drug.
October 2024
Biologic drugs, which include certain vaccines, insulin and monoclonal antibodies, are made from living cells or microorganisms; they are the fastest-growing medication class in the United States. Learn about biologic drugs and biosimilars, which have a shorter approval process and may be more affordable. As of August 2024 the FDA had approved 58 biosimilars for many reference biologic drugs.
September 2024
Learn about the clinically important and potentially dangerous drug interactions for the widely used anticoagulant apixaban (ELIQUIS). The most concerning interactions are with drugs that enhance the action of apixaban (causing bleeding) or diminish its effects (causing thrombotic events).
September 2024
The editor’s column discusses a recent example of tobacco industry funding of continuing medical education and calls on the Accreditation Council for Continuing Medical Education to revise its standards and ban such funding.
September 2024
The FDA recently approved two additional drugs for opioid use disorder, both of which are nasal spray formulations. One drug is high-dose naloxone and the other is a derivative of naloxone known as nalmefene (OPVEE). Naloxone nasal spray, which is sold over the counter, is a safer choice. The newer formulations are more expensive, usually no more effective and may trigger longer and more intense withdrawal.
September 2024
In 2023 the FDA approved ritlecitinib (LITFULO), an oral drug that suppresses the immune system, for the treatment of severe alopecia areata in adults and adolescents age 12 years and older. Public Citizen’s Health Research Group has designated this drug as Do Not Use because the possible limited benefits do not outweigh the serious harms.
September 2024
Learn about resmetirom (REZDIFFRA), the first drug that the FDA has approved for a severe form of nonalcoholic fatty liver disease known as nonalcoholic steatohepatitis (NASH). Because the clinical benefits of resmetirom have not been directly established and its long-term safety and effectiveness are unknown, Public Citizen’s Health Research Group has designated resmetirom as a Do Not Use drug.
August 2024
The tumor necrosis factor blocker adalimumab (HUMIRA and biosimilars) is used to treat rheumatoid arthritis and various autoimmune diseases. It is one of the best-selling drugs in the United States. Learn about the efficacy of adalimumab, its serious adverse effects and why Public Citizen’s Health Research Group has classified this biologic drug as Limited Use.
August 2024
The Food and Drug Administration is considering how to improve the agency’s “use of and processes for advisory committees.” The editor’s column discusses the importance of voting at advisory committee meetings and argues that de-emphasizing votes is a “bad idea.”
August 2024
First approved by the Food and Drug Administration in 1952, repository corticotropin injection (ACTHAR GEL) is a long-acting and expensive medication for the treatment of more than a dozen autoimmune and inflammatory diseases, such as exacerbations of multiple sclerosis in adults. Corticotropin usually performs no better than glucocorticoids, such as prednisone and prednisolone, for most of the same indications and should rarely be prescribed.
August 2024
Tianeptine is an addictive synthetic chemical substance with opioid-like effects that is associated with serious health risks and even death. The Food and Drug Administration (FDA) classifies tianeptine as an unsafe food additive and has not approved it for any medical use. Stronger FDA actions are needed to remove tianeptine from the U.S. market.
August 2024
People with subclinical hypothyroidism have normal levels of a form of thyroid hormone used by the body and usually have no symptoms. The diagnosis is based on laboratory test results. Learn about a large multicenter European study, published in 2024, that found that subclinical hypothyroidism often resolves without drugs in older adults.
July 2024
Adults aged 65 or older are at high risk of experiencing drug interactions and adverse events. This article highlights five drug classes that are associated with increased risks for older adults: benzodiazepines and Z drugs; anticholinergic medications; sulfonylureas, drugs for type 2 diabetes; cardiovascular and anti-thrombotic medications; and antipsychotics in older adults with dementia.
July 2024
In 2023, the Universities Allied for Essential Medicines North America filed a citizen petition with the FDA to increase enforcement of the ClinicalTrials.gov reporting requirements and impose fines when appropriate. Learn about the FDA’s response to the petition, which granted some of the requests and denied others.
July 2024
In December 2023, the FDA approved a DNA (genotyping) test for the risk of developing opioid use disorder (AvertD). Public Citizen’s Health Research Group opposed approval of the test because the pivotal clinical trial was flawed and because had high rates of both false negative and false positive results. Although the test is not yet widely available, we have classified it as Do Not Use.
July 2024
Almost one-third of older men experience lower urinary tract symptoms, such as hesitancy or slow urinary stream, dribbling or incomplete emptying of the bladder, urinary urgency or need to urinate many times during the day or at night. Learn about a recent clinical trial, published in the BMJ, that found that use of standardized assessments and lifestyle advice for men in the primary-care setting led to sustained reductions in urinary symptoms compared to usual care.
July 2024
Because many drug reactions are not reported to the FDA, drug safety information may not adequately represent the adverse events that patients experience. A study published in Drug Safety found that sociodemographic factors, such as living in a county with higher percentages of African American, American Indian or Alaska Native residents; higher rates of lack of access to health care; low English proficiency; and lower household income, contribute to lower rates of adverse event reporting.
June 2024
In January 2024, the FDA added a boxed warning — the agency’s most prominent warning — to the prescribing information for the osteoporosis drug denosumab (PROLIA) because of an increased risk of severe hypocalcemia in patients with advanced chronic kidney disease. The FDA approved denosumab in 2010. This article updates information on denosumab, which Public Citizen’s Health Research Group has designated as a Do Not Use drug.
June 2024
The “From the Editor” column discusses the withdrawal in March 2024 of the amyotrophic lateral sclerosis (ALS) drug AMX0035 (sodium phenylbutyrate and taurursodiol), sold under the brand name RELYVRIO. In a recently completed clinical trial, the drug did not provide any clinical benefit to ALS patients. The FDA needs to take steps to ensure that it never again approves a drug without clear evidence of efficacy.
June 2024
In October 2023, the FDA convened a workshop to discuss the use of solid, oral candy-like nonprescription drugs and supplements. These formulations have become a common delivery system for multivitamins and other dietary supplements as well as over-the-counter drugs. Learn about the pros and cons of drug formulations that look or taste like candy.
June 2024
This article discusses recent FDA warnings about eye drops and recalls of various eye-drop products. Most of the actions were triggered by concerns about faulty production processes that may have resulted in bacterial contamination of certain brands or manufacturing lots.
June 2024
The human papillomavirus (HPV) vaccine protects individuals from developing cervical cancer and other cancers caused by the virus, including vulvar, vaginal, anal, oropharyngeal (throat) and other head and neck cancers. Learn about a recent large, long-term observational study conducted in Scotland that adds to the evidence that HPV vaccination prevents the development of invasive cervical cancer and that even one or two doses of a bivalent (two-strain) vaccine administered one month apart are beneficial if given at 12 or 13 years of age.
June 2024
May 2024
In May 2023, the FDA approved fezolinetant (VEOZAH) for the treatment of moderate-to-severe hot flashes (vasomotor symptoms) due to menopause. Unlike hormone therapy, the drug was approved only for the treatment of hot flashes, not for any of the other symptoms of menopause. Learn why Public Citizen’s Health Research Group has designated fezolinetant as a Do Not Use drug.
May 2024
The “From the Editor” column discusses the withdrawal of the controversial Alzheimer’s disease drug aducanumab (ADUHELM) from the U.S. market and recent developments with the related drug lecanemab (LEQMBI), which the FDA approved in 2023. Public Citizen’s Health Research Group has designated lecanemab as a Do Not Use drug. Lecanemab has brain-swelling and bleeding risks and neither cures nor reverses Alzheimer’s disease.
May 2024
Learn about nirmatrelvir and ritonavir (PAXLOVID), an FDA-approved treatment for acute COVID-19 infection. The drug has potential benefits in preventing serious COVID-19 infections in patients with heightened risk, particularly if they are treated early in the course of their infection and if the risk of potentially dangerous drug interactions can be appropriately managed. When the potential benefits are small, such as for people at low risk of disease progression, nirmatrelvir and ritonavir should not be used.
May 2024
This article discusses ways to save money on prescription drugs without compromising on quality. The approaches discussed include using generic drugs, choosing an affordable formulation, comparing prices and reaching out to discount programs and drug assistance programs.
May 2024
Learn about a recent study that found that major drug interactions are common among outpatient children with Medicaid insurance and that these interactions often involve drugs that are routinely prescribed for children with common chronic health conditions.
April 2024
Apixaban (ELIQUIS and generics) is a type of blood thinner known as a direct-acting oral anticoagulant (DOAC). Public Citizen’s Health Research Group has previously classified all DOACs as Do Not Use drugs. Based on more recent evidence, we have reassessed the risk-benefit balance of apixaban and have changed our designation of this drug to Limited Use.
April 2024
The asthma and allergy drug montelukast (SINGULAIR and generics) has limited benefits and unique risks, such as neuropsychiatric adverse events. Nonetheless, each year more than 12 million people in the United States fill at least one prescription for the drug. This month’s From the Editor column discusses the challenges of communicating the safety concerns about montelukast to clinicians and patients and reducing use of the drug.
April 2024
Inhaled corticosteroids, a standard treatment for asthma and chronic obstructive pulmonary disease, have been suggested to treat COVID-19 because they have anti-inflammatory effects on the lungs. However, a recent randomized trial found that these medications are not effective in shortening the time to recovery from COVID-19.
April 2024
Learn about a recent clinical trial, conducted in Australia, that adds to the evidence from prior research that opioids are no better than placebo and some nonprescription medications (such as ibuprofen) for acute nonspecific musculoskeletal pain.
April 2024
April 2024
Learn about a recent study that found that the common antidepressants escitalopram (LEXAPRO and generics) and citalopram (CELEXA and generics) may increase the risk of arrhythmia (irregular heartbeat) in older adults taking the recommended dose. The drugs belong to a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs).
March 2024
Mental health conditions that result in suicide or death from overdose or poisoning are the leading causes of preventable postpartum deaths. In 2023, the FDA approved zuranolone (ZURZUVAE), an oral medication for postpartum depression. Learn why Public Citizen’s Health Research Group has classified zuranolone as Do Not Use for Seven Years.
March 2024
Dr. Sidney M. Wolfe, the cofounder of the Health Research Group and an iconic and inspirational champion of public health, died on January 1, 2024, at age 86. In his monthly column, Dr. Robert Steinbrook, the current Health Research Group director, reflects on Sid’s legacy and his vision, passion, and integrity.
March 2024
In December 2023, Public Citizen’s Health Research Group petitioned the Food and Drug Administration to promptly strengthen the safety warning on the labeling of BOTOX and related drugs. Learn about the petition and our concerns about the risk of iatrogenic botulism, a muscle-paralyzing disease, and related symptoms.
March 2024
Metformin is a recommended first-line treatment for patients with type 2 diabetes who are not able to control their blood sugar through diet and exercise alone. Metformin, however, has important drug interactions and can cause a serious condition called lactic acidosis, a buildup of lactic acid in the blood. Learn about metformin’s drug interactions.
March 2024
In 2023, the Food and Drug Administration (FDA) approved two cell-based gene therapies for the treatment of sickle cell disease. One of these treatments is the first FDA-approved treatment using CRISPR/Cas9 gene-editing technology. Although cell-based gene therapies for sickle cell disease are promising, they are new, and their long-term effectiveness and safety are not known.
February 2024
Proton pump inhibitors (PPIs) reduce the amount of stomach acid. They are available by prescription and over the counter, and their use has increased in recent years. Although PPIs are generally safe for short-term use, they have serious long-term risks.
February 2024
In November 2023, the Food and Drug Administration finalized its rules for the disclosure of risk information in television and radio direct-to-consumer advertisements of prescription drugs. Learn about the standards for disclosing a product’s major adverse effects and contraindications.
February 2024
In 2023, the U.S. Preventive Services Task Force reaffirmed its recommendation that all persons who are planning to or could become pregnant take a daily supplement containing 400 to 800 micrograms of folic acid starting at least one month before conception and continuing through the end of the first trimester of pregnancy. Learn about the evidence supporting this recommendation.
February 2024
Preventing strokes is a public health priority. A recent study found, however, that the use of daily low-dose aspirin was not beneficial in preventing a first stroke in healthy older adults. Among every 1,000 subjects taking low-dose aspirin over five years, there were 2.5 fewer strokes at the expense of 3.5 cases of bleeding in the brain.
February 2024
An egregious example of the low standards for the approval of new antibiotics is the Food and Drug Administration’s approval of Recarbio, a combination of three medications. A 2023 investigation by the medical journal The BMJ concluded that Recarbio was approved even though it had not demonstrated substantial evidence of clinical effectiveness.
January 2024
Osteoporosis occurs when there is a decrease in bone mineral density and bone quality that can weaken bones, making them susceptible to fracture easily. Learn about drugs that are associated with osteoporosis and related fractures.
January 2024
Medicare will use patient registries to collect data about new Alzheimer’s drugs. Learn why the use of patient registries is not an effective means to determine whether patients are more likely to have their lives improved or worsened by these medications.
January 2024
Severe respiratory syncytial virus (RSV) infection is an important cause of hospitalization in the very old and the very young. Learn about two recently approved RSV vaccines.
January 2024
Buying prescription medications from a licensed online pharmacy offers convenience and privacy and can save money. Learn what steps you can take to safely purchase prescription drugs online.
January 2024
In June 2023, the FDA approved donislecel (LANTIDRA) for the treatment of adults with type 1 diabetes who are unable to adequately control the disease because of repeated episodes of severe hypoglycemia, despite intensive management and education. Learn why Public Citizen’s Health Research Group has classified donislecel as a Do Not Use drug.
December 2023
Although influenza (flu) is usually a self-limiting illness, severe cases require treatment in the hospital and some patients die. A recent meta-analysis, which assessed combined data from multiple prior studies, found that oseltamivir (TAMIFLU) was no better than placebo in reducing the rate of hospitalizations.
December 2023
In the U.S., sponsors of clinical trials are required to register the trials and report the results to ClnicalTrials.gov. Learn why the FDA , without further delay, should fully enforce the reporting requirements.
December 2023
In 2019, the FDA approved romosozumab (EVENITY) for the treatment of osteoporosis in postmeopausal women who are at high risk of fractures (such as those who have had previous fractures) and for whom other osteoporosis therapies have not worked. Learn why Public Citizen’s Health Research Group has classified romosozumab as a Do Not Use drug.
December 2023
In 2022, people in the U.S. purchased as least 242 million over-the-counter products that contain oral phenylephrine at a cost of at least $1.8 billion. Learn why oral phenylephrine is not effective for the relief of nasal congestion and why the FDA should prioritize removal of over-the-counter oral phenylephrine products from the U.S. market.
December 2023
Learn about nonalcoholic fatty liver disease (NAFLD), a condition in which excess fat accumulates in the liver, and the form of this disease known as nonalcoholic steatohepatitits (NASH), which is associated with inflammation of the liver and in some instances can lead to fibrosis, cirrhosis and liver failure. At present, there are no medications that have been approved by the FDA to treat either condition.
December 2023
November 2023
B vitamins have been proposed as a means to lower the risk of developing Parkinson’s disease. A recent study found that long-term dietary and supplemental intake of these vitamins was not associated with a lower risk of the disease.
November 2023
Learn about the Beers Criteria, which are used for determining potentially inappropriate medication use in people age 65 and older; the criteria have recently been updated.
November 2023
Lifestyle changes not involving medications appear to offer some relief for people with recurrent migraine headaches. A recent review article assessed the evidence for changes related to stress management, sleep, diet and exercise. The review found that sleep-related issues were the only consistent lifestyle factor associated with migraine frequency.
November 2023
Palforzia, a peanut allergen protein powder, is an oral desensitization immunotherapy for children and adolescents (age four to 17 years) with a confirmed diagnosis of peanut allergy. Learn why Public Citizen’s Health Research Group has classified Palforzia as a Do Not Use drug.
November 2023
Melatonin, which is used to help with certain conditions such as jet lag and sleep-wake disorders, is regulated as a dietary supplement, not a drug. A recent study found that melatonin gummies sold in the U.S. contain inconsistent quantities of melatonin, and the quantity is usually higher than the amount listed on the product label.
November 2023
October 2023
The FDA recently approved lecanemab (LEQEMBI) for patients with mild cognitive impairment and in the mild dementia stages of the disease. Learn why Public Citizen’s Health Research Group has classified lecanemab as a Do Not Use drug.
October 2023
In 2010, the FDA proposed a rule about the disclosure of risk information in television and radio direct-to-consumer advertisements of prescription drugs. Thirteen years later, and if the Office of Management and Budget allows the regulation to be finalized, the presentation of risk information about drugs advertised directly to consumers should improve.
October 2023
In 2022, the FDA approved tirzepatide (MOUNJARO) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Learn about the evidence for the use of tirzepatide for diabetes and chronic weight management. As of mid-September 2023, the FDA had not approved tirzepatide for chronic weight management.
October 2023
Brexpiprazole (REXULTI) is an atypical antipsychotic drug that the FDA initially approved as an adjunctive treatment to antidepressants for major depressive disorder. In 2023, the FDA extended the indications to include the treatment of agitation associated with dementia due to Alzheimer’s disease. Learn why Public Citizen’s Health Research Group has classified brexpiprazole as a Do Not Use drug for the treatment of Alzheimer’s disease-associated dementia.
October 2023
A recent large adequately powered randomized clinical trial that directly compared furosemide and torsemide found that both drugs are equally effective in improving the survival of patients with heart failure.
October 2023
A recent large adequately powered randomized clinical trial that directly compared furosemide and torsemide found that both drugs are equally effective in improving the survival of patients with heart failure.
September 2023
A review study, published earlier in 2023 in The BMJ, found limited evidence of low or moderate quality supporting the effectiveness of antidepressants for several conditions associated with chronic pain, including fibromyalgia, neuropathic pain and chronic tension headache.
September 2023
Worst Pills, Best Pills News often highlights expensive drugs that have limited benefits and significant health risks. At the same time, some inexpensive and highly effective drugs are in such short supply that they are being rationed. The “From the Editor” column discusses the persistent problem of drug shortages in the United States.
September 2023
Patients taking the oral antidepressant drug desipramine (Norpramin) should be aware that it has clinically important interactions with many other prescription medications. Public Citizen’s Health Research Group has designated desipramine, a tricyclic antidepressant, as a Limited Use drug; antidepressants in other drug classes are safer and better tolerated.
September 2023
Thiazide diuretics often are prescribed to prevent recurrent kidney stones. However, a recent randomized, controlled trial found that hydrochlorothiazide was no better than placebo at preventing the recurrence of kidney stones.
September 2023
Learn about sofosbuvir, a highly effective antiviral medication that is used for chronic hepatitis C infection, alone or in combination with other antivirals.
August 2023
Semaglutide, an injectable glucagon-like peptide-1 agonist, is having its moment as a drug for weight loss. Learn about the substantial risks of semaglutide, including weight regain if the medication is stopped.
August 2023
The FDA has approved the antipsychotic medication brexpiprazole for agitation symptoms associated with dementia due to Alzheimer’s disease. Learn why Public Citizen’s Health Research Group urged the agency to reject the supplemental indication and why we believe that the drug’s small benefits do not outweigh its substantial risks.
August 2023
Patients taking the stomach-acid–suppressing drug cimetidine, which is available over the counter as a generic, should be aware of its clinically important interactions with many other prescription medications.
August 2023
The organic compounds known as nitrosamines are found in very low amounts in water and some foods; they may be carcinogenic to humans with exposure to high levels over a prolonged period. This article provides an update on oral prescription drugs recalled due to nitrosamine concentration.
August 2023
A recent clinical trial comparing chlorthalidone with hydrochlorothiazide found no difference between the two drugs in their effectiveness for preventing major cardiovascular events.
August 2023
In the article “Mindfulness as an Alternative to the Antidepressant Medication Escitalopram for Anxiety Disorder” in the July issue of Worst Pills, Best Pills News,[1] we discussed a draft recommendation for screening for anxiety disorders by the U.S. Preventive Services Task Force (USPSTF). Subsequently, the USPSTF finalized its recommendation to screen adults 64 years or younger for anxiety disorders. Citing insufficient evidence of benefit, the USPSTF did not recommend screening adults 65 years or older.[2] These recommendations may lead to more people seeking medical treatment for anxiety disorder. People with anxiety disorders should discuss with their clinicians whether nonpharmacological treatment options, such as psychotherapy or mindfulness-based interventions, are a good option.
July 2023
A recent study compared mindfulness to escitalopram (LEXAPRO), a commonly prescribed antidepressant medication, for patients diagnosed with an anxiety disorder. Although the study found that mindfulness meditation works, time and effort are needed to successfully complete the necessary mindfulness sessions and do regular home practice.
July 2023
FDA regulatory action has limited the amount of acetaminophen in prescription drug products, including opioid combination products, to 325 mg per tablet. Although the agency’s actions have helped to reduce the frequency of liver damage from acetaminophen-and-opioid combination products, there is more work to be done.
July 2023
A 28-day, fixed-dose, combined oral contraceptive marketed as NEXTSTELLIS has no proven advantage over older, well-studied, combined oral contraceptives. Public Citizen’s Health Research Group has designated Nextstellis as a Do Not Use medication, consistent with our designation of other drospirenone-containing combined oral contraceptives.
July 2023
Learn about the two FDA-approved fecal microbiota products that are indicated only for adult patients with recurring Clostridioides difficile infection; the products are meant to help restore the gut microbiome. One product is administered by enema; the other product can be taken orally.
July 2023
Treatment of opioid-use disorder is an important part of the public health response to the opioid epidemic in the United States. Learn about recent research that continues to support the effectiveness and safety of buprenorphine as a treatment for opioid-use disorder.
June 2023
Public Citizen’s Health Research Group has designated the chronic weight-management drug liraglutide (SAXENDA) as Do Not Use for all age groups. This article discusses the lack of strong evidence showing long-term, lasting and clinically meaningful benefits that outweigh the drug’s risks, both in obese adolescents and adults.
June 2023
Robert Steinbrook, M.D., the new Health Research Group Director at Public Citizen, introduces himself as the editor of Worst Pills, Best Pills News.
June 2023
Patients taking the stomach-acid-suppressing drug rabeprazole (ACIPHEX) should be aware that it has clinically important interactions with many other prescription medications. Public Citizen’s Health Research Group has designated rabeprazole, a protein pump inhibitor, as Limited Use.
June 2023
Some drugs, including commonly used prescription and over-the counter medications, can cause photosensitivity, increasing the skin’s vulnerability to sunlight. Nonsteroidal anti-inflammatory drugs and antibiotics are the drug classes with the strongest evidence for photosensitivity.
June 2023
The seizure medication gabapentin (GRALISE, NEURONTIN) is used to treat postsurgical pain, but that approach is controversial because of concerns about effectiveness and safety. Recent research found that such use is associated with an increased risk of delirium, antipsychotic use and pneumonia in the postsurgical period.
May 2023
Learn about recent research assessing the risk of withdrawal symptoms following the discontinuation of antidepressants.
May 2023
The departure of the long-standing director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research — whose office was responsible for the review and accelerated approval of drugmaker Biogen’s aducanumab (ADUHELM) for treatment of Alzheimer’s disease — from the agency is a welcome, but long overdue, development.
May 2023
Patients taking the antifungal drug voriconazole (VFEND), which is marketed in both oral and injectable forms, should be aware that it has clinically important interactions with many other prescription medications.
May 2023
Public Citizen’s Health Research Group has designated olanzapine/samidorphan (LYBALVI) as Do Not Use because of questionable effectiveness and concerning safety data, especially because samidorphan use plausibly increases the risk of opioid overdose.
May 2023
Findings from a recent large-scale, well-designed clinical trial showed no greater benefit of evening dosing over morning dosing of once-daily antihypertensive medications in terms of major cardiovascular outcomes (such as heart attack and stroke).
April 2023
As seven years have passed since Toujeo’s approval without new major safety concerns being identified, Public Citizen’s Health Research Group has now designated it as Limited Use — a treatment for diabetes that should be used only if treatment with less concentrated and cheaper forms of insulin have first been tried and found to be inadequate.
April 2023
In his editor’s column, Dr. Carome explains why the FDA’s new guidance on homeopathic drugs fails to adequately address the public health threat posed by the agency’s decades-long permissive approach to these illegal drug products.
April 2023
In this article, we discuss the U.S. Preventive Services Task Force’s recently updated recommendations against the use of menopausal hormone therapy to prevent chronic medical conditions, including cancer, heart disease, diabetes, dementia and stroke.
April 2023
Learn why Public Citizen’s Health Research Group has designated the new heart drug mavacamten as Do Not Use for Seven Years.
April 2023
Patients taking the commonly prescribed calcium channel blocker felodipine should be aware that it has clinically important interactions with many other prescription medications as well as the dietary supplement St. John’s wort.
April 2023
In this month’s news brief, we discuss the FDA’s November 2022 Drug Safety Communication about the agency’s ongoing evaluation of the risk of severe and symptomatic hypocalcemia in patients with advanced kidney disease, particularly those on dialysis, who received treatment with denosumab.
March 2023
Patients taking the widely prescribed hypothyroidism drug levothyroxine should be aware that it has clinically important interactions with many other prescription and over-the-counter medications, dietary supplements and even certain foods.
March 2023
In his editor’s column, Dr. Carome discusses the disturbing findings of a scathing report issued by two U.S. House of Representatives committees about the inappropriately close collaboration between drugmaker Biogen and the FDA during the analysis of data from the key clinical trials of the Alzheimer’s disease drug aducanumab (ADUHELM).
March 2023
A recent study showed that, compared with other diabetes drugs, gliptins (or dipeptidyl peptidase 4 [DPP-4] inhibitors) put patients at a higher relative risk of a range of gallbladder or biliary diseases, such as gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis).
March 2023
Learn about the numerous prescription and over-the-counter medications that can cause or exacerbate insomnia.
March 2023
A recently published study provided evidence that lithium treatment in persons with bipolar disorder may decrease the risk of osteoporosis.
February 2023
Data from a large, randomized clinical trial revealed that daily vitamin D supplementation does not lower the risk of new fractures in generally healthy community-dwelling people.
February 2023
In his editor’s column, Dr. Carome discusses the implications of new research documenting the extent of insulin rationing by diabetes patients in the United States due to Big Pharma’s relentless price gouging.
February 2023
Learn about a new study showing that patients taking rosuvastatin (CRESTOR, EZALLOR SPRINKLE) had a higher risk of proteinuria (abnormal levels of protein in the urine) and hematuria (blood in the urine) than those taking another statin, atorvastatin (LIPITOR).
February 2023
Patients taking the frequently prescribed antidepressant nortriptyline (PAMELOR) should be aware that it has clinically important and potentially dangerous interactions with many other prescription and over-the-counter medications.
February 2023
A recently published study confirmed that tofacitinib (XELJANZ, XELJANZ ER) increases the risk of severe and other infections compared to treatment with the tumor necrosis factor blocker drugs that demonstrate similar effectiveness for treating rheumatoid arthritis.
January 2023
Given the risks associated with Entresto, Public Citizen’s Health Research Group has classified it as Limited Use, to be used only in adults with heart failure with reduced ejection fraction.
January 2023
In his editor’s column, Dr. Carome explains how the FDA’s reliance on user fees from prescription drug manufacturers has resulted in corporate capture of the agency.
January 2023
Learn about new research showing that increased rates of overdose and mental health crises persist during the second year after initiation of opioid tapering among patients taking stable, long-term, high-dose prescriptions of these medications.
January 2023
Patients taking the drug sotalol (BETAPACE, BETAPACE AF, SORINE, SOTYLIZE) should be aware that it has clinically important and potentially dangerous interactions with many other prescription medications.
January 2023
Age-related macular degeneration is a leading cause of vision loss in older adults. Find out which patients with this condition can benefit from a combination of specific dietary supplements known as AREDS2.
December 2022
Given the serious risks of opioids, it is critical to dispose of any unused doses as soon as there is no longer a medical need for them. Learn how to do so safely by following the recommendations of the FDA.
December 2022
The need for a rule that would allow generic-drug companies to promptly update safety warnings in their product labeling is more critical than ever given that approximately 90% of all prescriptions dispensed in the U.S. are generic medications and the reality that new information about serious risks often comes to light after generic versions of a drug come on the market.
December 2022
Learn about the U.S. Preventive Services Task Force’s (USPSTF’s) updated recommendations regarding the use of daily aspirin to prevent heart attacks and strokes in patients without signs, symptoms or history of cardiovascular disease.
December 2022
Patients taking fluvoxamine (LUVOX), a selective serotonin reuptake inhibitor (SSRI), should be aware that it has clinically important interactions with many other prescription and over-the-counter medications.
December 2022
Recently published research provides the strongest evidence to date that erectile dysfunction drugs increase the risk of rare, serious adverse ocular events that can lead to vision loss.
December 2022
In this month’s news brief, we discuss a recently published study showing that in 2020, melatonin became the most frequently ingested substance among children and young adults reported to poison control centers in the U.S.
November 2022
Data from a recently published large observational study confirm that myocarditis and pericarditis are rare but usually reversible adverse effects associated with COVID-19 messenger RNA vaccination.
November 2022
In his editor’s column, Dr. Carome discusses the major provisions of the recently enacted Inflation Reduction Act of 2022 that will help make prescription drugs more affordable for Medicare patients.
November 2022
Learn about the numerous prescription medications and some over-the-counter drugs that can cause psychotic symptoms, including hallucinations.
November 2022
New research reveals that use of certain acetaminophen products that contain significant amounts of sodium is associated with an increased risk of developing cardiovascular disease and high blood pressure.
November 2022
Patients taking the commonly prescribed diuretic spironolactone should be aware that it has clinically important interactions with many other commonly used prescription and over-the-counter medications.
October 2022
The use of corticosteroids in patients with mild-to-moderate COVID-19, who are typically treated at home and do not require oxygen therapy, is not beneficial and can be harmful. Disturbingly, a recent study shows that substantial proportions of nonhospitalized COVID-19 patients were prescribed systemic steroids.
October 2022
To better protect consumers, the FDA must ensure that dietary-supplement makers who receive FDA warning letters promptly and permanently cease marketing illegal supplements that endanger consumers’ health.
October 2022
Patients taking the commonly prescribed antidepressant citalopram should be aware that it has clinically important and potentially dangerous interactions with many other prescription and over-the-counter medications.
October 2022
Lyme disease is the most common insect-borne illness, accounting for over half of all such disease. In this article, we discuss antibiotics that are routinely used to treat this infection.
October 2022
In support of our position against the use of duloxetine to treat osteoarthritis patients, a new study fails to show any benefit for adding the drug to usual care in primary care settings among hip or knee osteoarthritis patients with chronic pain.
October 2022
In this month’s news brief, we discuss a recent FDA warning about serious adverse effects associated with the use of the cancer drug duvelisib.
September 2022
Results of new research funded by the National Institutes of Health reveals that otherwise healthy, young children with uncomplicated community-acquired pneumonia generally do well with a five-day antibiotic course as long as they are monitored for continued improvement.
September 2022
Given the endless barrage of prescription-drug ads on TV, it is imperative that Congress immediately pass the Misleading Drug Ads Act to help ensure that consumers are not misled by TV ads that cleverly downplay the risks of prescrip¬tion medications while hyping the benefits.
September 2022
Learn why we have designated the recently approved insomnia drug daridorexant (QUVIVIQ) as Do Not Use.
September 2022
Patients taking the cholesterol-lowering drug pravastatin should be aware that it has clinically important interactions with many other prescription medications.
September 2022
In this month’s news brief, we discuss a recent FDA consumer advisory urging people not to use products that are marketed for the removal of moles and other skin lesions — such as seborrheic keratoses and skin tags — because of the risk of potentially dangerous adverse effects.
September 2022
Numerous prescription and over-the-counter drugs can cause or exacerbate urinary incontinence. Knowing which medications prescribed or recommended by your doctor cause urinary incontinence will allow you to take steps to prevent or minimize this common, troubling adverse drug effect.
August 2022
New research reveals that routine supplementation with high-dose vitamin D in older adults who are not vitamin D deficient is unlikely to reduce either overall mortality or cardiovascular mortality.
August 2022
In his editor’s column, Dr. Carome discusses results of a recently published study that revealed a stunning drop over the past decade in the proportion of new drugs approved by the FDA each year that were referred to an advisory committee.
August 2022
Patients taking the oral combination antiviral drug PAXLOVID (nirmatrelvir and ritonavir), which is used to treat COVID-19, should be aware that it has clinically important and potentially dangerous interactions with many other prescription medications.
August 2022
A recent clinical trial indicates that many persons with obsessive-compulsive disorder who respond favorably to joint behavioral and drug treatment may then safely taper their medication use very slowly to elimination, though careful follow-up clinical monitoring is still essential.
August 2022
Learn about the results of a new clinical trial funded by the Department of Veterans Affairs that compared the safety and effectiveness of allopurinol and feboxostat for treatment of gout.
July 2022
Medications are a leading cause of sexual dysfunction in women. Knowing which drugs prescribed or recommended by your doctor can cause sexual dysfunction will allow you to take steps to prevent or minimize this common, often troubling adverse drug effect.
July 2022
Americans clearly are fed up with the relentless price-gouging practices of the pharmaceutical industry and want Congress to finally pass legislation that would comprehensively reform drug pricing in the U.S. Patients cannot afford any further inaction by Congress on this issue.
July 2022
In January 2022, the FDA warned that dental problems have been reported in patients using buprenorphine-containing tablets and films that are taken by dissolving them in the mouth. These problems have included tooth decay, cavities, oral infections and loss of teeth.
July 2022
Findings from a new retrospective, real-world observational study that assessed switching among the most common generic levothyroxine products made by different manufacturers in the U.S. suggest that switching among these products is unlikely to have a substantial impact on treatment effects.
July 2022
Many studies have suggested that breast cancer risk, via prolactin elevation, is increased by antipsychotic medications, but the results were mixed and warranted further, more rigorous investigation. A recent, large observational study has added stronger evidence that certain antipsychotic medications increase breast cancer risk.
July 2022
In this month’s news brief, we discuss recent warning letters issued by the FDA to 12 companies for selling illegal over-the-counter drug products intended for skin lightening. The FDA noted that such products can cause serious adverse effects, including permanent discoloration of the skin.
June 2022
Public Citizen’s Health Research Group recommends that triptans only be used to treat migraine headaches after determining that acetaminophen or nonsteroidal anti-inflammatory drugs fail to work or cannot be taken due to allergies or other medical reasons.
June 2022
In his editor’s column, Dr. Michael Carome explains why Medicare officials’ April decision to restrict coverage for aducanumab to patients enrolled in clinical trials is a win for patients, Medicare beneficiaries, the American taxpayer and evidence-based medicine.
June 2022
Patients taking the drug quinidine should be aware that it has clinically important and potentially dangerous interactions with many other prescription medications.
June 2022
Learn about several drugs that can promote the formation of gallstones — stones in the gallbladder (a condition known as cholelithiasis) — and what you can do about it.
June 2022
Recently published research revealed that combination therapy with varenicline (CHANTIX) and a nicotine patch (HABITROL, NICODERM CQ) is no better than varenicline alone as a method to quit smoking.
May 2022
Hypertension is a major risk factor for heart disease and stroke. Results of new research showing that many people, including many being treated for hypertension, are taking medications that can raise their blood pressure.
May 2022
A recent FDA inspection of a compounding pharmacy engaged in large-scale production of sterile drugs identified dangerous unsanitary conditions that pose a clear and present danger to patients.
May 2022
Patients taking any of the widely used nonsteroidal anti-inflammatory drugs (NSAIDs) should be aware that they all have clinically important interactions with many other medications.
May 2022
Some patients with hip pain due to osteoarthritis chose to undergo steroid injections into the hip joint. Evidence from a recent observational study shows that such intra-articular steroid injections are associated with an increased risk of rapidly destructive hip disease, a serious long-term condition that involves rapid joint destruction and bone loss.
May 2022
Learn why the U.S. Preventive Services Task Force continues to recommend the use of low-dose aspirin to prevent preeclampsia in expectant mothers at high risk for the disorder.
May 2022
In this month’s Question and Answer, we respond to a reader’s question about whether patients with impaired kidney function should avoid taking bisphosphonates for treatment of osteoporosis.
April 2022
Learn about the serious adverse effects caused by the gastrointestinal drug metoclopramide, which we have designated as a Limited Use drug.
April 2022
In order to protect patients and public health, the FDA must take swift and aggressive enforcement actions against stem cell clinics that continue to manufacture or market stem cell products without the necessary FDA approval or substantial evidence of safety and effectiveness from rigorous clinical trials.
April 2022
Medications are a leading cause of sexual dysfunction in men. Knowing which drugs prescribed or recommended by your doctor can cause sexual dysfunction will allow you to take steps to prevent or minimize this common, often troubling adverse drug effect.
April 2022
Recently published research strongly suggests that treatment of acute pain after hospitalization or after outpatient dental surgery is best achieved with nonsteroidal anti-inflammatory drugs (NSAIDs) rather than opioids.
April 2022
A new well-designed study conducted by U.K. researchers found that mirtazapine is not beneficial for treating agitated behaviors in dementia patients and is potentially linked to an increased risk of death.
March 2022
Learn whether any of the drugs you are taking have been recalled due to contamination with cancer-causing nitrosamines and, if so, what steps you should take.
March 2022
In December 2021, the U.S. House of Representatives’ Committee on Oversight and Reform issued a final report documenting a wide range of egregious business practices that have resulted in ever-increasing price gouging of American consumers and the Medicare program by Big Pharma.
March 2022
More than 700 medications have been implicated in inducing diarrhea, accounting for nearly 7% of all adverse drug events. Knowing which medications prescribed or recommended by your doctor cause diarrhea will allow you to take steps to prevent or minimize this common adverse drug effect.
March 2022
Patients taking any of the widely prescribed angiotensin receptor blockers used to treat hypertension, among other disorders, should be aware that they have clinically important interactions with many other commonly used prescription and over-the-counter medications.
March 2022
Despite the suggestion that cannabidiol may have pain-relieving or anti-inflammatory effects, the totality of the evidence thus far has led international experts to conclude that this substance should not be recommended for pain management. Results of a recently published clinical trial reinforce that conclusion by showing that cannabidiol is ineffective as a treatment for arthritis pain.
February 2022
Learn why the recombinant zoster vaccine SHINGRIX is the right choice for preventing the viral infection herpes zoster — commonly known as shingles — as well as serious long-term complications of the infection.
February 2022
To protect Medicare beneficiaries from skyrocketing premiums and deductibles, the Centers for Medicare and Medicaid Services must promptly announce that it will not cover the unaffordable Alzheimer’s disease drug aducanumab (ADUHELM) under the Medicare program until there is definitive evidence that the drug provides substantial cognitive benefit to Alzheimer’s disease patients.
February 2022
Patients taking the commonly prescribed antidepressant fluoxetine should be aware that it has clinically important and potentially dangerous interactions with many other prescription and over-the-counter medications.
February 2022
It is estimated that more than a quarter of adult Americans take a magnesium supplement. However, preference should be given to relying on dietary sources of this critical mineral whenever possible to avoid adverse effects.
February 2022
Results of a large, well-designed, randomized clinical trial recently published in a leading medical journal provided strong evidence that the commonly prescribed selective serotonin reuptake inhibitor antidepressant fluoxetine was not effective for preventing depression in the first six months after a stroke.
January 2022
This article summarizes the current evidence on the use of ivermectin for treatment of COVID-19, which does not support its use for this purpose.
January 2022
The country desperately needs an FDA leader who will reverse the decades-long trend in which the agency’s relationship with the pharmaceutical and medical-device industries has grown dangerously cozier – resulting in regulatory capture of the agency by industry. Dr. Robert Califf would not be that leader.
January 2022
Numerous prescription and over-the-counter drugs can cause or exacerbate constipation. Knowing which medications prescribed or recommended by your doctor cause constipation will allow you to take steps to prevent or minimize this common, troubling adverse drug effect.
January 2022
Learn why the FDA has limited the approved uses and strengthened the product labeling warnings for the oral drug tofacitinib (XELJANZ, XELJANZ XR), which is approved for treatment of rheumatoid arthritis and certain other inflammatory diseases.
January 2022
In this article, we discuss results of new research indicate that in men with acute UTIs and no fever, a 7-day course of oral antibiotics appears to be just as good for eradicating the infection as the commonly used 14-day course. Importantly, shorter courses of treatment can reduce the risk of adverse effects of antibiotic therapy.
January 2022
In this month’s news brief, we discuss the FDA’s recent consumer alert warning that children who are accidentally exposed to fentanyl transdermal patches, know by the brand name DURAGESIC, are at risk of life-threatening overdose, even after the patches have been used for the typical full three days.
December 2021
Learn why we have designated St. John’s wort, an herbal dietary supplement that is commonly available in capsules, tablets or teas, as Do Not Use.
December 2021
In his editor’s column, Dr. Michael Carome highlights a new Public Citizen report that provided a glimpse of how much Big Pharma benefits from the American health care system overpaying for drugs.
December 2021
The FDA issued a Drug Safety Communication warning that abuse and misuse of the over-the-counter nasal decongestant drug propylhexedrine, a stimulant, can cause serious harm, including heart and mental health problems.
December 2021
In this article, we review results of a recent randomized trial that found vitamin D supplementation was not useful for preventing depression in relatively healthy adults.
December 2021
In this article, we review the process for diagnosing attention deficit hyperactivity disorder (ADHD) in children and adolescents and evaluate the available treatment options for managing it.
December 2021
In this month’s news brief, we discuss the FDA’s recent waring that over-the-counter alcohol-based hand sanitizers, especially if used in enclosed spaces or poorly ventilated locations, can cause headaches, nausea and dizziness.
November 2021
Learn about the health benefits of consuming an adequate amount of dietary potassium. To help readers assess their potassium intake, we offer a list of potassium-rich foods.
November 2021
In his editor’s column, Dr. Michael Carome explains why you should mute your TV when you see ads for the dietary supplement apoaequorin (PREVAGEN) and avoid being duped into buying this worthless supplement.
November 2021
Patients taking the oral antifungal drug itraconazole (SPORANOX, TOLSURA) should be aware that it has clinically important interactions with many other prescription medications that can affect the safety or effectiveness of itraconazole or the interacting drugs.
November 2021
In this article, we discuss the results of a randomized clinical trial that compared low- and regular-dose aspirin for preventing another heart attack or stroke in patients with known atherosclerotic cardiovascular disease.
November 2021
Patients often wonder what steps they can take to minimize their chances of suffering a serious adverse drug reaction. This article reviews 10 simple rules developed by Public Citizen’s Health Research Group for ensuring safer drug use.
October 2021
Patients taking bisphosphonates need to know that these drugs are associated with a wide range of potentially serious adverse effects.
October 2021
Finally, after months of foot-dragging, the Department of Health and Human Services’ Office of Inspector General has heeded our call for an investigation into the unprecedented and inappropriately close collaboration between Biogen and the FDA during the analysis of data from the key clinical trials of aducanumab (ADUHELM) for treatment of Alzheimer’s disease, which dangerously compromised the integrity of the FDA’s review of the drug.
October 2021
Learn about some of the commonly used medications that may lead to hair loss, also known as alopecia.
October 2021
In this article, we discuss new research showing that prolonged use of acetaminophen at recommended dosages in conjunction with excessive drinking or fasting may lead to catastrophic liver failure.
October 2021
Patients taking the commonly used stomach-acid–suppressing drugs lansoprazole (PREVACID, PREVACID 24 HR) and dexlansoprazole (DEXILANT) should be aware that these drugs have clinically important interactions with many other prescription medications.
September 2021
Learn why Public Citizen’s Health Research Group has designated desmopressin sublingual tablets (NOCDURNA) as Do Not Use.
September 2021
A recent Government Account¬ability Office report found that direct-to-consumer prescription-drug advertising may be a major factor contributing to rising spending on medications by the Medicare program and its beneficiaries.
September 2021
In this article, we discuss the results of a recent rigorously conducted study showing that therapy with the thyroid-hormone drug levothyroxine in older adults with subclinical hypo-thyroidism (a mild form of underactive thyroid) who had depressive symptoms provided no significant benefit.
September 2021
Gastrointestinal bleeding is a common cause of hospitalization and in severe cases can result in death. Find out which commonly used medications can cause gastrointestinal bleeding.
September 2021
New research reveals marked overuse of central nervous system-active medications in dementia patients despite the substantial risks, including an increased risk of premature death.
August 2021
Unfounded claims about the supportive roles of vitamin C and zinc for treating COVID-19 infection have led to increased demand and expenditures for these supplements, among others. Evidence from a recent study that was conducted by Cleveland Clinic researchers refutes these claims.
August 2021
In his editor’s column, Dr. Michael Carome discusses why the FDA’s June approval of Biogen’s monoclonal-antibody drug aducanumab (ADUHELM) for the treatment of Alzheimer’s disease was one of the worst decisions in the agency’s history.
August 2021
In this article, we discuss the most recent smoking-cessation recommendations from the U.S. Preventive Services Task Force and the underlying research supporting these recommendations.
August 2021
Patients taking the widely prescribed calcium channel blocker nifedipine (PROCARDIA, PROCARDIA XL) should be aware that it has clinically important interactions with many other prescription medications.
August 2021
Learn why we have designated celecoxib, a widely used selective COX-2 inhibitor that belongs to a drug class called nonsteroidal anti-inflammatory drugs, as Do Not Use.
July 2021
In this article, we discuss an important new warning issued by the FDA about preliminary results from a safety clinical trial that showed increased risks of serious heart-related adverse effects and cancer in rheumatoid arthritis patients taking the oral drug tofacitinib.
July 2021
In his editor’s column, Dr. Michael Carome advises readers to remain vigilant for businesses peddling COVID-19 products that are fraudulent, a waste of money and potentially harmful.
July 2021
Patients taking the commonly prescribed abnormal heart rhythm drug amiodarone should be aware that it has clinically important interactions with many other prescription medications.
July 2021
Learn why tianeptine — an addictive synthetic chemical compound that has led to abuse, physical dependence and withdrawal adverse reactions similar to those of opioids — has emerged as a growing public health threat in the U.S. and internationally.
July 2021
Knowledge about key information found in a prescription drug’s professional label can be an important tool for consumers seeking to improve their health while avoiding drug-induced injuries.
July 2021
In this month’s Question & Answer, we respond to a reader’s question about what steps can be taken to prevent or manage common adverse reactions due to COVID-19 vaccines.
June 2021
Patients taking the commonly prescribed antibiotic erythromycin should be aware that it has clinically important interactions with many other prescription medications.
June 2021
In his editor’s column, Dr. Michael Carome lambasts the FDA for its policy that allowed some hand sanitizers to be marketed in the U.S. during the COVID-19 pandemic that were tainted with carcinogenic benzene.
June 2021
Learn why taking daily oral omega-3 fatty oral supplements containing a combination of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) may not be good for your heart.
June 2021
In this article, we review data from new research showing that even short-term (14 or fewer days) use of oral corticosteroids can increase your risk of serious adverse effects.
June 2021
Results of recently published studies suggest that use of the potent stomach-acid–suppressing proton inhibitor medications in children may lead to small increases in the risks of fractures and asthma.
June 2021
In this month’s News Brief, we discuss a recent safety advisory issued by drug regulators in Canada warning of multiple reports of children experiencing acetaminophen poisoning after ingesting adult acetaminophen easy-to-swallow tablets that look like candy.
May 2021
Learn why we have designated rivaroxaban, one of the so-called “novel” oral anticoagulants (blood thinners), as Do Not Use.
May 2021
In his editor’s column, Dr. Michael Carome discusses a troubling report that detailed how drugmaker Merck & Co. and the FDA failed to add a warning about the potential risk of suicidal thoughts in men taking the company’s anti-baldness drug PROPECIA to the drug’s U.S. product labeling.
May 2021
In September 2020, the FDA announced that it would require the manufacturers of all benzodiazepines to update the black-box warning (the strongest warning that the agency can require) for these drugs to describe risks of abuse, addiction and other related adverse reactions. Such action was long overdue.
May 2021
In this article, we review results of new research that examined a specific form of nondrug psychological therapy, referred to as cognitive behavioral therapy for insomnia, for management of chronic insomnia in patients with other major physical or mental disorders.
May 2021
Neuroleptic malignant syndrome is a life-threatening neurological disorder most often caused by neuroleptic (antipsychotic) medications, which are used to treat schizophrenia and certain other psychiatric disorders, among other things. The syndrome also can be caused by certain other drugs used to treat nausea and depression, as well as by the sudden discontinuation of a dopamine agonist (drugs that are used most commonly to treat Parkinson’s disease).
May 2021
In this month’s Question & Answer feature, we respond to a reader’s question about whether the potassium-sparing diuretic spironolactone (ALDACTONE, CAROSPIR) can cause magnesium deficiency.
April 2021
Recently published research demonstrated that bisphosphonate drugs are useful for preventing osteoporosis-related hip fractures, but that continuous bisphosphonate therapy beyond five years appears to offer no additional benefit for preventing such fractures.
April 2021
According to a troubling report issued in January by the Government Accountability Office — an independent, nonpartisan federal watchdog agency that works for Congress — the COVID-19 pandemic has caused severe reductions in the FDA’s entire inspection program, with inspections of foreign drugmakers brought to a virtual standstill.
April 2021
Patients taking the commonly prescribed drug atorvastatin, which is a member of the statin family of cholesterol-lowering drugs, should be aware that it has clinically important interactions with many other prescription medications.
April 2021
Soon after the coronavirus pandemic began, theoretical concerns were raised about the possibility that the widely prescribed angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) may increase the risk of contracting the coronavirus and predispose COVID-19 patients to more severe illness. Results of a randomized controlled trial provide new evidence that ACE inhibitors and ARBs can be safely continued in patients hospitalized with COVID-19.
April 2021
Idarucizumab (PRAXBIND) received accelerated approval from the FDA in 2015 for reversal of the effect of the new oral anticoagulant (blood thinner) dabigatran (PRADAXA) when needed before emergency surgery or urgent procedures or in life-threating or uncontrolled bleeding. Learn why we have designated idarucizumab and dabigatran as Do Not Use.
April 2021
In this month’s Question & Answer feature, we respond to a reader’s question about whether we had any new information regarding the risks of allergic reactions in recipients for the two-dose Pfizer-BioNTech and Moderna messenger RNA COVID-19 vaccines.
March 2021
In this article, we discuss key evidence supporting the conclusion that low-dose aspirin should not be used for the sole purpose of preventing any type of cancer, an indication for which the drug is not approved by the FDA.
March 2021
In his editor’s column, Dr. Michael Carome applauds the U.S. Department of Health and Human Services Office of Inspector General (OIG) for issuing a “Special Fraud Alert” highlighting the “inherent risks” of illegal fraud associated with pharmaceutical and medical device com¬panies paying physicians and other health care professionals to speak at company-sponsored events.
March 2021
Patients taking the commonly prescribed epilepsy drug carbamazepine (CARBATROL, EPITOL, EQUETRO, TEGRETOL, TERIL) should be aware that it has clinically important interactions with numerous other prescription and over-the-counter medications.
March 2021
Gabapentin (NEURONTIN, HORIZANT, GRALISE) is frequently prescribed for uses not approved by the FDA (so-called off-label uses), especially for chronic pain. A recently published clinical trial of the drug for treatment of chronic pelvic pain in women underscores why such off-label use, which we oppose, should be avoided.
March 2021
Learn why the FDA in October 2020 warned that pregnant women in general should avoid using nonsteroidal anti-inflammatory drugs (NSAIDs) at about 20 weeks or later in pregnancy because of the rare risks of pregnancy complications and serious harm to an unborn baby.
March 2021
In this month’s Question & Answer feature, we respond to a reader’s question about whether the stomach-acid–suppressing drug esomeprazole (NEXIUM, NEXIUM 24HR, VIMOVO) has the same drug interactions as the closely related drug omeprazole (PRILOSEC, PRILOSEC OTC, ZEGERID).
February 2021
Andexanet (ANDEXXA) received accelerated approval from the FDA for emergency reversal of life-threatening or uncontrolled bleeding caused by the use of two new oral anticoagulants: apixaban (ELIQUIS) and rivaroxaban (XARELTO). Learn why we have designated andexanet and these two anticoagulants as Do Not Use.
February 2021
In his editor’s column, Dr. Michael Carome explains why we encourage readers eligible to receive either of the first two COVID-19 vaccines granted Emergency Use Authorizations by the FDA to get vaccinated when the vaccines become available.
February 2021
In this article, we review four postmarketing studies Purdue Pharma submitted to the FDA that evaluated the alleged abuse-deterrent properties of the company’s reformulated OxyContin and the agency’s independent assessment of the studies’ results. The data failed to show any meaningful reductions in overall opioid abuse or overdoses since the reformulated Oxycontin was approved in 2010.
February 2021
Magnesium deficiency, due to either inadequate dietary intake, impaired intestinal absorption or excessive urinary loss of the mineral, results in low blood magnesium levels — a condition known as hypomagnesemia — and a wide range of adverse health effects. Importantly, many commonly used drugs also can cause magnesium depletion.
February 2021
Dietary supplements that contain more than the recommended daily intake of biotin, also known as vitamin B7, can significantly interfere with many important clinical laboratory blood tests (including those for heart disease and thyroid problems), falsely altering their results. Incorrect test results can lead to misdiagnosis and inappropriate treatment of health conditions, which may have serious or even deadly consequences.
February 2021
In this month’s news brief, we report on FDA-required changes to the product labeling for hydrochlorothiazide (MICROZIDE), a thiazide diuretic drug (“water pill”), warning about a small increased risk of non-melanoma skin cancer associated with use of the drug.
January 2021
We previously designated Duavee as “Do Not Use for Seven Years” because, at the time of its approval by the FDA in 2013, it did not represent a clear clinical breakthrough over standard hormone replacement therapy for postmenopausal women. Learn why we have now updated our designation of the drug to Do Not Use.
January 2021
In his editor’s column, Dr. Michael Carome discusses how unscrupulous companies exploited pandemic-related shortages of hand sanitizers and consumer panic by marketing hand sanitizers that contained dangerous ingredients and thus violated regulatory standards established by the FDA.
January 2021
Patients taking the widely prescribed angiotensin-converting enzyme (ACE) inhibitors, such as benazepril (LOTENSIN) and lisinopril (PRINIVIL, QBRELIS, ZESTRIL), should be aware that these medications have clinically important interactions with many other prescription and over-the-counter medications.
January 2021
In this article, we review results of a new study that sheds further light on the association between the use of specific antidepressants during early pregnancy and the small risk of birth defects.
January 2021
Results of two recently published large, well-designed, randomized clinical trials provide important new evidence against using allopurinol (LOPURIN, ZYLOPRIM) to slow the rate of kidney function decline in patients with chronic kidney disease, a use of the drug that is not approved by the FDA.
December 2020
Combining opioids with other central nervous system depressants — mainly alcoholic beverages or benzodiazepines — greatly increases the risk of opioid overdose and death. These dangers are highlighted by new research showing that alcohol and benzodiazepines were commonly co-involved in U.S. opioid overdose deaths in recent years.
December 2020
In his editor’s column, Dr. Michael Carome discusses a recent FDA warning letter to Sprout Pharmaceuticals accusing the company of airing of an illegal radio ad that made “false or misleading claims about the risks” associated with flibanserin (ADDYI) — a drug intended to increase sexual desire in premenopausal women with hypoactive (low) sexual desire disorder that is often erroneously dubbed the “female VIAGRA” and that we have designated as Do Not Use.
December 2020
In this article, we review the results of randomized clinical trials showing that the anti-inflammatory corticosteroid dexamethasone reduces the risk of death in patients hospitalized with COVID-19 who require supplemental oxygen or mechanical ventilation.
December 2020
Patients taking the widely prescribed calcium channel blocker diltiazem (CARDIZEM, CARTIA XT, TAZTIA XT, TIAZAC) should be aware that it has clinically important interactions with many other prescription medications.
December 2020
Find out why the FDA-approved high-dose form of liraglutide, which was originally marketed at a lower dose for treatment of type 2 diabetes, is not a safe option for managing weight loss.
December 2020
In this month’s Question & Answer feature, we respond to a reader’s question about whether the risks of montelukast (SINGULAIR) outweigh its benefits when it is used for chronic obstructive pulmonary disease (COPD).
November 2020
Early during the coronavirus pandemic, hydroxychloroquine and chloroquine were considered potentially useful treatments for COVID-19. In this article, we discuss results of randomized clinical trials showing that hydroxychloroquine is not effective for treating or preventing COVID-19.
November 2020
In his editor’s column, Dr. Michael Carome discusses U.S. Department of Justice charges brought against generic drug maker Teva for engaging in illegal price-gouging schemes for multiple prescription drugs.
November 2020
Since 2018, the FDA has found that certain commonly used medications contained unacceptable levels of nitrosamine impurities (contaminants) that are considered probable human carcinogens. Learn about the risks of nitrosamines and specific drugs that have been found to be contaminated with these compounds.
November 2020
Supplements for male fertility often contain folic acid and zinc, likely because both substances have been shown to play key roles in the formation and maintenance of normal healthy sperm. However, data from a recently published clinical trial funded by the National Institutes of Health showed supplementation with folic acid and zinc in men among couples undergoing infertility treatment does not increase the chances of achieving a successful pregnancy.
November 2020
We review new guidelines for treating life-threatening allergic reactions (known as anaphylaxis) recently issued by the American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma and Immunology.
November 2020
In this month’s Question & Answer feature, we respond to a reader’s question asking about our recommended alternatives to the opioid analgesic tramadol (CONZIP, ULTRACET, ULTRAM), which we have designated as Do Not Use.
October 2020
Learn why patients with type 1 diabetes should never use any of the type 2 diabetes drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are often referred to as “flozins” or “gliflozins.”
October 2020
In his editor’s column, Dr. Michael Carome discusses a recent report published in Morbidity and Mortality Weekly Reports that hammers home the potentially life-threatening dangers of using these illegal dietary supplements.
October 2020
Marked increases in the prescribing of the gabapentinoids gabapentin and pregabalin, particularly for uses not approved by the FDA (so-called off-label uses), indicate that these drugs are widely overprescribed and misused in the U.S. In this article, we review three recent studies that characterized the growth and extent of gabapentinoid overuse during the past two decades.
October 2020
Ingestion of prescription medications or over-the-counter products is a common cause of poisoning among children. A recently published study found that adults frequently are to blame for this avoidable problem.
October 2020
Patients taking the commonly used stomach-acid–suppressing drug omeprazole should be aware that it has clinically important interactions with many other prescription medications.
October 2020
In this month’s news brief, we report on shortages of the inhaled asthma drug albuterol that have occurred because of the coronavirus pandemic.
September 2020
An updated report from the Centers for Disease Control and Prevention underscores the continued threat of antibiotic resistance in the U.S. and highlights the emerging areas of concern and actions needed to combat this major public health problem.
September 2020
In recent years, there has been a surge in the use of compounded topical pain creams as an alternative to oral pain medications, such as non-steroidal anti-inflammatory drugs and opioids. However, a committee of experts convened by the National Academies of Sciences, Engineering, and Medicine recently concluded that there is a lack of evidence to support the safety and effectiveness of these compounded products.
September 2020
In this article, we discuss the results of a recent large observational study that provide added support for the concern that testosterone therapy heightens the risk of dangerous blood clot formation.
September 2020
Medications are the mainstay of treatment for most patients with seizure disorders, and more than two dozen such drugs have been approved by the FDA. We review one of the oldest seizure drugs, phe¬nytoin (DILANTIN, PHENYTEK). Patients using the drug need to be aware of its many potentially serious adverse effects.
September 2020
Although impaired driving usu¬ally is caused by alcohol or marijuana, many commonly used prescription and over-the-counter medications also can impair one’s ability to drive safely. Learn about several classes of medications that can cause this serious problem to protect yourself, your passengers and others who share the road with you.
August 2020
Learn about important new safety warnings issued by the FDA regarding the schizophrenia medica¬tion clozapine (CLOZARIL, VERSA¬CLOZ) and the asthma/allergy drug montelukast (SINGULAIR).
August 2020
Soon after the novel coronavirus began infecting people in the U.S., unscrupulous companies rushed to sell products not approved by the FDA with fake claims that they could prevent, treat or cure coronavirus disease 2019 (COVID-19). Consumers need to be aware that such products are fraudulent, a waste of money and potentially harmful.
August 2020
Patients taking the commonly used blood thinner warfarin (COUMADIN, JANTOVEN) should be aware that it has clinically important interactions with numerous other prescription and over-the-counter medications, as well as some dietary supplements.
August 2020
In this article, we discuss whether vitamin D and calcium dietary supplements are useful for promoting bone health and preventing bone fractures.
August 2020
Because of the better safety profile of newer second- and third-generation antihistamines, Public Citizen’s Health Research Group has previously recommended their use over older first-generation antihistamines for both allergic rhinitis and urticaria. A recent position statement by the Canadian Society of Allergy and Clinical Immunology that summarized the research evidence about these drugs reinforces our recommendation.
July 2020
Patients taking the commonly prescribed antibiotic azithromycin (ZITHROMAX) should be aware that it has clinically important dangerous interactions with many other prescription medications.
July 2020
In his editor’s column, Dr. Michael Carome explains why President Trump’s reckless promotion of chloroquine and hydroxychloroquine as “game-changing” treatments for COVID-19 was so dangerous.
July 2020
We summarize the available evidence from well-designed clinical trials that support the use of the dietary supplement melatonin for treating jet lag, but not other conditions.
July 2020
New research reveals that potent, prescription-strength topical steroids can be purchased over the counter readily in many U.S. cities. Learn how to protect yourself and your loved ones from these illegal and potentially harmful products.
July 2020
If you do not have cardiovascular disease, you should not take aspirin to prevent a first heart attack, stroke or other cardiovascular event, particularly if you are over the age of 60, because the benefits of such treatment generally do not exceed its bleeding risk.
July 2020
In this month’s Question & Answer, we provide a list of websites that describe the appearance of prescription pills, resources that can help consumers protect themselves from life-threatening pharmacist errors.
June 2020
The insomnia drug zolpidem belongs to a family of drugs known as the non-benzodiazepines or “Z drugs.” Learn why we for years have designated this drug as Do Not Use.
June 2020
Learn about Gilead Sciences’ greedy attempt to profiteer off of the catastrophic coronavirus (COVID-19) pandemic by seek¬ing and receiving a lucrative orphan drug designation from the FDA for an experimental drug being tested as a treatment for COVID-19.
June 2020
Patients taking the commonly prescribed cholesterol-lowering drug simvastatin (FLOLIPID, VYTORIN, ZOCOR) should be aware that it has clinically important interactions with many other prescription medications.
June 2020
In this review of restless legs syndrome (RLS), we discuss the limitations of the available drug treatments for the disorder and the nondrug approaches that are the safest options for people with mild to moderate RLS symptoms.
June 2020
Except for one purified cannabidiol product approved by the FDA for treatment of two rare forms of childhood epilepsy, cannabidiol products marketed in the U.S. are illegal. Find out why the FDA is cracking down on companies selling these illegal drugs.
May 2020
There are more than 1,000 prescription and over-the-counter medications, as well as certain herbal and dietary supplements, that are implicated in liver injury, and the list continues to grow.
May 2020
In his editor’s column, Dr. Michael Carome calls for greater FDA transparency regarding which drugs are in short supply because of the coronavirus pandemic and the resulting manufacturing disruptions in China and elsewhere.
May 2020
Learn why you should avoid taking metoprolol or any other beta blocker if you have COPD and have not previously suffered a heart attack and do not have heart failure.
May 2020
We explain why the norelgestromin-ethinyl estradiol patch is too dangerous to use and describe safer birth control medication options.
May 2020
We summarize results of new research showing that thiazides or thiazide-like diuretics, such as hydrochlorothiazide (MICROZIDE), appear to be the most effective and safest medications for initial treatment of hypertension.
May 2020
In this month’s news brief, we discuss why the FDA decided to ask the manufacturer of the weight-loss drug lorcaserin to voluntarily withdraw the medication from the U.S. market.
April 2020
In this article, we explain why consumers need to beware of dietary supplements containing the illegal drug piracetam that are promoted to enhance cognitive performance, mood, sleep and longevity.
April 2020
In his editor’s column, Dr. Michael Carome discusses findings of a recent exposé published in The New York Times that highlighted how overworked pharmacists at major national pharmacy chains — such as CVS, Rite Aid and Walgreens — have endangered patients by making potentially fatal errors when filling and dispensing prescriptions.
April 2020
Patients taking the commonly prescribed antibiotic clarithromycin (BIAXIN XL) should be aware that it has clinically important interactions with many other prescription medications.
April 2020
Learn why flibanserin is the wrong choice for women who are burdened by persistent low sexual desire.
April 2020
For patients taking opioid analgesics and other drugs that depress breathing and those with lung diseases such as chronic obstructive pulmonary disease, use of gabapentin (GRALISE, HORIZANT, NEURONTIN) or pregabalin (LYRICA) could have deadly consequences.
March 2020
Patients taking the widely prescribed calcium channel blocker verapamil — which is used to treat high blood pressure, coronary artery disease and certain abnormal heart rhythms — should be aware that it has clinically important interactions with many other prescription medications.
March 2020
Recently released court documents reveal the great lengths to which senior executives at Purdue Pharma — including members of the billionaire Sackler family who founded and own the company — went to downplay Oxycontin’s risks of addiction and abuse.
March 2020
New research linking menopausal hormone use to an increased risk of breast cancer reaffirms the importance of using such hormone therapies at the lowest effective dose and for the shortest duration needed.
March 2020
Learn why women should avoid using BRISDELLE, the first and only nonhormonal drug approved by the FDA for treatment of hot flashes associated with menopause.
March 2020
We discuss why pregnant women who have a history of spontaneous preterm birth should not take the injected synthetic hormone hydroxyprogesterone caproate (MAKENA) to prevent another preterm birth.
February 2020
In this second of a two-part series, we review some of the many commonly prescribed medications that can damage your eyes and the steps that you can take to protect yourself from these adverse effects. The first part in this series appeared in our December 2019 issue.
February 2020
A recent warning publicized by the FDA suggests that although purchasing medications from Dollar Tree may appear to be good for your pocketbook, doing so may be dangerous to your health.
February 2020
Dietary supplements containing the trace mineral selenium for many years have been widely touted for the prevention of cancer. But the available scientific evidence shows that selenium is not useful for preventing cancer.
February 2020
Public Citizen’s Health Research Group has designated amiodarone as Limited Use because long-term use of this drug can cause many types of adverse effects that can range from mild to life threatening. The drug should be used only when other therapies are ineffective or cannot be tolerated.
February 2020
Learn why Primatene Mist, an over-the-counter form of the bronchodilator drug epinephrine, is a poor choice for treating asthma.
February 2020
In this month’s news brief, we discuss Public Citizen’s recent petition to the FDA to move the opioid tramadol to a more restrictive classification of controlled substances because it is overprescribed, often misused, highly addictive and potentially deadly.
January 2020
For many years, we have classified both finasteride products as Do Not Use. Read our updated review to find out why.
January 2020
In his editor’s column, Dr. Michael Carome discusses a government watchdog’s finding that the Drug Enforcement Administration allowed drug manufacturers to produce substantially larger quantities of opioids from 2002 to 2013, thus helping to fuel the opioid overdose epidemic.
January 2020
Learn about the results of new research suggesting that implementation of laws expanding naloxone access by authorizing pharmacists to dispense the drug without a prescription may result in fewer opioid-related deaths.
January 2020
Patients taking the commonly prescribed drug methotrexate, which is used to treat certain autoimmune diseases and several types of cancer, should be aware that it has clinically important interactions with many other prescription and over-the-counter medications.
January 2020
Despite its importance in maintaining clear airways and lung health, cough is one of the most common symptoms for which patients seek medical attention and is responsible for millions of doctor visits in the U.S. every year. Learn why the cough medications dextromethorphan and benzonatate generally should be avoided, particularly in children.
January 2020
In this month’s news brief, we highlight a recent letter that the FDA issued to drugmaker Vivus that cited the company for making false or misleading claims on a promotional consumer-directed webpage for its oral weight-loss prescription drug QSYMIA, which we have designated as Do Not Use.
December 2019
In this first of a two-part series, we review some of the many commonly prescribed medications that can damage your eyes and the steps that you can take to protect yourself from these adverse effects. The second part in this series will appear in our February 2020 issue.
December 2019
In his editor’s column, Dr. Michael Carome discusses the failure of drug companies, researchers and the FDA to recognize the overwhelming evidence dating back to the early 1900s demonstrating that the new diabetes drugs known as “flozins” can cause life-threatening ketoacidosis.
December 2019
Patients taking the commonly prescribed antifungal drug fluconazole (DIFLUCAN) should be aware that it has clinically important interactions with many other prescription medications. Some of these interactions can lead to an increased risk of fatal heart rhythm abnormalities.
December 2019
Learn about results of two large, well-designed, randomized clinical trials funded by the National Institutes of Health demonstrating that high-dose vitamin D supplementation was not useful for preventing cancer, cardiovascular disease or diabetes.
December 2019
Read this article to find out which drug treatment for attention deficit hyperactivity disorder has a greater risk of psychosis in adolescents and young adults.
December 2019
Read our response to a reader who asked whether the drug pantoprazole (PROTONIX), which suppresses stomach acid, could have caused a false-positive urine screening test result for tetrahydrocannabinol (THC) — the chemical responsible for most of marijuana’s psychological effects.
November 2019
Learn about the many dangers that make the diet drug orlistat the wrong choice for patients who are trying to lose weight.
November 2019
In his editor’s column, Dr. Michael Carome reviews the results of a recent Gallup poll showing that Americans now view the pharmaceutical industry more negatively than any other major industry in the U.S.
November 2019
For most people with hearing loss, the condition likely is age-related or due to long-term exposure to loud noise. But for some patients, the cause of the problem can be found in the medicine cabinet.
November 2019
Dentists often prescribe antibiotics before dental procedures as prophylaxis to prevent infection from the release of bacteria from the mouth into the bloodstream. Find out which patients should receive such preventive antibiotics before dental procedures.
November 2019
In this article, we describe a common condition known as subclinical hypothyroidism and discuss the newest guidelines regarding which patients with this condition should be treated with thyroid hormone replacement.
November 2019
In this month’s news brief, we report actions taken by the FDA and regulators in other countries in response to the discovery of a probable human carcinogen in a widely used medication that suppresses stomach acid.
October 2019
Unused, unneeded or expired drugs in homes present a number of risks, including intentional or accidental overdose in humans (particularly young children). Learn how to safely dispose of these drugs.
October 2019
In his editor’s column, Dr. Michael Carome discusses how FDA Commissioner Scott Gottlieb’s resumption of close ties to the pharmaceutical industry following his resignation from the agency created a cloud of justifiable distrust about actions taken by the FDA under his leadership.
October 2019
Next to Parkinson’s disease, drug-induced parkinsonism is the second most common cause of parkinsonism, accounting for about 8-12% of all parkinsonism cases. Find out which commonly used drugs can cause this condition.
October 2019
The FDA recently issued two important safety alerts for doctors and patients. The first alert described risks of serious, often fatal injuries linked to use of the three so-called “Z-drugs” for insomnia. The second warned women of childbearing age not to use vinpocetine, an ingredient found in many widely available dietary supplements.
October 2019
This article discusses important warnings issued by drug regulators in Canada and Ireland about new evidence of an increased risk of congenital birth defects associated with use of the stimulant drugs modafinil and armodafinil.
October 2019
In this month’s news brief, we report new data from the Centers for Disease Control and Prevention regarding the public health risks posed by kratom and kratom-containing dietary supplements, which have been falsely touted by some marketers as safe treatments for a variety of conditions, including anxiety, depression, opioid use disorder and pain.
September 2019
Doctors often prescribe antibiotics to treat acute exacerbations of chronic obstructive pulmonary disease (COPD), which are characterized by increased shortness of breath, cough, sputum production and wheezing. But for some patients, the risks of such antibiotic treatment outweigh the benefits.
September 2019
In his editor’s column, Dr. Michael Carome discusses Public Citizen’s most recent legal maneuver to force the FDA to respond to our June 2016 petition seeking stronger warnings about the risk of compulsive or uncontrollable behaviors in the product labeling for a class of drugs known as dopamine agonists.
September 2019
Fungal infections of the toenails and fingernails, a condition known as onychomycosis, are common. Learn why you should never take oral itraconazole or terbinafine to treat these cosmetic, non-health-threatening nail infections.
September 2019
Patients taking the commonly prescribed epilepsy drug phenytoin (DILANTIN, PHENYTEK), one of the oldest epilepsy drugs, should be aware that it has clinically impor¬tant interactions with many other prescription and over-the-counter medications. Some of these interactions can lead to phenytoin toxicity, and others can lead to ineffective seizure control.
September 2019
Rosacea is a chronic skin condition affecting 13 million Americans. Find out steps to take to prevent symptom flare-ups and learn which topical drug therapies are most effective and safest for treating this condition.
August 2019
Most U.S. adults drink alcohol at least occasionally. Many also take prescription or over-the-counter drugs that have the potential to inter¬act adversely with alcohol. Avoid serious harm by knowing which drugs should not be taken in combination with alcohol.
August 2019
Allegations made in a recent lawsuit filed in federal court by 44 states suggest that 20 generic drug companies perpetrated a multi-billion-dollar fraud on the American public over the past decade.
August 2019
Learn why Public Citizen’s Health Research Group advises against using any central nervous system stimulant drugs for weight loss.
August 2019
The FDA has approved five medications for treatment of cold sores — sometimes referred to as fever blisters, oral herpes or herpes labialis. Find out which of these drugs offer the most benefit.
August 2019
Accounting for approximately 41 million prescriptions dis¬pensed in the U.S. in 2017, the opioid analgesic tramadol is among the most widely used painkillers. New research linking tramadol to an increased risk of death reinforces our long-standing Do Not Use designation for this drug.
July 2019
Learn why the widely used proton pump inhibitors should be reserved for certain patients with stomach-acid disorders and only taken at the lowest possible dose for the shortest possible duration needed.
July 2019
Too often, senior executives of leading pharmaceutical companies that engage in illegal marketing of drugs and other serious crimes escape criminal prosecution. But this was not the case for the billionaire founder of Insys Therapeutics.
July 2019
Read about the growing body of evidence showing that the commonly prescribed fluoroquinolone antibiotics increase the risk of potentially fatal ruptures or tears of the aorta, the largest blood vessel in the body.
July 2019
A reader asked whether the FDA reviews and approves homeopathic drugs. Our answer should make you think twice about using these products.
July 2019
Find out about the many prescription medications that can interact in dangerous ways with the four drugs approved by the FDA for treating erectile dysfunction in men.
July 2019
More and more patients are being treated with an expanding array of potent immunosuppressive drugs that require special screening and monitoring to minimize the risk of serious harm. But new research reveals that too many patients receiving these drugs are not undergoing the appropriate screening and monitoring tests.
June 2019
Patients who have difficulty swallowing pills will sometimes crush tablets or open capsules and sprinkle the resulting powder, fragments or granules into food or liquids. Other patients will resort to chewing their pills before swallowing. Find out the dangers posed by taking such measures.
June 2019
In his editor’s column, Dr. Michael Carome advocates federal legislation that would abolish the harmful tax breaks given to Big Pharma for the costs of direct-to-consumer prescription drug advertising.
June 2019
Learn why Public Citizen’s Health Research Group has designated the asthma drugs montelukast and zafirlukast as Do Not Use.
June 2019
Read about the many prescription drugs that can interact in dangerous ways with grapefruit or grapefruit products.
June 2019
In this article, we discuss preliminary data from an ongoing clinical trial that prompted the FDA to issue a new warning about potentially fatal blood clots caused by tofacitinib, an oral drug used to treat rheumatoid arthritis and other inflammatory diseases.
May 2019
Approximately 10 years ago, testosterone makers launched a massive direct-to-consumer advertising campaign to promote the use of testosterone for normal age-related declines in testosterone in men. Learn why such use of testosterone can be dangerous without providing any proven benefit.
May 2019
The FDA’s recent warning about a dozen companies that marketed illegal products purported to treat or prevent Alzheimer’s disease highlights the importance of ignoring advertisements promoting miracle cures for serious diseases.
May 2019
In this article, we explain why the FDA should not have approved indacaterol, a long-acting inhaled bronchodilator, for long-term treatment of COPD without first requiring further clinical trials testing lower doses of the drug than the currently approved dose.
May 2019
Read about the many prescription medications that can interact in dangerous ways with colchicine, a commonly used drug for treatment of acute gout attacks.
May 2019
For men, abnormally large breasts can be distressing and embarrassing. Find out about the numerous drugs that can cause breast enlargement in men.
April 2019
Learn why we have designated Prolia as Do Not Use for treatment of osteoporosis in women and men.
April 2019
Many diabetes patients, including some with health insurance, can no longer afford to take the dosage of life-saving insulin prescribed by their doctors because of price gouging by the pharmaceutical industry. For some of these patients, the rationing of unaffordable insulin has proved to be fatal.
April 2019
Drugs are the most frequent cause of taste disturbances. In this article, we identify more than 60 commonly used prescription medications that have been linked to problems with taste.
April 2019
In this article, we discuss a new reason for why finasteride should not be used by men to treat symptoms of prostate enlargement or male pattern baldness.
April 2019
Many women are plagued by frequent bladder infections, and use of antibiotics to treat bladder infections comprises a major proportion of antibiotic use around the globe. Read about new research showing that increased water intake in women markedly reduces the frequency of bladder infections and the need for antibiotics.
April 2019
In this month’s news brief, we report on Ironwood Pharmaceuticals’ recent decision to cease marketing its dangerous gout drug lesinurad (ZURAMPIC, DUZALLO). Several years ago, we had designated the drug as Do Not Use because its substantial risks far outweighed its benefits.
March 2019
Millions of Americans take anticoagulants on a long-term basis to prevent the formation of potentially harmful clots. Learn why such patients should avoid using nonsteroidal anti-inflammatory drugs.
March 2019
In his editor’s column, Dr. Michael Carome laments the FDA’s troubling decision to withdraw a proposed rule that would have allowed generic drug companies to promptly update safety warnings in their product labels.
March 2019
Read about the many prescription medications that can interact in dangerous ways with lithium, the drug of choice for treating bipolar disorder, also known as manic depression.
March 2019
Restless legs syndrome is a common neurological movement and sensory disorder that affects 5 to 10 percent of the population. In this article, we identify some of the many drugs that can cause or worsen this disorder.
March 2019
Somatropin was first approved by the FDA in 1987 for the treatment of short stature in children with growth hormone (GH) deficiency. Find out why we recommend not using somatropin in children with short stature who have normal GH levels; people who develop GH deficiency in adulthood; or in healthy individuals as an anti-aging agent, to improve athletic performance or for body-building.
February 2019
Aspirin is widely used to prevent heart attacks and strokes in the elderly. Read this article to learn whether such use of aspirin is the right choice for you.
February 2019
In his editor’s column, Dr. Michael Carome slams the FDA for its reckless approval of a dangerous new opioid that will be marketed under the brand name Dsuvia.
February 2019
For many years, we have designated the prescription sleep medication zolpidem as Do Not Use. We review the results of new research exposing the frequent misuse of this dangerous medication.
February 2019
In this month’s news brief, we report on actions taken by the FDA to stop the flow of tainted medications made by a Chinese drug manufacturer into the U.S.
February 2019
Low back pain is a frequent reason for outpatient and emergency room visits among adults. Read why treatment with corticosteroids is a poor choice for treating this common condition.
February 2019
This article discusses new research linking use of oral diclofenac, a nonsteroidal anti-inflammatory drug, to an increased risk of heart attacks, strokes and other adverse cardiovascular events.
January 2019
Read about the many prescription and over-the-counter medications that can interact in dangerous ways with clopidogrel, a widely used anti-platelet drug.
January 2019
In his editor’s column, Dr. Michael Carome recounts how a Florida medical clinic deceived patients by falsifying scientific journal citations in its promotion of a now-illegal heart-toxic drug called cesium chloride for treatment of cancer.
January 2019
Learn about a rare but potentially fatal bacterial infection in the area of the genitals that has been linked to the diabetes drugs known as sodium-glucose cotransporter-2 inhibitors, commonly called “flozins.”
January 2019
In this article, we review new research showing that statins are associated with a potentially disabling autoimmune muscle disorder known as idiopathic inflammatory myositis, a rare disorder that is distinct from the much more common type of muscle injury seen with statins.
January 2019
Find out about the risks and benefits of apomorphine, an injectable medicine approved by the FDA for treatment of specific symptoms that occur in patients with advanced Parkinson’s disease.
January 2019
In response to a reader’s question about our article “Metformin: First-Choice Drug for Type 2 Diabetes” in the August 2018 issue, we discuss the risk of diarrhea and other adverse gastrointestinal effects that may occur when taking metformin.
December 2018
Dietary supplements containing cesium chloride or other types of cesium salts are among the most hazardous supplements currently marketed in the U.S. Read this article to find out why.
December 2018
In his editor’s column, Dr. Michael Carome, prompted by a recent letter from one of our readers, discusses why our recommendations and designations for specific drugs sometimes change based on new information.
December 2018
Baricitinib is the most recent drug approved by the FDA for treatment of patients with rheumatoid arthritis. Read our assessment of this dangerous drug.
December 2018
In this article we discuss new research showing that patients with acute respiratory illnesses too often are treated inappropriately with corticosteroid drugs, exposing them to unnecessary risks.
December 2018
Learn how patients can initiate a discussion with their doctors to begin the process of weaning off benzodiazepines, a class of highly overprescribed sedative hypnotic drugs primarily used to treat anxiety and insomnia.
November 2018
Read about the numerous medications that can interact with digoxin, a drug commonly prescribed for heart failure and atrial fibrillation. These interactions can result in either digoxin toxicity or decreased digoxin effectiveness depending on the other drug being used concomitantly.
November 2018
In his editor’s column, Dr. Michael Carome discusses the implications of a major initiative by a large group of U.S. hospitals to establish their own not-for-profit generic pharmaceutical company.
November 2018
If you are a smoker, quitting is the most important thing you can do for your health. Learn why we recommend that varenicline only be used a last-resort drug for smoking cessation.
November 2018
This article reviews the recent recommendation issued by the U.S. Preventive Services Task Force (USPSTF), an independent volunteer panel of national experts in disease prevention, against older adults taking extra vitamin D to prevent falls.
November 2018
Find out why women of child-bearing age should avoid taking valproate for migraines and should use it only for seizure or bipolar disorder if other medicines fail to adequately control these conditions or cause unacceptable adverse effects.
November 2018
In this month’s news brief, we report on the Food and Drug Administration’s recent action regarding our petition to prohibit the use of heart-toxic cesium chloride — which has been promoted as an alternative treatment for cancer — in pharmacy compounding.
October 2018
The FDA has approved four drugs for treating Alzheimer’s disease, a devastating brain disorder that affects nearly 6 million Americans, most of whom are elderly. Learn why we have designated each of these drugs as Do Not Use.
October 2018
In this article, we summarize the results of a recent research study showing that use of medications that have depression as a potential adverse effect is very common. We also identify some of the many prescription medications that can cause depression symptoms, including suicidal thoughts or behavior.
October 2018
For certain types of epilepsy, lamotrigine is an appropriate treatment for preventing seizures. Learn about the common and serious adverse effects that can occur while taking this drug and how to take this drug safely.
October 2018
We have received numerous questions from readers asking what to do about the recent recalls of valsartan-containing drugs sold by certain companies that were found to be tainted with a probable carcinogen. In this article, we offer advice for those patients who have been taking valsartan.
October 2018
Several readers have asked us whether the FDA’s recent approval of a drug that reverses the anticoagulant effect of apixaban (ELIQUIS) and rivaroxaban (XARELTO) alters our classification of these two drugs as Do Not Use. Read our answer.
October 2018
In his editor’s column, Dr. Michael Carome discusses the implications of a recent government report which found that annual out-of-pocket expenses for brand-name drugs covered under Medicare Part D have skyrocketed in recent years.
September 2018
Read about the more than two dozen medications that can have clinically important interactions with aripiprazole, one of the widely used newer atypical antipsychotic drugs that is approved by the FDA for treatment of several disorders including schizophrenia, bipolar disorder and depression.
September 2018
In this article, we discuss results of new research linking the widely overused fluoroquinolone antibiotics to an increased risk of life-threatening damage to the body’s largest blood vessel, the aorta.
September 2018
Hear our recommendations on the use of medroxyprogesterone, a prescription medication containing a synthetic form of the female hormone progesterone that is most commonly used for contraception and hormone therapy in women.
September 2018
Learn why benzocaine-containing gels and liquids should never be used to treat teething discomfort and about Public Citizen’s Health Research Group’s successful campaign to force the FDA to pull these products from the market.
September 2018
In his editor’s column, Dr. Michael Carome reviews the relationship between the development of a deeply entrenched industry-friendly culture within the FDA and the agency’s increasingly lax oversight of prescription drugs.
August 2018
Learn why metformin is the drug of choice for the initial treatment of patients with type 2 diabetes who are not able to control their blood sugar through diet and exercise alone and who do not have severe kidney impairment.
August 2018
Countless companies heavily promote dietary supplements containing omega-3 fatty acids as the solution to many health problems, including dry eyes. But results of a new research study funded by the National Institutes of Health demonstrate that omega-3 fatty acids are not a good choice for treating dry eyes.
August 2018
In this article, we review the dangers of using opioid-containing cough and cold medicines in children younger than age 18.
August 2018
In his editor’s column, Dr. Michael Carome discusses the outrageous tactics that sales representatives from drugmaker Insys Therapeutics allegedly used to illegally promote fentanyl sublingual spray (SUBSYS), a rapid-acting, highly addictive, dangerous opioid that is sprayed under the tongue.
August 2018
If you are a smoker, quitting is the most important thing you can do for your health. Find out whether bupropion (ZYBAN) is an appropriate treatment option to increase your chances of successfully quitting.
July 2018
Overdosing on commonly used nonsteroidal anti-inflammatory drugs can increase your risk of potentially serious adverse effects, including gastrointestinal bleeding and kidney damage. Learn how to protect yourself from unintentional overdoses of these medications.
July 2018
In his editor’s column, Dr. Michael Carome discusses a rarely used authority of the federal government that would lower the price for the opioid-overdose antidote naloxone and save lives.
July 2018
Inhaled corticosteroids are one of the mainstays of asthma treatment in adults and children, and increasing the dose of these medications when early signs of worsening asthma control occur is a commonly recommended strategy. Find out whether this treatment strategy is a safe and effective choice.
July 2018
Tremor is the single most common movement disorder, affecting millions of people in the U.S. If you have tremors, could one of your drugs be the cause? Read this article to learn the answer.
July 2018
In this article, we present the findings of our most recent report cataloging all major financial settlements that the pharmaceutical industry has been forced to sign with federal and state governments since 1991. The report’s most striking finding is a recent precipitous drop in federal criminal penalties against drug companies.
July 2018
In this month’s news brief, we report on the Food and Drug Administration’s announcement that a medication for multiple sclerosis is being withdrawn from the market because of serious safety concerns.
June 2018
This article lists practical steps to take to avoid death, hospitalization or other medical problems caused by heat stress. It also identifies over 100 drugs that can impair your response to heat and thereby increase your risk of heat-induced illness and death.
June 2018
In his editor’s column, Dr. Michael Carome discusses an analysis by researchers at Harvard University that suggests that patients and doctors are being misled about the benefits of drugs approved under the FDA’s “breakthrough therapies” pathway.
June 2018
Clarithromycin is an oral antibiotic that is commonly used to treat a wide range of bacterial infections. Learn why patients with heart disease should avoid this antibiotic unless no other suitable antibiotic is available.
June 2018
Apixaban is a new oral anticoagulant (blood thinner) that was first approved by the FDA in 2012 for decreasing the risk of blood clots in certain patients. Find out why older anticoagulant drugs, such as warfarin (COUMADIN, JANTOVEN), are a better choice.
June 2018
All but one of the clobetasol propionate products are classified as super-high potency topical corticosteroids. They are approximately 1,000 times more potent than over-the-counter 1-percent hydrocortisone. This article offers advice on how to use these products safely.
May 2018
Prasugrel is an oral antiplatelet drug that was approved by the FDA in 2009 as an add-on treatment to aspirin to prevent clots from forming that may cause a heart attack or stroke in certain patients with coronary artery disease. Learn why we recommend avoiding this medication.
May 2018
Pharmaceutical companies spend billions of dollars annually advertising their products directly to consumers on TV. But as Worst Pills, Best Pills News Editor Dr. Michael Carome explains, prescription drug TV ads often fail to fully adhere to FDA regulations governing direct-to-consumer ads.
May 2018
In this month’s News Brief, we report the sentencing of the former supervisory pharmacist at the now-shuttered New England Compounding Center located in Framingham, Massachusetts to eight years in prison for his role in the deadly nationwide fungal meningitis outbreak in 2012 that had been linked to tainted steroid drugs made by the company.
May 2018
When the FDA approved febuxostat in 2009 for treating high uric acid blood levels in patients with gout, we advised readers not to use the drug until at least February 2016 based on our longstanding “Seven-Year Rule.” Read this article to hear results of new research that prompted us to now designate febuxostat as Do Not Use.
May 2018
This article reviews the recent recommendation issued by the U.S. Preventive Services Task
Force, an independent volunteer panel of national experts in disease prevention, against the use of hormone replacement therapy in postmenopausal women in order to prevent chronic conditions such as heart disease, stroke, diabetes, dementia, cancer and osteoporosis.
May 2018
Find out why the muscle relaxant baclofen is a reasonable choice for treating reversible muscle spasms in patients with multiple sclerosis but should not be used to treat spasticity due to spinal cord injuries or other spinal cord diseases.
May 2018
In 2017, the FDA announced its intention to consider allowing drug companies to reduce the amount of risk information they disclose to consumers in direct-to-consumer prescription drug television or radio ads. This article discusses why the FDA’s proposal would be bad for consumers.
April 2018
In his editor’s column, Dr. Michael Carome offers advice on how to avoid being conned by unscrupulous companies promising miracle treatments for opioid addiction and withdrawal.
April 2018
Topiramate is a second-generation antiepileptic drug that was originally approved by the FDA in 1996. In this article, we discuss why topiramate is an appropriate option for treating certain seizure disorders but should not be used for treatment of migraine headaches.
April 2018
Extended-release niacin is approved by the FDA to reduce elevated cholesterol levels and to reduce the risk of recurrent, nonfatal heart attacks in patients with histories of previous heart attacks and elevated cholesterol levels. Learn why we just changed the designation of niacin extended-release tablets from Limited Use to Do Not Use.
April 2018
When the beta blocker nebivolol was approved by the FDA in 2007, we advised readers not to use the drug until 2015, in accordance with our seven-year rule. Find out why we now have designated nebivolol as Limited Use and whether it is the right choice for treating hypertension.
April 2018
Read this article to learn about recent FDA public health advisories warning against the use of kratom and kratom-containing dietary supplements, which have been falsely touted by some marketers as safe treatments that have broad healing properties.
March 2018
Patients often wonder what steps they can take to minimize their chances of suffering a serious adverse drug reaction. This article reviews 10 simple rules developed by Public Citizen’s Health Research Group for ensuring safer drug use.
March 2018
In his editor’s column, Dr. Michael Carome highlights the most recent wave of price hikes by major pharmaceutical companies at the start of 2018.
March 2018
The FDA has approved gabapentin (NEURONTIN) for several conditions, including a type of seizure disorder, shingles pain and restless leg syndrome. Hear our recommendations for who should use gabapentin and who should avoid it.
March 2018
Last year, the FDA warned that a drug used to treat high blood potassium levels can interfere with the absorption of many other oral medications. Learn the name of this drug and how to take it safely when using other drugs.
March 2018
We respond to readers’ questions about our October 2017 article regarding the use of vitamin E for preventing or treating mild cognitive impairment or Alzheimer’s disease and our December 2017 article regarding the use of desmopressin spray (NOCTIVA) for treating nighttime urination symptoms.
March 2018
Meclizine is a drug that is commonly used to treat symptoms of motion sickness. Find out why we have designated this drug as Do Not Use.
February 2018
Fentanyl is a dangerous synthetic opioid that has been involved in an increasing number of overdose deaths in the U.S. Learn why this drug should be used only by cancer patients with breakthrough cancer-related pain.
February 2018
In 2007, Congress passed legislation aimed at improving the disclosure of risk information in TV ads for prescription drugs by mandating that ads present this information in a “clear, conspicuous, and neutral manner.” Worst Pills, Best Pills News Editor Dr. Michael Carome takes the FDA to task for never implementing the requirements of this 2007 law.
February 2018
Obeticholic acid is a second-line treatment for patients with a rare liver disease called primary biliary cholangitis. In this article, we discuss how to appropriately dose the drug in order to avoid life-threatening liver damage.
February 2018
No other schizophrenia medicine is more dangerous than clozapine. Learn about the drug’s serious unique risks and why it should be used only by severely ill schizophrenia patients who have failed to respond adequately to other antipsychotic medications.
February 2018
Abnormal involuntary movements (movement disorders) occur as adverse events associated with many widely used medications and can cause substantial hardship for affected individuals. Find out which drugs are associated with these adverse effects.
February 2018
In this month’s News Brief, we report on Public Citizen’s Health Research Group’s petition to the FDA to ban a cancer treatment ingredient from use in pharmacy compounding because of serious health risks to humans and no evidence of benefit.
January 2018
Olmesartan (BENICAR) is one of eight drugs in the family of commonly used blood pressure-lowering medications known as angiotensin II receptor blockers. Learn about the severe, life-threatening gastrointestinal adverse effects of olmesartan that could land you in the hospital.
January 2018
Worst Pills, Best Pills News Editor Dr. Michael Carome discusses the recent arrest of John Kapoor, the billionaire founder of Insys Therapeutics — the drug company that markets fentanyl sublingual spray (SUBSYS), a highly addictive, dangerous opioid drug. Kapoor has been charged with “leading a nationwide conspiracy” to profit by bribing doctors to inappropriately prescribe the company’s fentanyl spray product.
January 2018
Every year, more than 300,000 older Americans are hospitalized due to hip fractures, and almost all of these fractures are caused by falls. Read about new research further linking use of sleeping pills to an increased risk of falls and serious injury.
January 2018
Milnacipran (SAVELLA) was approved by the Food and Drug
Administration in 2009 for the treatment of fibromyalgia in adults, which remains its only approved use. In this article, we review data showing that the drug is ineffective for treating fibromyalgia and dangerous.
January 2018
Overactive bladder is a bothersome — but not serious — medical problem that becomes more common with age. Find out why mirabegron is the wrong choice for treating this condition.
December 2017
In this article, we explain why the serious adverse effects of the injected diabetes drug pramlintide far outweigh the drug’s limited benefits.
December 2017
Worst Pills, Best Pills News Editor Dr. Michael Carome discusses how the opioid drug industry successfully lobbied Congress to pass a dangerous bill that effectively stripped the Drug Enforcement Agency of one of its strongest enforcement tools for fighting the illegal diversion of opioid drugs.
December 2017
Weight gain is an adverse event associated with many widely used medications and may lead to significant overweight and obesity, especially in susceptible individuals. Find out which drugs have this adverse effect.
December 2017
Nighttime urination is a common symptom that becomes more common with increasing age. Learn why the only drug approved for treating this symptom offers only meager benefits along with unacceptable risks.
December 2017
Rifaximin was approved by the FDA in May 2015 for treating irritable bowel syndrome with diarrhea as the predominant symptom in adults. Find out about the drug’s serious adverse effects that outweigh its limited benefits.
November 2017
Learn why edoxaban, one of the new blood thinners approved by the FDA, is not the best option for preventing dangerous blood clots in patients with atrial fibrillation.
November 2017
Over the past decade, the number of clinics in the U.S. that peddle unproven stem cell "treatments" directly to consumers exploded from a handful in 2010 to as many as 570 in 2016. Find out what the FDA is finally doing to clamp down on the marketing of illegal stem cell treatments.
November 2017
The injection of corticosteroids into the knee joints of patients with osteoarthritis of the knee is a widespread practice. Find out the results of new research funded by the National Institutes of Health showing that such injections actually may accelerate joint damage.
November 2017
In this article, we describe a common condition known as subclinical hypothyroidism and discuss which patients with this condition should be treated with thyroid hormone replacement.
November 2017
In this month’s news brief, we report the FDA’s reckless decision to deny Public Citizen’s petition to ban a dangerous anti-fungal drug.
November 2017
Doctors often prescribe pregabalin for a neuropathic pain condition known as sciatica, a use that is not approved by FDA. Find out why pregabalin is a bad choice for treating sciatica.
October 2017
In August, the U.S. Senate unanimously passed the so-called Right to Try Act. Worst Pills, Best Pills News Editor Dr. Michael Carome explains how this deceptively named bill would put countless patients at risk by undermining important FDA safety rules related to the use of unapproved, experimental medications.
October 2017
In this month’s news brief, we report on the FDA’s recent decision to partially grant a petition from Public Citizen to require the addition of a warning about a dangerous drug-drug interaction to product labeling of repaglinide-containing diabetes medications.
October 2017
Tofacitinib is one of the newer medications approved by the FDA for treatment of rheumatoid arthritis. Learn why we have designated this drug as Do Not Use.
October 2017
Canagliflozin is one of three medications in the newest diabetes drug class. In this article, we discuss why the FDA recently required that a black-box warning about the risk of amputations be added to the product labeling of canagliflozin.
October 2017
Dietary supplement makers often tout vitamin E products for a variety of purported health benefits, including the promotion of brain health. Find out why vitamin E supplements are unlikely to prevent cognitive decline and may cause serious harm if taken in doses exceeding the recommended dietary allowance.
October 2017
Hear how drugmaker Alkermes has engaged in a novel but troubling marketing campaign to increase sales of its once-monthly injected version of naltrexone (VIVITROL) for treatment of opioid addiction.
September 2017
In March 2017, a federal jury found the co-owner of a now-bankrupt Massachusetts compounding pharmacy guilty on more than 50 counts of racketeering and mail fraud for his role in the deadly nationwide fungal meningitis outbreak in 2012, which had been linked to tainted steroid drugs. Read the troubling details of how the company’s co-owner escaped being convicted of second-degree murder.
September 2017
Following a deadly fungal meningitis outbreak linked to a Massachusetts compounding pharmacy’s tainted steroid drugs, Congress in 2013 passed a law to strengthen the FDA’s oversight of the compounding pharmacy industry. Learn about reckless legislation now being considered by Congress that would reverse the 2013 law.
September 2017
In this article, we discuss new data from well-designed randomized controlled trials that show that testosterone treatment in older men with low testosterone blood levels does not improve memory or other cognitive functions and actually increases the buildup of cholesterol in coronary arteries.
September 2017
Learn why Public Citizen’s Health Research Group has designated CONTRAVE, a combination weight-loss medication that was approved by the FDA in 2014, as Do Not Use.
September 2017
The FDA recently required that the product labeling for several of the newest hepatitis C drugs be revised to include a black-box warning, the strongest warning that the agency can require. Find out what the new warning says.
September 2017
To address the growing epidemic of prescription opioid drug overdoses in the U.S., many drugmakers have attempted to develop opioid pills that are supposedly resistant to being manipulated in ways that make them easier to abuse. In this article, we highlight problems with these so-called abuse-deterrent opioid formulations.
August 2017
Worst Pills, Best Pills News Editor Dr. Michael Carome assesses the implications of the FDA’s recent request that a major pharmaceutical company remove from the market its reformulated extended-release opioid product.
August 2017
Millions of people in the U.S. take blood thinners or antiplatelet medications to prevent the formation of potentially harmful clots in the heart, large veins or arteries. In this article, we report new research that examined the risk of one of the most serious bleeding complications associated with these drugs: subdural hematomas in the head.
August 2017
Although health care professionals often advise patients on whether the medications they are taking may interact with each other, they do not always discuss how various foods may interact with medications. Learn about some of these dangerous food-drug interactions and how to protect yourself.
August 2017
Many medicines can cause diarrhea, which can be severe and life-threatening in some cases. Find out which drugs have this adverse effect.
August 2017
Alopecia, or excessive hair loss, is a common problem among both men and women, and it can have a considerable negative impact on the body image and emotional well-being of affected individuals. In this article, we present our recommendations regarding drugs that are approved for treating hair loss.
July 2017
Eluxadoline was approved by the FDA in May 2015 for treating irritable bowel syndrome with diarrhea as the predominant symptom in adults. Learn about the drug’s serious adverse effects that outweigh its limited benefits.
July 2017
For years, the Food and Drug Administration has repeatedly warned the public about dietary supplements that have been spiked illegally with hidden drugs. Find out which dangerous drug is now showing up in dietary supplements that are being promoted for increasing sexual desire and libido in women.
July 2017
In this article, we discuss how two families of commonly used stomach acid suppressants may make patients more susceptible to Clostridium difficile infection, which can lead to severe, sometimes life-threatening diarrhea.
July 2017
Nocturnal or nighttime leg cramps (charley horses) are very common in adults, afflicting nearly half of those over the age of 50. Find out why magnesium supplements are not the solution for this often distressing condition.
July 2017
Parents may be tempted to try assorted teething remedies for their infants. Learn about certain homeopathic products for teething that have been recalled because they were linked to a large number of serious injuries in infants.
July 2017
In this month’s Question & Answer section, we respond to a reader's question about how patients with high blood pressure should increase their dietary intake of potassium.
June 2017
The food and dietary supplement industries have been swift to capitalize on the excitement surrounding the microbes living on or within our bodies by selling products that contain probiotics, or live microor¬ganisms purported to improve health by altering the microbiome. In this article, we explain which claims about probiotics have been tested in clinical trials — and why many probiotic supplements are very likely a waste of money.
June 2017
Learn about landmark legislation recently introduced in the U.S. Senate that would lower the cost of prescription medications for all Americans, increase access to drugs for consumers and hold pharma¬ceutical corporations accountable for wrongdoing.
June 2017
Many adverse drug reactions are severe enough to cause serious injury, hospitalization and even death. Find out which outpatient medications are most likely to cause adverse events that necessitate a visit to the emergency room.
June 2017
For many years, we have designated the weight-loss drug orlistat (XENICAL, ALLI) as Do Not Use because it exposes patients to serious risks that greatly outweigh its minimal benefits. In this article, we describe data from a new study showing that orlistat’s side effects were seriously underreported in published medical journal articles for the clinical trials that the drugmaker conducted to support the drug’s approval.
June 2017
We discuss new studies confirming that the widely used angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers can potentially harm the kidneys and cause dangerous elevations in blood potassium levels. These studies also indicated that many doctors are not heeding recommenda¬tions to look out for these side effects.
May 2017
Find out which commonly used prescription and over-the-counter diarrhea medications can cause dangerous abnormal heart rhythms and cardiac arrest if taken at higher-than-recommended doses.
May 2017
On March 10, President Donald Trump nominated Dr. Scott Gottlieb to be the next FDA commissioner. Worst Pills, Best Pills News Editor Dr. Michael Carome explains why Gottlieb’s appointment would fur¬ther accelerate a decades-long trend in which FDA leadership too often makes decisions that are aligned more with the interests of the pharmaceutical industry than with those of patients.
May 2017
We describe the troubling story of how a pharmaceutical company manipulated the scientific literature to inappropriately promote the use of citalopram (CELEXA) for the treatment of de¬pression in children and teens despite the fact that the drug was not approved by the FDA for this use.
May 2017
The lung diseases asthma and chronic obstructive pulmonary disease together afflict 40 million Americans and can result in disability and life-threatening complications for many affected individuals. In this article, we present our recommendations for using SYMBICORT, a combination of the long-acting beta agonist formoterol and the inhaled corticosteroid budesonide, to treat these lung diseases.
May 2017
Urinary incontinence — the inability to control the passage of urine — is a widespread problem that affects an estimated 25 million American adults. Learn about lifestyle changes and non-drug therapies that should be the first-choice treatments for incontinence, as well as the best drugs to use as second-choice treatment options.
April 2017
Overall, use of testosterone medications in the U.S. grew by nearly 10-fold from 2000 to 2011, and by 2013, more than 5 million U.S. prescriptions for testosterone were being filled annually. In this article, we discuss new research findings showing that testosterone products fail to provide benefit to many of the men who are using them.
April 2017
Worst Pills, Best Pills News Editor Dr. Michael Carome warns readers not to be deceived by the slick advertising campaign recently launched by the Pharmaceutical Research and Manufacturers of America — the leading industry trade group representing brand-name pharmaceutical companies.
April 2017
Find out which medications that are used to treat psoriasis (a chronic condition that causes patches of scaly and inflamed skin) are particularly dangerous during pregnancy because they carry well-established, high risks of birth defects.
April 2017
Flibanserin (ADDYI) was billed as the "female Viagra" because it was intended to increase sexual desire in women with "hypoactive sexual desire disorder," or low interest in sex. Learn why this dangerous drug fortunately has failed to be the blockbuster that many expected it to be.
April 2017
Levetiracetam (KEPPRA, ROWEEPRA, SPRITAM) and its long-acting variant, levetiracetam extended-release (KEPPRA XR), are approved by the FDA for preventing seizures in patients with epilepsy. Find out who is most likely to benefit from using these drugs and what adverse reactions to watch out for when taking them.
April 2017
We review the results of a new study demonstrating that patients using testosterone products have a significantly increased risk of developing life-threatening blood clots in large veins, most often in the legs.
March 2017
If you regularly watch nightly national news on TV, you have probably seen ads promising improved memory if you take the dietary supplement apoaequorin (PREVAGEN). Learn why these claims from the maker of PREVAGEN represent an apparent elaborate hoax.
March 2017
In October 2014, Public Citizen joined four other consumer advocacy and research groups to petition the FDA to strengthen the existing black-box warning on the label of the smoking cessation drug varenicline. In December, the agency instead decided to move recklessly in the opposite direction by removing the black-box warning from the label. In this article, we discuss the dangerous precedent set by this decision.
March 2017
In this article, we discuss three new drugs approved by the FDA in 2016 that Worst Pills, Best Pills News has identified as ineffective or lacking in evidence to support key claims made on products’ labels. The drugs discussed include one intended to treat a rare form of muscular dystrophy and two supposedly abuse-deterrent opioid pain drugs.
March 2017
Spironolactone is a diuretic (water pill) that has been used for decades to treat certain patients with high blood pressure, heart failure, swelling (water retention) and other conditions. Find out who is most likely to benefit from using this drug and who should avoid it because of its dangerous adverse effects.
March 2017
Bipolar disorder, also known as manic depression, is a serious chronic mental illness that afflicts approximately 5.4 million people in the U.S. In this article, we review the benefits and safety of several drugs that are commonly used to treat this disorder.
March 2017
Learn about the unacceptable dangers posed by lorcaserin, a diet drug that was approved by the FDA in 2012 and that has similarities to the previously banned diet drug fenfluramine.
February 2017
One of the biggest-selling but most overprescribed classes of antibiotics in the U.S. is the family called fluoroquinolones. Learn why the FDA required the addition of new black-box warnings to the labels of these antibiotics that describe risks of several disabling and potentially permanent side effects.
February 2017
Worst Pills, Best Pills News editor Dr. Michael Carome discusses the dangerous giveaways to the pharmaceutical and medical device industries that are buried within the massive 21st Century Cures Act passed by the lame-duck Congress in December 2016.
February 2017
Beta blockers have long been a mainstay of hypertension drug treatment. While these drugs remain useful for some patients, we now no longer recommend them as the starting treatment for hypertension except in special circumstances. Read this article to find out why our views on beta blockers have changed.
February 2017
This article presents the results of new research showing that many parents make significant errors when measuring the dose of liquid medications for their children. Learn how to minimize dosing errors when administering children’s liquid medications.
February 2017
From 2000 to 2014, almost half a million people died of drug overdoses in the U.S. Many of these deaths were fatal opioid overdoses, which have quadrupled in the U.S. since 1999. Learn why buprenorphine now outpaces methadone as a treatment of choice for opioid addiction.
February 2017
In this month's Questions & Answers section, we respond to two readers' important questions about our recent article about the treatment of attention deficit hyperactivity disorder.
January 2017
Falls remain by far the leading cause of injuries among adults age 65 and older in the U.S. In this article, we identify many of the drugs that can increase your risk of falling and offer advice on how to protect yourself from fall-related injuries.
January 2017
Worst Pills, Best Pills News editor Dr. Michael Carome discusses highlights of the debate between the pharmaceutical and medical device industry and patient safety advocates at a recent FDA public hearing regarding the agency’s rules on off-label promotion — the pharmaceutical and medical device industry practice of promoting prod¬ucts for unapproved uses.
January 2017
Keeping high blood pressure under control is essential to preventing long-term complications of hypertension, including cardiovascular disease, stroke and kidney failure. Learn about the steps you can take to boost your adherence to your blood pressure medication treatment.
January 2017
Find out why the risks of linaclotide far exceed its benefits for treating patients with irritable bowel syndrome and constipation, and learn about safer alternative treatments for these conditions.
January 2017
In October 2014, Public Citizen joined four other consumer advocacy and research groups to petition the FDA to strengthen the existing black-box warning on the label of the smoking cessation drug varenicline. Find out why the FDA now is considering moving recklessly in the opposite direction by removing the black-box warning from the label.
January 2017
In this month Questions & Answers section, we respond to a reader's question about whether calcium-containing antacids, such as TUMS, for heartburn may increase the risk of adverse cardiovascular events.
December 2016
The ever-increasing prices for prescription medications are often in the news these days, with some products carrying eye-popping price tags of more than $100,000 per year. Typically the highest prices are for newer, brand-name products. Yet a more surprising pricing story has begun to emerge over the past few years: the rising cost of generic medications.
December 2016
Learn why the decision by FDA’s leaders to approve a new medication for a rare muscle disorder, over the strenuous objections of the agency’s scientific experts, threatens to undermine public health.
December 2016
In this article, we explain why FDA-approved bioidentical hormone medications are preferred over custom-mixed (compounded) products for treating hormone-related disorders.
December 2016
In this article, we explore recent research showing that the older drug levodopa-carbidopa has a more favorable benefit-risk balance than ropinirole and other newer dopamine agonists for initial treatment of early Parkinson’s disease.
December 2016
Find out why Public Citizen’s Health Research Group has designated suvorexant as Do Not Use and what steps you can take to improve your sleep without relying on medications.
November 2016
Worst Pills, Best Pills News editor Dr. Michael Carome discusses how drug manufacturer Mylan assumed the banner of most infamous price gouger among pharmaceutical corporations in the U.S.
November 2016
For many years we have recommended never combining the high blood pressure medications aliskiren and ACE inhibitors. In this article, we review new research showing that this combination of drugs poses unacceptable risks in heart failure patients and provides no additional benefit over an ACE inhibitor alone.
November 2016
Not all thyroid hormone replacement medications are the same, and some are not even approved for use in the U.S. Learn which of these medications you should take — and which ones you should not take — to treat hypothyroidism (underactive thyroid).
November 2016
TOUJEO is a newer, long-acting, once-daily insulin approved by the Food and Drug Administration for the treatment of Type 1 and Type 2 diabetes in adults. Learn why you should avoid using this drug until at least 2022.
November 2016
In this month's News Brief section, we report on action taken by the Food and Drug Administration to add important new warnings to the labeling of all opioid and benzodiazepines drugs.
November 2016
Find out which commonly used antibiotic can cause psychosis, hallucinations, delirium, mood disorders, sleep disturbances and cognitive impairment.
October 2016
The number of children diagnosed with attention deficit hyperactivity disorder (ADHD) and treated with drugs has increased dramatically over the past decade. Learn the steps needed for an accurate ADHD diagnosis and understand the variety of treatments available before working with your child's doctor on a plan for treatment.
October 2016
Worst Pills, Best Pills News editor Dr. Michael Carome discusses the implications of a recent Public Citizen report showing that the overwhelming majority of patient groups that opposed a recent Medicare Part B plan to rein in drug costs have financial ties to pharmaceutical corporations.
October 2016
Bacterial skin infections are very common, resulting in several million visits to health care professionals annually. In this article, we explain the best treatment options for different types of bacterial skin infections.
October 2016
Over the past year, the Food and Drug Administration has issued a series of new warnings about serious and, in some cases, potentially fatal events linked to the newest class of diabetes drugs. These drugs, known as "flozins," are being heavily promoted in TV ads. Learn more about these newly identified dangers and why you should avoid all flozins.
October 2016
For children younger than 6 with ADHD, drug treatment is not the first choice. Find out the non-drug approach recommended by the American Academy of Pediatrics that parents and teachers can use to manage these very young ADHD patients.
October 2016
In this month Questions & Answers section, we respond to a reader's question asking for advice on how patients can find out if their doctors have taken money from the pharmaceutical industry.
September 2016
Find out which leading drugmaker has reaped billions of dollars in profits in the U.S. by charging unaffordable prices for its hepatitis C drugs, then shifting those profits offshore, enabling it to dodge nearly $10 billion in U.S. taxes.
September 2016
The FDA's approval of lesinurad despite serious safety concerns and limited evidence of benefits represents another example of the agency's reckless approach to the oversight of prescription drugs. Read our independent analysis of the data considered by the FDA when it approved this new gout drug and our assessment of why you should not use it.
September 2016
In 2004, Parke-Davis, the manufacturer of gabapentin (NEURONTIN), pleaded guilty to felony charges for illegal marketing of the drug, including for "off-label" uses not approved by the FDA. Protect yourself and your loved ones from unnecessary risk by learning which claims about gabapentin are supported by sound science and which are not.
September 2016
In this month Questions & Answers section, we offer advice on how readers can approach their doctors about medicines that we have designated as either Do Not Use or Do Not Use for Seven Years.
September 2016
Readers of Worst Pills, Best Pills News are aware that all benzodiazepine tranquilizers and sleeping pills, except for alprazolam (XANAX) and clonazepam (KLONOPIN), are now considered Do Not Use drugs. In this article, we explain why combining these drugs with opioid painkillers could kill you.
September 2016
Dabigatran is one of several new, heavily promoted anticoagulant drugs (blood thinners) approved by the FDA in recent years. Learn why you should ignore the television ads and not use this dangerous drug.
August 2016
Worst Pills, Best Pills News editor Dr. Michael Carome discusses the recent arrest of two former drug company employees for allegedly running a brazen scheme to bribe doctors to prescribe millions of dollars' worth of a powerful synthetic opioid.
August 2016
Incretin mimetics, one of the newer classes of diabetes drugs, are widely prescribed in the U.S. Find out why Public Citizen's Health Research Group recommends against using any of these medications.
August 2016
Beta blockers, which are widely used and effective in treating high blood pressure, heart disease and heart failure, are often started in patients prior to surgery in an effort to prevent cardiovascular complications. Learn why starting beta blockers immediately before undergoing surgery may be dangerous.
August 2016
In this article, we review new research linking use of the heartburn and ulcer medications known as proton pump inhibitors to an increased risk of dementia.
August 2016
Numerous high-dose dietary supplements are now broadly marketed to promote general eye health. Find out who can benefit from — and who should not take — these supplements and which ingredients to look for on the label.
August 2016
In this month's news briefs, we report on the FDA's decision to require new black-box warnings in the labeling of all immediate-release opioid drugs about the risks of abuse, addiction, overdose and death, as well as the agency's recent drug safety alert reminding consumers not to purchase over-the-counter chelation products. We also discuss the decision of a major drugmaker to terminate its involvement in the marketing of an inhaled form of insulin.
July 2016
Public Citizen's Health Research Group has long warned about the serious risks of the commonly used group of heartburn drugs known as proton pump inhibitors. In this article, we discuss new research suggesting that chronic kidney disease is another potential side effect of these drugs.
July 2016
When health care providers prescribe antibiotics to patients who do not need them, these drugs endanger both the patients taking them and the public at large. Find out why.
July 2016
Many people take vitamin supplements to promote bone and muscle health. But taking too much vitamin D may have dangerous consequences. Read this article to find out how much vitamin D is safe.
July 2016
Summer is a terrific time for healthy outdoor activities, such as walking, hiking, biking and swim¬ming. But for an unlucky few, certain medications can lead to adverse skin reactions following exposure to the sun. Find out whether you are at risk and how to protect yourself.
July 2016
For most people with hair loss, the condition usually is age-related or due to the genes they inherited from their parents. But for some patients, the cause of the problem can be found in the medicine cabinet. Learn about some commonly used medications that can cause hair loss.
June 2016
Worst Pills, Best Pills News editor Dr. Michael Carome highlights new research showing that the large sums of money pharmaceutical and medical device companies funnel to physicians too often play an inappropriate role in physicians’ prescribing decisions.
June 2016
Symptoms of benign (noncancerous) prostate enlargement afflict most men age 60 or older. In this article, we discuss new research showing that a group of drugs often used to treat this condition slightly increase the risk of falls and fractures. We offer important advice on how to minimize these risks.
June 2016
Drug labels provide important information regarding the benefits and risks of prescription medications. In this article, we offer guidance on where to find these drug labels and identify the sections of the label that provide the most useful information for patients.
June 2016
Shingles is a very common disease caused by the chicken (herpes zoster) virus. Elderly adults are particularly vulnerable to developing this painful and sometimes debilitating condition. Learn the facts about shingles and how you can lower your risk of developing it.
June 2016
Tiotropium (SPIRIVA) is a frequently prescribed drug administered via oral inhalers for chronic obstructive pulmonary disease (COPD). The drug is available in two types of inhaler devices. One of these should never be used. Find out which one.
May 2016
Urinary tract infections (UTIs) are very common, accounting for more than 10 million visits to doctors’ offices and 2 million to 3 million emergency department visits in the U.S. in 2007. Hear our take on which antibiotics are safest for treating these infections.
May 2016
Animated characters are a feature of an increasing number of TV ads for prescription drugs. Find out why the FDA is concerned that these characters may mislead consumers about the risks and benefits of the medications being promoted and what the agency intends to do about this.
May 2016
Memantine (NAMENDA) recently has been one of the drugs for Alzheimer’s disease most heavily promoted through direct-to-consumer advertising. Learn why we have designated memantine as Do Not Use.
May 2016
In this month’s Question & Answer feature, we respond to a reader’s request to explain why we recommend use of bisphosphonates for certain patients with osteoporosis despite our warnings about their risks.
May 2016
Last month, we discussed the risks and benefits of second- and third-generation antihistamines for treatment of nasal allergies. In this second of a two-part series, we explain why first-generation or "sedating" antihistamines are not a safe option for managing nasal allergies.
May 2016
For various reasons, many prescribed medications go unused. Such leftover medications can pose a hazard to family members, especially young children, and the environment. Find out the best ways to safely dispose of unused prescription medications.
April 2016
Worst Pills, Best Pills News editor Dr. Michael Carome explains why the new FDA Commissioner, who was confirmed by the Senate in February, was a poor choice to lead such a critically important agency of the U.S. Public Health Service.
April 2016
If you watch TV, you likely have seen ads touting the advantages of the new oral antico-agulant (blood thinner) rivaroxaban (XARELTO). Learn why we have designated this drug as Do Not Use for Seven Years (until at least July 2018).
April 2016
With spring time pollen counts soaring, many patients with seasonal nasal allergies will be looking for relief from allergy medications. Learn the best available treatments to stay safe and relatively symptom-free during allergy season and throughout the year.
April 2016
Low back pain is the fifth most common reason for outpatient doc¬tor visits and leads to 2.6 million emergency room visits in the U.S. every year. This article reviews results of the newest research on which pain relievers are safest and most effective for managing severe low back pain.
April 2016
In this article, we discuss results of new research linking the widely overused fluoroquinolone antibiotics to an increased risk of life-threatening damage to the body’s largest blood vessel, the aorta.
March 2016
Learn about six new drugs approved by the FDA in 2015 that Worst Pills, Best Pills News has identified as dangerous or ineffective. The drugs include two for lowering high cholesterol levels, one for removing excess fat below the chin, and another for treating gout, among others.
March 2016
Since 1999, more than 140,000 people in the U.S. have died from overdoses related to opioid pain medication. Worst Pills, Best Pills News editor Dr. Michael Carome applauds a new proposal from the Centers for Disease Control and Prevention to rein in the overprescribing of opioids and reverse this rising death toll.
March 2016
In this month’s news brief, we report on the Department of Justice taking long-overdue action against a Dallas-area compounding pharmacy for making contaminated drugs and for unsanitary production conditions.
March 2016
Too often, consumers are exposed to dietary supplements that have been spiked illegally with hidden drug ingredients or contaminated with other potentially dangerous substances. In this article, we report on recent legal actions taken by the FDA, the Department of Justice, and the Federal Trade Commission to stem the flow of these dangerous products.
March 2016
This article explores one of the newer classes of drugs for treating depression: serotonin-norepinephrine reuptake inhibitors (SNRIs). Find out which SNRIs are safe for treating depression and which should be avoided.
March 2016
Patients with rheumatoid arthritis have a wide array of medication choices for reducing joint pain and inflammation and slowing the progression of joint damage. The most potent such drugs are a group of medications known as disease-modifying anti-rheumatic drugs (DMARDs). Learn about the serious risks posed by these drugs and when they should be used.
February 2016
Worst Pills, Best Pills News editor Dr. Michael Carome expresses outrage over disclosures that senior Food and Drug Administration representatives colluded with a leading medical device trade association in writing legislation that would weaken regulatory standards for medical devices.
February 2016
St. John’s wort, an over-the-counter herbal supplement, has been around for centuries, and many patients have been using it in recent years to self-medicate for depression. In this article, we explain why St. John’s wort should not be used to treat this disease.
February 2016
Allopurinol (LOPURIN, ZYLOPRIM) is an appropriate first-choice drug for treating gout and kidney stones caused by excess uric acid levels in the blood or urine. But you should not use allopurinol to treat high blood uric acid levels if you don’t have these disorders. Read this article to learn why.
February 2016
Urinary incontinence, or loss of bladder control, is a common and often embarrassing problem that can have a huge impact on quality of life. Find out which drugs can cause this problem.
February 2016
In our news brief this month, we report on two recent warnings issued by the Food and Drug Administration about the diabetes drugs known as SGLT2 inhibitors, more commonly known as “flozins.” This family of drugs, all designated as Do Not Use, includes canagliflozin (INVOKAMET, INVOKANA), dapagliflozin (FARXIGA) and empagliflozin (JARDIANCE).
February 2016
Statins have long been a mainstay of treatment for patients with high LDL (“bad” cholesterol) and cardiovascular disease. In this article, we explain why you should avoid combining a nonstatin cholesterol-lowering dug with a statin.
January 2016
Worst Pills, Best Pills News editor Dr. Michael Carome discusses the implications of new research showing that patients taking prescription drugs for uses not approved by the Food and Drug Administration are more likely to suffer adverse reactions.
January 2016
Learn why Health Canada, an agency similar to the Food and Drug Administration, warned Canadian consumers not to combine repaglinide-containing diabetes medications (PRANDIN or PRANDIMET) with the anti-platelet drug clopidogrel (PLAVIX).
January 2016
In this month’s Questions & Answers feature, we address readers’ questions about using several non-traditional treatments for osteoarthritis pain, including cetyl myristoleate, s-adenosylmethionine or SAMe, and aloe vera.
January 2016
For the approximately 5 million Americans suffering from chronic heart failure, there is a wide array of lifesaving drug treatments. Find out our take on the most recent expert guidelines for treating this disease.
January 2016
In this article, we review results from a well-designed clinical trial funded by the National Institutes of Health that debunks the cognitive health claims for dietary supplements containing omega-3 fatty acids or the antioxidants lutein and zeaxanthin.
January 2016
Patients taking drugs to treat high blood pressure often are directed to stop their medication at least 24 hours before surgery. Learn why restarting these medications as soon as possible after surgery could save your life.
December 2015
Find out why this new form of insulin, which is inhaled as a powder, is a dangerous alternative to injected forms of insulin and never should have been approved by the Food and Drug Administration for the treatment of diabetes.
December 2015
Worst Pills, Best Pills News editor Dr. Michael Carome examines the possible implications of the rising tide of public anger over the high prices charged by pharma¬ceutical companies in the U.S.
December 2015
Some powerful antipsychotic drugs originally developed to treat schizophrenia now have been approved to treat depression. Learn about the serious side effects of these drugs that make it advisable to explore other, safer options for managing depression.
December 2015
In this article, we review new evidence suggesting that long-acting opioids are associated with a higher risk of unintentional life-threatening over¬doses than short-acting forms of these drugs.
December 2015
A recent study revealed that some cardiologists prescribe blood thinners to atrial fibrillation patients who don’t need them because their risk of stroke is very low. Read this article to learn who these patients are.
December 2015
In our news brief this month, we discuss Public Citizen's recent petition to the Food and Drug Administration to correct the labeling of a new drug approved for treatment of an uncommon sleep disorder in totally blind people. The agency mistakenly approved a label that expanded the drug's use to nonblind patients.
November 2015
Worst Pills, Best Pills News editor Dr. Michael Carome discusses disturbing results from a recent study revealing that pharmaceutical companies too often violate the law by failing to promptly report unexpected serious adverse events linked to use of their products. Delays in report¬ing such events undermine a key component of our nation’s system for monitoring the safety of prescription drugs.
November 2015
In our news brief this month, we report on the Food and Drug Administration's reckless decision to approve flibanserin (ADDYI), the first drug to treat hypo¬active sexual desire disorder in premenopausal women.
November 2015
Insulin pumps have been promoted as an important technological advancement in diabetes care. Find out why Public Citizen’s Health Research Group considers these devices too dangerous to use.
November 2015
In this article, we provide a detailed update of the various drugs available for the long-term management of chronic obstructive pulmonary disease (COPD). Learn which drugs are safest for treating COPD and which ones we have designated as Do Not Use.
November 2015
For most people with hearing loss, the condition likely is age-related or due to long-term exposure to loud noise. But for some patients, the cause of the problem can be found in the medicine cabinet. Learn about some commonly used medications that can cause hearing disorders.
October 2015
In this month's Question and Answers feature, we respond to readers' questions about our June article on injected drugs for age-related macular degeneration.
October 2015
Learn more about a recent federal court decision that threatens to return us to the days of the late 19th and early 20th centuries, when snake-oil salesmen touted "remedies" that were too often ineffective — and sometimes dangerous.
October 2015
Find out why the recently approved high-dose form of liraglutide, which was originally marketed for treatment of Type 2 diabetes, is not a safe option for managing weight loss
October 2015
Fluoroquinolones are the biggest-selling and most overprescribed classes of antibiotics in the U.S. Learn why Public Citizen's Health Research Group designates two of the five available fluoroquinolones as Do Not Use and why the other three should be used only in limited circumstances.
October 2015
In this article, we discuss the most recent evidence linking the use of hormone replacement therapy in women after menopause to increased risk of heart attacks, strokes and other serious cardiovascular problems.
September 2015
In our news brief this month, we report on a recent FDA safety warning about permanent disfiguring skin color changes caused by a medication patch used for treating attention-deficit hyperactivity disorder.
September 2015
Last year, the FDA proposed a guidance that would give drug com¬panies free rein to tell doctors that medications are less dangerous than the FDA has concluded. Find out the serious threat posed by this guidance and action you can take to stop it.
September 2015
In response to our recent article on osteoporosis, a reader asks for our opinion regarding the use of the dietary supplement PROSTEON for this disorder. See our independent assessment of this supplement.
September 2015
In July, the FDA announced that the agency will be requiring manufacturers to stop selling 16 types of prescription ear drops. These drugs have never been approved as safe and effective for their marketed uses. Find out the names of these drugs so you can protect yourself and your family members from these potentially harmful and unproven remedies.
September 2015
Don't fall prey to a drug company's slick marketing campaign of a dangerous drug recently approved by the FDA for treatment of a newly designated disease called "binge eating disorder."
September 2015
Worst Pills, Best Pills News editor Dr. Michael Carome discusses the FDA’s recent safety alert announcing that the agency is strengthening existing warnings in the product labels for all non-aspirin nonsteroidal anti-inflammatory drugs about increased risk of heart attack and stroke.
September 2015
Learn why the new combination of conjugated estrogens plus bazedoxifene (DUAVEE) is a bad choice for treating hot flashes and improving bone health in menopausal women.
August 2015
Learn about one disturbing pharmaceutical industry trend contributing to skyrocketing prices of certain lifesaving medications that have been on the market for decades.
August 2015
Proton pump inhibitors, a widely used class of heartburn drugs, and essentially all antibiotics increase your risk of C. difficile infections, which can cause severe, even life-threatening diarrhea illness. Read this article to find out how to protect yourself from this dangerous infection.
August 2015
Asthma is a common disease afflicting more than 16 million American adults and 6 million children. Find out the safest and most effective options for managing this chronic lung disease.
August 2015
A reader asks whether a recent change in her thyroid disorder symptoms could have been caused by switching from a brand name to generic thyroid hormone replacement drug. See our advice regarding concerns about such thyroid medication changes.
August 2015
The airwaves are filled with ads promoting the newest class of diabetes medications, often referred to as “flozins.” In this article, we review the serious safety concerns that have prompted us to designate all flozins as Do Not Use.
August 2015
Learn about recent evidence suggesting that anticholinergic drugs — which include many antidepressants, antihistamines and overactive bladder control medications — may increase the risk for developing Alzheimer’s disease and other types of dementia in the elderly.
July 2015
In a recent complaint to the FDA, we took several makers of diabetes drugs to task for direct-to-consumer ads that promote the drugs for unapproved uses. Find out the names of the drugs targeted in our complaint and the nature of the off-label uses being promoted in the ads.
July 2015
Recent research revealed that many patients consume alcohol while using drugs that may can cause dangerous side effects when combined with alcohol. Read this article to learn about the many ways alcohol can adversely interact with prescription and over-the-counter medications.
July 2015
Worst Pills, Best Pills News editor Dr. Michael Carome discusses an unusual lawsuit filed by a drug company against the FDA that seeks to bypass the agency’s drug approval process and the prohibition against off-label promotion.
July 2015
Patients with osteoarthritis have many treatment options. Find out which ones are safest for relieving osteoarthritis pain.
July 2015
In this month’s news brief, we discuss Public Citizen’s recent petition to the FDA calling for a ban on all oral forms of a commonly used antifungal drug.
June 2015
Find out which commonly used antibiotic can increase your risk of sudden death if it is combined with either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), which are among the most widely prescribed drugs in the U.S.
June 2015
Worst Pills, Best Pills News editor Dr. Michael Carome discusses three recent events that reinforce the importance of being wary when considering the use of dietary supplements.
June 2015
In our news briefs this month, we report on a recent FDA warning about the dangers of relying on over-the-counter homeopathic products to treat asthma. We also discuss the FDA’s very first approval of a biosimilar, which is essentially a generic version of a biologic drug.
June 2015
Learn why increasing the amount of potassium in your diet can help lower your blood pressure and reduce your risk of suffering a stroke. To help readers assess their potassium intake, we offer a list of potassium-rich foods.
June 2015
Health Canada, the Canadian equivalent of the U.S. Food and Drug Administration, recently warned physicians and patients about safety concerns regarding two drugs commonly used to treat Alzheimer’s disease. Find out the names of these drugs and the newly identified serious adverse events linked to them.
June 2015
Age-related macular degeneration is a leading cause of blindness and serious decreases in vision among patients age 50 and older. In this article, we provide our independent expert assessment of the available drug treatments for this disorder.
May 2015
Drug treatment can prevent broken bones in some women with osteoporosis. But drugs are not always necessary and can cause harmful side effects, especially when treatment lasts longer than needed. Read this article to learn who should take osteoporosis drugs, which drugs to take and for how long.
May 2015
On March 3, the Food and Drug Administration finally announced that it was requiring that the labels of all approved prescription testosterone products include a warning about the possible increased risk of heart attacks and strokes. Worst Pills, Best Pills News editor Dr. Michael Carome criticizes the agency for recklessly dragging its feet prior to requiring these warnings.
May 2015
For years, Public Citizen’s Health Research Group has designated tramadol as a Do Not Use drug. We discuss results of a new study providing an additional reason for avoiding tramadol: The drug has been linked to the occurrence of dangerously low blood sugar.
May 2015
Recent studies have confirmed that a significant cause of falls in the elderly is medication (and often overmedication) with drugs for high blood pressure, resulting in blood pressures low enough to increase the risk of falling — with attendant fractures and head injuries. Learn who is most at risk and what the blood pressure goal should be for patients age 60 or older.
May 2015
This article discusses evidence from recent research that calls into question the benefits of taking drugs, such as niacin, to raise blood levels of high-density lipoprotein (HDL), often called “good” cholesterol.
April 2015
Patients should never take more than one of the following drugs used to treat high blood pressure at the same time: an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), and aliskiren. Learn why doing so could have serious, even fatal consequences.
April 2015
Worst Pills, Best Pills News editor Dr. Michael Carome reviews a new scheme being perpetrated by some health insurance companies in order to maximize profits: to discourage certain high-cost patients from enrolling in their health plans.
April 2015
Rosacea is a chronic skin condition affecting 13 million Americans. Find out steps to take to prevent symptom flare-ups, and learn which topical drug therapies are most effective and safest for treating this condition.
April 2015
In December 2014, a federal grand jury in Boston indicted 14 executives and employees of a Massachusetts compounding phar¬macy on 131 criminal charges in connec¬tion with a deadly nationwide fungal meningitis outbreak. Learn the shocking details of how the company put the lives of thousands of patients around the country at risk.
April 2015
This article discusses recent research showing increasing frequency of benzodiazepine use as people get older in the U.S. We also review results of a new study showing a possible link between use of these drugs and an increased risk of developing Alzheimer’s disease.
March 2015
Patients often wonder what steps they can take to minimize their chances of suffering a serious adverse drug reaction. This article reviews 10 simple rules developed by Public Citizen’s Health Research Group for ensuring safer drug use.
March 2015
In his editor’s column, Dr. Michael Carome discusses how companies that make biologic medications are using their political clout to price-gouge and maintain indefinite monopolies on their products, costing consumers billions of dollars.
March 2015
In October 2014, Public Citizen joined four other consumer advocacy and research groups to petition the FDA to require stronger warnings on the label of the smoking cessation drug varenicline (CHANTIX). Learn about the drug’s severe psychiatric and neurological side effects that could potentially lead to fatal consequences.
March 2015
Pharmaceutical companies market patient assistance programs as a goodwill solution to assist patients who are struggling to pay for expensive prescription drugs. Find out why these programs may encourage physicians to prescribe more expensive drugs instead of less expensive, equally effective alternatives, including generic products.
March 2015
The most recently issued prescribing guidelines for cholesterol-lowering statin drugs were partly based on a new patient risk calculator that significantly overestimates patients’ risk of developing cardiovascular disease. Learn how this overestimation will lead to overprescribing of statin drugs to patients who will not benefit from using them.
March 2015
In our news brief this month, we report on the FDA’s recent approval of a new, high-dose, extended-release formulation of the opioid drug oxycodone (HYSLINGA). Although this new version of the drug is designed to deter abuse, it may be more dangerous than other oxycodone products. Read this article to find out why.
March 2015
In a new feature that will appear periodically in issues of Worst Pills, Best Pills News, we respond to some selected questions posed by our readers. In this month’s issue, we respond to questions regarding (a) whether the widely advertised drug adalimumab (HUMIRA) is a new wonder drug, and (b) what should you do if you are already taking rivaroxaban (XARELTO).
February 2015
Patients who have difficulty swallowing pills will sometimes crush tablets or open capsules and sprinkle the resulting powder, fragments or granules into food or liquids. Other patients will resort to chewing their pills before swallowing. Find out the dangers posed by taking such measures.
February 2015
In 2014, alarm bells sounded as the prices of many commonly used generic drugs spiked, in some cases by staggering amounts. Read Dr. Michael Carome’s column to find out how Congress and the Justice Department are investigating this price gouging.
February 2015
After a more than three-year delay and a Public Citizen lawsuit filed against the FDA, the agency finally responded to our petition for stronger label warnings on a class of medications, known as proton pump inhibitors, commonly used to treat heartburn. This article discusses the new warnings that the FDA has required in response to our petition.
February 2015
This reprint of a British Medical Journal column by Health Research Group founder and former Worst Pills, Best Pills News editor Dr. Sidney Wolfe discusses how user fees paid by the drug industry to the FDA have compromised the agency’s drug review process and undermined drug safety.
February 2015
In 2014, the U.S. Preventive Services Task Force issued new recommendations regarding the use of low-dose aspirin by pregnant women to reduce the risk of developing preeclampsia, a potentially life-threatening condition. Learn about the risk factors for this serious condition and who is most likely to benefit from taking low-dose aspirin.
January 2015
Find out which drugs used to treat Parkinson’s disease, restless legs syndrome and the hormone disorder hyperprolactinemia can cause uncontrollable impulsive behaviors, including compulsive gambling and shopping, hypersexuality, and binge eating.
January 2015
Given the changes in the makeup of the U.S. Senate following the November elections, Congress is likely to pass new legislation that will weaken the FDA’s rules for ensuring that drugs are safe and effective. Read Dr. Michael Carome’s column to find out why.
January 2015
One of the supposed major advantages of the anticoagulant dabigatran (PRADAXA) touted by its manufacturer is that patients can take a fixed dose of the drug and do not need to undergo periodic monitoring with blood tests to adjust the dose. This article presents new research data that casts doubt on the safety of this fixed-dose approach.
January 2015
In a new feature that will appear periodically in issues of Worst Pills, Best Pills News, we highlight recent important news items related to drug safety. In this month’s news briefs, we report on (a) a recent FDA warning about over-the-counter drugs that can make you drowsy; (b) action taken by the Federal Trade Commission against a company for false advertising of green coffee beans as a miracle weight loss remedy; and (c) the American Academy of Neurology’s position statement cautioning against the use of narcotic drugs for treatment of chronic noncancer pain.
January 2015
Since 2003, Public Citizen’s Health Research Group has advised readers not to use rosuvastatin (CRESTOR). Learn about the newest research indicating that rosuvastatin is more dangerous than other available statin drugs.
January 2015
The FDA recently approved a drug for treatment of a sleep disorder that occurs primarily in people who are totally blind. Find out the name of this new drug and learn about concerns that the company may seek to market the drug to a much wider population of patients who are not blind.
December 2014
LYRICA is heavily promoted for treatment of chronic pain due to fibromyalgia and other conditions. Learn why Public Citizen’s Health Research Group advises against using the drug to treat these painful conditions.
December 2014
In his editor’s column, Dr. Michael Carome discusses the implications of data recently released by the federal government that reveals the staggering amount of money drug and medical device companies are paying doctors and teaching hospitals.
December 2014
In this review of restless legs syndrome (RLS), we discuss the limitations of the available drug treatments for the disorder and the nondrug approaches that are the safest options for people with mild to moderate RLS symptoms.
December 2014
Read about the dangers posed by albiglutide, yet another new diabetes drug designated as Do Not Use by Public Citizen’s Health Research Group because it offers no unique benefits but does pose unique risks.
December 2014
If you are one of the millions of patients in the U.S. who take blood thinners on a long-term basis to prevent potentially harmful clots in the heart, veins or arteries, read this article to learn why you should avoid taking NSAIDS or aspirin unless absolutely necessary.
November 2014
One year ago, the American College of Cardiology and the American Heart Association released controversial new guidelines on treating high cholesterol. Get Public Citizen’s Health Research Group’s independent take on these new guidelines.
November 2014
In his editor’s column, Dr. Carome takes the FDA to task for using the agency’s homepage to promote specific medical devices and medications. By becoming the promoter of the products it regulates, the FDA undermines its objectivity and independence.
November 2014
Serious adverse reactions often occur when different drugs are taken together. Find out which antibiotics diabetic patients taking glipizide (GLUCOTROL, GLUCOTROL XL) or glyburide (DIABETA, GLUCOVANCE, GLYNASE) should avoid because of an increased risk of life-threatening drops in blood sugar levels.
November 2014
For many years, Public Citizen’s Health Research Group has recommended against using sleeping pills to treat insomnia. This article reviews the serious risks of the newest sleep medication approved by the FDA.
November 2014
Learn about new warnings recently issued by the FDA about the bone drug denosumab, a medicine previously designated as Do Not Use by Public Citizen’s Health Research Group.
October 2014
Learn why benzocaine-containing gels and liquids should never be used to treat teething discomfort and about the actions Public Citizen’s Health Research Group has taken to end the use of these dangerous products in infants.
October 2014
Stopping beneficial medications threatens patient health. In his monthly editor’s column, Dr. Michael Carome discusses an intriguing new study showing that patients are more likely to stop taking important medications when pharmacies substitute one generic version of a drug for another differing in shape or color.
October 2014
Many men with localized prostate cancer are being treated unnecessarily with a commonly used class of drugs. Find out which drugs are being overused.
October 2014
The Food and Drug Administration’s recent recommendation to lower the starting dose of the insomnia drug eszopiclone is insufficient to address the drug’s dangers. Learn why Public Citizen’s Health Research Group continues to designate eszopiclone as Do Not Use.
October 2014
Many commonly used over-the-counter acne products pose a risk of serious allergic reactions in children and adults. This article provides information on how to minimize the risk when starting treatment with one of these products.
September 2014
Learn about the many dangers of one of the newest diabetes drugs approved in the U.S., dapagliflozin, which has been designated as Do Not Use by Public Citizen’s Health Research Group.
September 2014
The recent refusal of two companies to immediately recall potentially contaminated sterile drugs when requested to do so by the Food and Drug Administration highlights a serious gap in the agency’s regulatory authority. Learn more about the companies involved and the action that must be taken by Congress to address the public health threat posed by such industry obstinacy.
September 2014
In December 2013, new guidelines for treatment of high blood pressure were issued by a group of experts appointed by the National Institutes of Health. The guidelines stirred much controversy in the medical community. Get the Public Citizen Health Research Group’s independent take on these new guidelines.
September 2014
Perhaps you have seen some of the recent newspaper coverage of a National Cancer Institute-funded study suggesting that long-term aspirin use may be associated with a decreased risk of pancreatic cancer. In this article, Public Citizen’s Health Research Group reviews the study, compares it with earlier evidence and offers our recommendations.
September 2014
News stories often excitedly report about the results of the latest medical study. Learn about the three main types of medical studies and find out which type provides the most reliable information for assessing the risks and benefits of drugs and other medical treatments.
August 2014
Atrial fibrillation is one of the most common heart rhythm disorders, afflicting more than 2.7 million Americans. Learn about the most recent guidelines for treating this disorder, issued by the American College of Cardiology and the American Heart Association, and about Public Citizen’s Health Research Group’s assessment of those guidelines.
August 2014
The FDA recently required manufacturers of all approved testosterone products to include a general warning on the product labeling about the risk of developing blood clots in veins. Find out why the new warning is dangerously incomplete.
August 2014
Numerous advertisements in magazines and on television and the Internet tout the miraculous age-reversing and bodybuilding properties of synthetic growth hormone treatment. This article critically reviews the evidence surrounding these health claims.
August 2014
Learn why Public Citizen’s Health Research Group has designated the following three new Type 2 diabetes drugs as Do Not Use: alogliptin (NESINA), the combination of alogliptin and metformin (KAZANO), and the combination of alogliptin and pioglitazone (OSENI).
July 2014
For many years, Public Citizen’s Health Research Group has recommended against using tranquilizers and sleeping pills to treat insomnia and anxiety. This article presents new evidence linking use of these drugs to an increased risk of premature death.
July 2014
In his editor’s column, Dr. Carome takes the Food and Drug Administration (FDA) to task for its obsessive focus on drug approval times as a measure of agency success. Focusing on such metrics to assess the agency’s performance is misguided and dangerous.
July 2014
In 2007, the FDA enthusiastically suggested that newly available genetic tests would help doctors select the best dose of warfarin — one of the oldest and most widely prescribed blood thinners (anticoagulants) — for individual patients. Find out why the FDA’s enthusiasm about the promise of genetic testing in the management of warfarin dosing was premature and overstated.
July 2014
Dietary supplement companies tout the mineral selenium as possibly being able to reduce the risk of prostate cancer and other diseases. Learn about new evidence showing that high doses of selenium may actually increase the risk of prostate cancer.
July 2014
Steroid injections are very commonly used to treat back pain. Find out why Public Citizen’s Health Research Group now recommends against such treatment.
June 2014
Learn about the dangers of the heavily promoted drug ospemifene (OSPHENA), which was recently approved by the FDA to treat pain during sexual intercourse, and about much safer alternatives for treating this condition.
June 2014
In his editor’s column, Dr. Carome explains why the FDA’s distorted view of itself as a part¬ner with the pharmaceutical and medical device industries is incompatible with its role as the regulator of these industries and its mission to protect public health.
June 2014
Learn about new research that provides further evidence affirming our designation of celecoxib (CE¬LEBREX) as a Do Not Use drug and that has prompted us to reclassify diclofenac (VOLTAREN) from Limited Use to Do Not Use. Also find out which NSAIDs are least likely to cause adverse cardiovascular events, such as heart attacks and strokes.
June 2014
Clopidogrel is a widely used drug for reducing the risk of a new heart attack or stroke or cardiovascular death in patients who have had a recent heart attack, stroke or established pe-ripheral vascular disease. This article provides a detailed overview of the drug, including potential serious side effects and important precautions to follow when taking the drug.
May 2014
Learn about the dangers of using calcitonin-containing drugs for treatment of osteoporosis and find out why the Food and Drug Administration, in contrast to regulators in Canada and Europe, has acted recklessly by failing to ban nasal calcitonin products.
May 2014
In a desperate attempt to prevent the FDA’s November 2013 proposed rule on generic drug labeling from being finalized, the generic drug industry has offered up many groundless objections. In his editor’s column, Dr. Carome outlines the reasons why this rule must be implemented to ensure patient safety.
May 2014
The treatment options for Type 2 diabetes can be overwhelming. This article provides a comprehensive summary of our independent expert views on the best approaches for preventing and treating this common disease.
May 2014
If you have chronic obstructive pulmonary disease (COPD) and suffer or have suffered a heart attack, you should be treated with a beta blocker. Such treatment could save your life. Find out why and learn which beta blockers are safest for COPD patients.
April 2014
The FDA recently issued an alert about serious, and even fatal, kidney and heart risks from exceeding the recommended dose of over-the counter sodium phosphate products used to treat constipation. This article reviews the data that led to the FDA’s alert and provides advice on how to avoid these serious harms when taking sodium phosphate products.
April 2014
On Jan. 23, 2014, the FDA issued an order banning from the U.S. market any drugs produced by a factory owned by a leading manufacturer of generic drugs sold in the U.S. Read this commentary to find out why.
April 2014
Do not use the contraceptive drug NUVARING. Multiple studies have shown increased risk of blood clotting with drugs from the same family as NUVARING, and some have shown increased risk with NUVARING itself. Learn about safer, equally effective forms of contraception that are widely available.
April 2014
Learn about new evidence demonstrating the dangers of combining calcium channel blockers, a widely used class of drugs for treating high blood pressure, with the commonly used macrolide antibiotic clarithromycin and other related antibiotics. Also find out which macrolide antibiotic does not have this dangerous interaction with calcium channel blockers.
March 2014
There is a growing body of evidence indicating that testosterone treatment exposes men to an increased risk of adverse cardiovascular events, such as heart attack and stroke, as well as death.
This article reviews the results of two recently published studies that provide the most compelling evidence yet linking testosterone use to increased cardiovascular risk.
March 2014
In his first column as the editor of Worst Pills, Best Pills News, Dr. Michael Carome highlights the major flaws in a new federal law on compounded drugs and criticizes the FDA’s initial failure to clearly communicate to the public that compounded drugs are riskier than FDA-approved drugs.
March 2014
Learn about new drugs approved by the FDA in 2013 that Worst Pills Best Pills has identified as dangerous or ineffective. The drugs include two for diabetes, two for chronic obstructive pulmonary disease and an over-the-counter drug for overactive bladder, among others.
March 2014
Dr. Sidney Wolfe, founding editor of Worst Pills, Best Pills News, concludes that “there is pathological lack of corporate integrity in many drug companies.” Read this article to find out why.
February 2014
Do not use the newly approved diabetes drug INVOKANA. It offers no benefits over existing drugs but can result in serious risks, including hypotension and impaired kidney function, outlined in the article.
February 2014
Learn about the new editor of the Worst Pills, Best Pills newsletter and website, Dr. Michael Carome. The founding editor, Dr. Sidney Wolfe, will continue writing articles for the newsletter, including some of his new regular columns for the British Medical Journal.
February 2014
The FDA has announced that accidental exposure to a prescription narcotic patch has been fatal to children. Learn what precautions to take to protect the young people around you.
February 2014
Some degrees of depression are less likely to respond to treatment with an antidepressant. This article reviews the evidence and evaluates 27 different antidepressants, labeling many as Do Not Use or Limited Use.
January 2014
A newly marketed drug for treating hot flashes of menopause, BRISDELLE, is a lower dose of the familiar antidepressant PAXIL. This article discusses its risks and barely-evident effectiveness.
January 2014
When the manufacturer of the amphetamine ADDERALL criticized a Los Angeles boutique for selling T-shirts emblazoned with the drug’s name, it stated that the shirts “glorify[y] the misuse and diversion of a federally controlled prescription drug.” But the pharmaceutical company itself was cited by the Food and Drug Administration for overpromoting the drug to increase sales.
January 2014
The dangers of hormone replacement therapy (HRT) are in direct proportion to the length of time for which they are used. This article discusses strategies for keeping dosage and exposure to a minimum and recommends only using HRT for debilitating hot flash symptoms. Nondrug remedies for milder symptoms also are discussed.
January 2014
A dangerous and easily substituted antifungal drug presents yet another example of Europeans being more protected from dangerous medicines by their regulatory authorities than Americans.
December 2013
We oppose the use of all sleeping pills, based on experts’ findings that “nonpharmacological treatments not only cause fewer side effects, but … can sustain long-term improvements more successfully than pharmacological treatments.” Read this article to learn about some suggested nondrug approaches.
December 2013
Public Citizen stopped the chair of an FDA advisory committee from being the star attraction at an expensive conference for drug industry personnel. The planned session was intended to help the industry more easily get drugs approved by FDA advisory committees. Such activity demeans and undermines the crucial advisory committee process and highlights the need for an explicit FDA ethics policy.
December 2013
Yet another dietary supplement — this one intended for weight reduction and body-building — turns out to have life-threatening toxicity. In this case, the supplement has been linked to an outbreak of acute hepatitis.
December 2013
Are Americans more resistant to the risks and more likely to benefit from certain drugs than Europeans? Or is the European Medicines Agency (EMA) more resistant than the U.S. Food and Drug Administration (FDA) to the drug industry’s desire to get approval for drugs with unique risks but without compensating benefits? This article discusses two recently FDA-approved diet drugs deemed too unsafe for Europeans.
December 2013
Learn about the problems of a common over-the-counter laxative, widely used for children but never approved for their use. We discuss the preferable, safer alternatives for treating constipation.
November 2013
A familiar and heavily promoted remedy for colds, zinc has not been found to have very important benefits. This article analyzes studies purporting to show such benefits.
November 2013
This month will see the launch of yet another highly promoted drug to treat the hot flashes of menopause. Like almost all of its predecessors, it has clear risks and also lacks strong evidence of usefulness.
November 2013
Read about the benefits and risks of this vaccine for women, as well as the doubts about its usefulness for men.
November 2013
Lomitapide is approved to treat a rare genetic condition affecting approximately 300 people in the U.S. Yet it may ultimately be used to lower cholesterol in many more people, and it presents serious safety concerns.
October 2013
The federal government recently issued guidelines discouraging the use of antipsychotic medications to treat dementia in nursing home patients, promoting nonpharmacologic approaches to such treatment. Antipsychotic use among elderly patients is associated with increased chances of death, as well as other serious side effects.
October 2013
Several major drug companies have been implicated in scandals involving bribery of foreign doctors and illegal payments to foreign government officials. Learn which companies have paid penalties to the U.S. Securities and Exchange Commission to settle charges of corrupt foreign practices.
October 2013
If you or a loved one has chronic obstructive pulmonary disease (COPD), sometimes known as emphysema, and suffers from periodic acute COPD exacerbations requiring steroids, you should know that new research demonstrates that a five-day course of steroids for treating such exacerbations works just as well as a conventional 14-day course.
October 2013
The FDA recently issued a safety alert warning consumers that an intravenous fluid known as hydroxyethyl starch, sometimes used to replenish fluids in critically ill patients, can cause serious kidney damage and death. Learn about the basis for this warning and the available safer, less expensive alternatives.
September 2013
The FDA is considering relaxing the restrictions on the unacceptably dangerous drug rosiglitazone (AVANDIA) so that more people can access it, even while it remains banned in European countries.
September 2013
Many doctors lack knowledge of how to prescribe statins appropriately. Learn what happens with this is combined with patients watching TV ads about these drugs.
September 2013
This article discusses the latest example of a failed drug for treating Alzheimer's disease. It also examines other ineffective FDA-approved drugs for treating the condition, as well as recent promising evidence for successful nondrug approaches, especially for those with mild cognitive impairment.
September 2013
The overuse of acid reflux drugs in adults has been well documented. Even worse, there is now evidence of an 11-fold increase in the use of these drugs to treat infants, mostly due to a benign condition for which the risks clearly outweigh any benefit. The article discusses effective, time-honored, nondrug remedies for this benign condition.
August 2013
A new study casts serious doubt on the usefulness of long-popular niacin products to treat or prevent cardiovascular disease.
August 2013
CEOs of major drug companies are getting increasingly large benefits packages while their companies are paying massively larger criminal and civil penalties for illegal activities.
August 2013
If you are thinking of using newly approved over-the-counter oxybutyin (OXYTROL FOR WOMEN) to treat overactive bladder, find out why you should first check with your doctor and learn about possible adverse reactions.
August 2013
Six recently approved diabetes drugs have been linked to an increased risk of pancreatitis and possibly pancreatic cancer.
July 2013
Dr. Carome will be directing Public Citizen’s Health Research Group, but Dr. Wolfe will still be working on the issues he has previously focused on, such as drug safety.
July 2013
A recently published article mirrors our now-35-year-old publication “Off Diabetes Pills” in suggesting alternatives to pharmaceutical treatment for a large proportion of adult-onset diabetics.
July 2013
The article reviews evidence that one of the biggest-selling asthma drugs lacks evidence of a unique benefit and has been found to cause a variety of adverse psychiatric events, including nightmares, hallucinations and aggressiveness, especially in children.
July 2013
These two widely used diuretics (water pills) are equally effective in lowering blood pressure, but one of them is linked to many more adverse effects than the other.
July 2013
Learn tips for bypassing deceptive drug advertising to obtain truly unbiased, noncommercial health information.
June 2013
This article provides the newest information on a big-selling osteoporosis drug that can actually cause fractures as well as numerous other adverse reactions, further explaining its categorization on WorstPills.org as DO NOT USE.
June 2013
To protect yourself and others, when your doctor pulls out a pen to write a prescription for an antibiotic, you should ask him or her, especially if you are not feeling very sick: Do I really need this? And why?
June 2013
A recent study contradicted earlier beliefs by finding that vitamin D supplements (CALCIFEROL) given to people with osteoarthritis of the knee were ineffective in relieving knee pain or slowing damage to the knee joint.
June 2013
For people who have had heart attacks, strokes and other cardiovascular diseases, statins can prevent further damage. But for primary prevention — in people without such disease — a number of articles raise serious questions about whether the risks of statins outweigh the benefits.
June 2013
These updates provide new information that has become available since we published our last articles regarding these three categories of drugs.
May 2013
The article reviews evidence that quite often, to "enhance" the effectiveness of usually ineffective dietary supplements for weight loss, companies are illegally lacing such products with the dangerous, now-banned prescription weight-loss drug sibutramine (MERIDIA). Male-enhancement and muscle-building supplements also often illegally hide dangerous drugs in unknown quantities.
May 2013
A study documents how little information about important drug risks is disclosed by the drug salespeople who visit so many doctors. Their strategy for increasing sales: Accentuate the positive and almost entirely eliminate the negative about these medicines.
May 2013
The article discusses evidence that five widely used drugs for rheumatoid arthritis can increase the risk of shingles. If you are using one of these drugs, learn what you can do to reduce such risks.
May 2013
An update on last month's article about three relatively new, widely used stroke prevention drugs: dabigatran (PRADAXA), rivaroxaban (XARELTO) and apixaban (ELIQUIS).
May 2013
The article discusses possible breathing risks of nebivolol (BYSTOLIC)and how other, older drugs — just as effective as this relatively new high blood pressure drug — are preferred because more is known about their risks.
April 2013
Recent evidence points to increased acute kidney injury associated with combining nonsteroidal anti-inflammatory drugs (NSAIDs) with two antihypertensive drugs: a diuretic plus either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB). Find out the names of these drugs. This is especially important for patients with hypertension, diabetes, congestive heart failure or chronic kidney disease, because such patients are routinely treated with diuretics, ACE inhibitors and ARBs.
April 2013
Last summer, the European equivalent of the Food and Drug Administration told Europeans not to use a particular drug for osteoporosis. Learn about this drug, which has been used by more than 100,000 U.S. women since then despite evidence of increased cancer risk.
April 2013
Learn about three new drugs to prevent stroke – so new that their risks relative to those of a much older drug, warfarin (Coumadin), are unknown.
April 2013
Learn about new warnings concerning multiple formulations of a widely used sleeping pill. The levels of the drug remaining in the blood the morning after use may be high enough to impair activities requiring mental alertness, including driving.
March 2013
What kind of headache is not relieved by pain medications but actually caused by their frequent overuse? The article describes which painkillers can cause medication overuse headaches (MOH) when used too frequently over specified durations of time.
March 2013
Find out why the most commonly prescribed drug of any kind in the U.S., hydrocodone, needs tighter restrictions to prevent emergency room visits, overdose deaths and other serious consequences of its massive overuse. Production and use of hydrocodone in this country amounts to 99 percent of that for the entire world. Is the rest of the world wrong and we are right?
March 2013
Find out which drugs approved in 2012 have risks greatly exceeding their benefits or no meaningful benefits. If you are using any of the DO NOT USE drugs reviewed in the article, talk to your doctor before stopping their use.
March 2013
Approximately 20 percent of prescriptions for elderly patients in primary care settings are inappropriate, leading to adverse reactions that are entirely preventable. The article lists some of the most common inappropriately prescribed drugs.
February 2013
MIRAPEX (pramipexole) is a drug frequently used for restless leg syndrome, for which there are other safer, effective nondrug treatments, as discussed in the article. It also is used for Parkinson's disease. A recent review has found that this drug can increase the risk of heart failure. Find out how to recognize early symptoms of heart failure.
February 2013
Although there are not many cases in the United States, multiple drug-resistant tuberculosis (MDR TB) is a serious international problem. In a trial for a new drug for MDR TB, bedaquiline (SIRTURO), those receiving the drug were five times more likely to die than those receiving a placebo. Instead of looking into this more carefully, the Food and Drug Administration (FDA) approved the drug with the warning: “In one clinical trial, more deaths were seen in people who were treated with SIRTURO compared to people who did not receive SIRTURO.”
February 2013
Commonly known as emphysema, chronic obstructive pulmonary disease (COPD) affects an estimated 24 million Americans, only half of whom are diagnosed. This article presents recent information regarding the use of drug treatments, including inhaled anti-inflammatory steroids, as well as important nondrug treatments that can be used as an adjunct to drug therapy.
February 2013
Even though safer treatments than lindane for lice and scabies are available, and despite Public Citizen’s efforts to ban this dangerous pesticide, the FDA continues to allow it on the market. This article discusses safer alternative treatments.
January 2013
Find out the serious risks, often requiring hospitalization, to infants and young children who accidentally swallow the liquids in nasal sprays or eye drops. The article lists the three most dangerous ingredients that are found in several big-selling brand name products, also listed in the article.
January 2013
Read about the history, from an investigation by the London Times, of how the world's first major drug company, Bayer, developed and got the trademark on one of the most dangerous over-the-counter drugs in history, Heroin. It was given this name because Bayer employees, given the drug as part of an experiment, felt "heroic" after using it. Read on.....
January 2013
Find out the names of 11 different drugs in this popular family of tranquillizers and sleeping pills that can increase the risk of dementia 30 to 40 percent in older adults.
January 2013
Find out why, if you are using any of nine different popular dietary supplements and you are planning to have surgery, you need to tell your doctor so you can stop using them at a safe interval before your operation. The intervals range from at least 24 hours before surgery to two weeks, the latter the case for most of the nine supplements.
January 2013
This article reviews the latest recommendations on how much calcium and vitamin D are best for people. The right amount depends on both your age and whether you are male or female. Also, learn about the upper safe levels of both calcium and Vitamin D so that you do not take amounts that can be dangerous.
December 2012
Public Citizen has a long history of opposing the dangerous under-regulation of large-scale pharmacy compounders such as the New England Compounding Center, which is at the center of the recent outbreak of fungal meningitis caused by contaminated injectable steroids. Learn how this current nationwide disaster, and its related deaths, could have been prevented.
December 2012
The FDA sided with a large drug company in refusing to pull from the market a dangerous drug for treating Alzheimer's disease, which Public Citizen had asked the government to ban. What went wrong and why?
December 2012
Topics discussed include evidence that overuse of migraine drugs may cause headache rather than relieve it. Also, a widely prescribed antidepressant, in higher doses, can cause heart arrhythmias, manifested as dizziness, palpitations or fainting. Finally, another widely used antidepressant can cause a life-threatening condition called neuroleptic malignant syndrome, which can include extremely high body temperature, fast heart rate, rapidly changing blood pressure and mental changes.
December 2012
It is dangerous to take any of the 18 popular blood pressure drugs of one type (ACE inhibitors) in combination with any of the 14 blood pressure drugs of another type (ARBs). It also is dangerous to take a drug in either of these classes in combination with a newer high blood pressure drug, aliskiren (TEKTURNA). Find out why.
November 2012
Find out the latest about the pharmaceutical industry continuing to remain the number one defrauder of the Federal government. Why does this continue and what are an increasing number of states doing about it?
November 2012
Find out why many doctors are skeptical of medical journal articles reporting the results of drug industry-funded studies. Apparently for self-interested reasons, the editor of a leading medical journal unfortunately disagrees with this healthy skepticism.
November 2012
Find out the names and ingredients of topical muscle and joint pain relievers that can cause moderate to severe local burns and how you can protect yourself.
November 2012
The recent epidemic of life-threatening and fatal infections from contaminated spinal steroid injections is a reminder of the larger issue of their use, even if not contaminated. The article discusses risks that remain even with properly manufactured medications, describing how patients and physicians should know when not to use steroids, consider the risks and benefits of the procedure, and understand other treatment options before using steroids to treat lower back pain.
November 2012
Find out about the latest evidence that statins such as LIPITOR, LESCOL, ALTOPREV, MEVACOR, LIVALO, PRAVACHOL, CRESTOR and ZOCOR can cause fatigue and reduced energy levels, especially in women. The authors concluded that "These effects, germane to quality of life, merit consideration when prescribing or contemplating use of statins, particularly in groups without expected net morbidity/mortality benefit."
October 2012
The article reviews current evidence on 16 dietary supplements based on a large number of studies testing their effectiveness.
October 2012
An invited editorial by Worst Pills, Best Pills News editor Dr. Sidney Wolfe in the October Australian Prescriber explains the factual basis for our recommendation not to use any new drug — except for relatively rare breakthrough drugs — until it has been on the market for seven years.
October 2012
The recent FDA approval of the first two new diet drugs in 13 years occasions our review of the safety problems of both drugs and the history of previous diet drugs, taken off the market because of serious cardiovascular dangers. Two recent well-controlled studies, one in adults and one in children, document the benefit of reasonable diet and exercise programs as the only safe and effective way to lose weight.
October 2012
A recent study challenges the assumption that men and women with pre-existing cardiovascular disease benefit equally from the use of statins to prevent subsequent death or strokes.
September 2012
Learn about the wide range of countries in which Pfizer illegally bribed government officials in order to sell more of the company's drugs.
September 2012
The article reviews the effectiveness and safety of a variety of drugs and strategies to help people stop smoking but also stresses the importance of interpersonal support for those trying to quit this deadly habit.
September 2012
The article reviews a recent petition to the FDA seeking improvements on the labels of prescription opioids (narcotics). The label change would prevent drug companies from promoting these drugs for noncancer pain for dangerously long periods of time, at doses that are too high, and for uses other than severe pain in noncancer patients. The petition was signed by 37 public health experts, including leaders in the fields of pain medicine, addiction and primary care; the health commissioners of New York City and New York state; and Dr. Sidney Wolfe, director of Public Citizen’s Health Research Group.
August 2012
Learn the details of the large problem of misprescribing antibiotics for sinusitis, symptoms of the condition, limited indications for antibiotic use and alternative treatments for this very common illness.
August 2012
Find out how a seemingly large $3 billion criminal and civil penalty levied against GlaxoSmithKline — because of its small size relative to the drugmaker’s profits and the absence of jail time for any of the company’s officials — tacitly encourages drug companies to continue illegal activities.
August 2012
Find out how using seemingly benign benzocaine gels and liquids for mouth and gum pain can lead to a rare but serious, and sometimes fatal, condition in infants and babies.
August 2012
We review a recent study concerning the lack of evidence that antidepressants are effective in elderly, demented people. Find out the risks involved with antidepressant use in this population and learn about the safer, more effective nondrug approaches to treating depression in elderly adults.
August 2012
We review recent evidence that azithromycin (ZITHROMAX, as in Z-PAK) and levofloxacin (LEVAQUIN), used for relatively short periods, significantly increased the risk of cardiovascular risks such as sudden cardiac death in some patients, compared to the risks in people not taking antibiotics. The overprescribing of these drugs is also discussed.
July 2012
Find out the most common symptoms of the vision-threatening condition retinal detachment and how, although rarely, it can be caused by commonly used antibiotics such as ciprofloxacin (CIPRO) and levofloxacin (LEVAQUIN). We also discuss evidence that these antibiotics are overused.
July 2012
We discuss how Pfizer, after its patent on the billions-a-year-selling LIPITOR went off patent, used desperate means to delay giving patients options for much less expensive generic versions of the drug, marketed as atorvastatin.
July 2012
Find out why we recommend that you do not use the recently approved high blood pressure drug azilsartan.
July 2012
This article updates and expands our earlier list of drugs that can have harmful interactions with grapefruit juice. The list now includes 82 different drugs.
June 2012
We review the dangers of the extremely popular drug duloxetine (CYMBALTA) and discuss why you should not use it to treat depression, anxiety or pain.
June 2012
Do large "gifts" from drug companies to doctors make a difference in the care that patients get? Find out how to view a partial list of drug companies to check whether your physician is getting such payments and how the government is delaying the disclosure of payments from all drug companies.
June 2012
This article lists practical steps to take to avoid death, hospitalization or other medical problems caused by heat stress. It also contains a list of 123 drugs that can impair your response to heat.
May 2012
The article lists many drugs that treat high blood pressure but can also increase the risk of gout. If you have gout, ask your doctor whether your dose of any of these drugs could be reduced or whether you should switch to a medication with a lower gout risk. However, hypertension control is of utmost importance.
May 2012
The proportion of patients 65 or older in drug trial reports was lower than half the proportion in the treated population who were 65 or older, leading authors of a recent analysis to conclude that drugmakers should study an appropriate and larger proportion of older adults for drugs that will predictably be used by them.
May 2012
The article explains why you should not use the newly approved diabetes drug exenatide (BYDUREON), a long-acting dosage form of the previously approved BYETTA. Important safety concerns cited in the drug’s label and FDA warnings are also discussed.
May 2012
There is little doubt from earlier studies that using aspirin to prevent cardiovascular death in patients who already have cardiovascular disease is effective. A new review found that aspirin, taken daily or every other day in low doses for primary prevention of cardiovascular death in patients without existing cardiovascular disease, was not effective in these patients in either reducing cardiovascular death or death from cancer. It did, however, increase clinically important bleeding events in these patients.
April 2012
Find out why you should not use four recently approved heart drugs — dronedarone (MULTAQ), prasugrel (EFFIENT), dabigatran (PRADAXA) and rivaroxaban (XARELTO) — for at least seven years.
April 2012
A thorough review of studies that document the benefits — $1 trillion saved in the past 10 years — of our increasing use of generic drugs.
April 2012
This article discusses drugs you should and should not use as the allergy season commences.
March 2012
Find out why you should not use any of the three recently-approved diabetes drugs known as "gliptins".
March 2012
Last year, FDA Commissioner Dr. Margaret Hamburg told an audience at our D.C. Headquarters that FDA needed to allow more people with drug industry financial conflicts in order to get enough qualified doctors to fill its advisory committees. Find out why she was wrong and how she backed off this dangerous idea.
March 2012
The article discusses the reasons why we have categorized JUVISYNC as a DO NOT USE drug.
March 2012
The article discusses why taking certain antidepressants after a heart attack may increase the risk of bleeding. Find out which ones are the culprits.
February 2012
What kinds of prescription and over-the-counter products are responsible for the unintentional ingestion of these drugs by children? Such poisonings result in the hospitalization, admission to intensive care units and injury of thousands of children a year. How can they be prevented?
February 2012
A very recent study found that each year, children in this country get 10 million antibiotic prescriptions that are clearly unnecessary, creating risks of adverse reactions without any possible benefit.
February 2012
Over 15.2 million prescriptions were filled in 2010 for the brand-name or generic versions of two essentially identical drugs (fenofibrate [TRICOR] and fenofibric acid [TRILIPIX]) that clearly do not add any benefits to taking statin drugs alone but add to the risks.
February 2012
Shortly after allowing our editor only allotted time to present his views during the public session of an FDA committee meeting discussing the drugs YAZ and YASMIN, the FDA reconsidered and said he could participate as a committee member but would not be allowed to vote at the meeting. Ultimately, Dr. Wolfe participated as a nonvoting member, under protest.
February 2012
A recent study shows there is significant harm from using widely advertised vitamin E dietary supplements. Not surprisingly, the study was not funded by vitamin E manufacturers but by the U.S. National Institutes of Health.
January 2012
Find out how to prevent emergency hospitalizations from two commonly used drugs, warfarin (COUMADIN) and clopidogrel (PLAVIX). There are approximately 33,000 emergency hospitalizations a year from warfarin alone. This article includes a list of more than 50 drugs that can have harmful interactions with warfarin and/or clopidogrel.
January 2012
Read about how the Worst Pills, Best Pills News editor was not allowed to vote on the safety of a big-selling drug because he thought it was unsafe.
December 2011
Find out about 12 drugs that can interact with widely prescribed quetiapine -- 12 million prescriptions sold in 2010 -- to cause serious, sometimes fatal, heart arrhythmias.
December 2011
Patients pay more when brand-name drug companies legally "bribe" generic companies to delay the selling of less expensive products.
December 2011
Find out how using a combination of two commonly prescribed drugs (a total of 30 million prescriptions filled annually in the U.S.) can cause life-threatening increases in blood potassium, a risk that has led to hospitalization.
December 2011
Read about the results of a study comparing higher doses of saw palmetto extract with a placebo for treating some common symptoms of benign prostate enlargement (such as urinary retention and incomplete emptying of the bladder).
November 2011
Find out the full list of serious problems with pioglitazone (ACTOS) that cause it to be a DO NOT USE drug, of which bladder cancer is but the latest.
November 2011
Learn about the results of a study concerning people's faith in the validity of the FDA drug-approval process and in the agency's restrictions on drug advertising.
November 2011
PPIs are now one of the most widely used classes of prescription drugs, with an estimated one out of every 20 people in the developed world currently taking one of these medications. However, given that recent research shows PPIs may be habit-forming, that the majority of PPI use is probably inappropriate, with minimal or no benefit to the patient, and that new, life-threatening risks with long-term therapy are continually emerging, it is time for the medical community to re-evaluate the role of PPIs in everyday practice.
October 2011
Treatment for enlarged prostate is not always required. Find out which family of drugs is best should treatment be needed.
October 2011
We share the results of a 2011 Health Affairs study.
October 2011
Read more for information on inhaled anticholinergic drugs and the risk they pose to older men with chronic obstructive pulmonary disease (COPD).
October 2011
Following our April 2011 petition to the FDA to have weight-loss drug orlistat removed from the market, we review the serious adverse effects associated with its over-the-counter and prescription forms.
September 2011
Find out how using a combination of two drugs, one from each of these two families, can increase the risks of kidney toxicity and dangerously higher blood levels of potassium compared to use of one of these two families of drugs alone. The article lists 10 different drugs in the first class and seven in the second class. Worse yet, most of the patients in the study were prescribed the combination to treat conditions for which the combination has not proven to be beneficial.
September 2011
Find out how Merck tried, unsuccessfully, to keep from being sued by stockholders who accused the company of withholding information about the risks of Vioxx.
September 2011
Find out why the FDA is now requiring patient warnings on this drug about an increased risk of cardiovascular adverse events in patients with existing cardiovascular disease. This adds to the growing list, including many psychiatric adverse effects, of problems associated with varenicline.
September 2011
Each year 67,000 women undergo surgery for pelvic organ prolapse (POP) involving transvaginal placement of nonabsorbable surgical mesh that commonly results in many serious and potentially life-threatening complications. Find out why safer, equally effective non-mesh surgery is a better alternative.
September 2011
PPIs are now one of the most widely used classes of prescription drugs, with an estimated one out of every 20 people in the developed world currently taking one of these medications. However, given that recent research shows PPIs may be habit-forming, that the majority of PPI use is probably inappropriate, with minimal or no benefit to the patient, and that new, life-threatening risks with long-term therapy are continually emerging, it is time for the medical community to re-evaluate the role of PPIs in everyday practice.
August 2011
Many of the millions of older adults who take thyroid pills are taking too much each day, with significantly increased risks of bone fractures. Find out what to do.
August 2011
NIASPAN (extended-dose niacin) alone may still be useful, but in a study published in 2011, it did not add any benefit when taken along with the statin simvastatin.
August 2011
Most prescriptions for antipsychotic drugs to people in nursing homes are inappropriate and quite dangerous. Find out what you can do to protect your family or friends.
August 2011
Find out how a generic manufacturer got an exclusive "brand name" for its previously generic gout drug, colchicine, and increased the price by 125 times.
July 2011
The article reviews evidence that taking any of eight different classes of prescription drugs can significantly increase the risks of being involved in a traffic accident in which someone is injured. Find out what the classes of drugs are.
July 2011
In addition to its use for Alzheimer's disease, the drug rivastigmine (EXELON) is used to treat critically ill patients with delirium in intensive care units (ICUs). In a November 2010 study, those getting the drug had a death rate almost three times higher than those getting a placebo.
July 2011
Find out what outside experts, in published medical journal articles, think about the usefulness of the currently available drugs for treating Alzheimer's disease.
July 2011
Find out about a life-threatening intestinal condition that can be caused by feeding premature infants infant formula or pumped breast milk treated with this thickening agent.
July 2011
Find out why Public Citizen and an expert in Alzheimer's disease from Johns Hopkins have asked the FDA to ban the recently approved Alzheimer's drug, Aricept 23, from the market.
July 2011
There was an error in a paragraph describing interpretation of the results of the blood test hemoglobin A1c (HbA1c), which is used to assess the body’s control of sugar (glucose).
June 2011
Find out why a drug widely used to treat prostate enlargement should not be used to prevent prostate cancer.
June 2011
This article lists 355 drugs with names that are often confused with similar-sounding drug names. Find out what you can do to prevent getting the wrong drug.
June 2011
Find out how Johnson & Johnson officials "violated the Foreign Corrupt Practices Act (FCPA) by bribing public doctors in several European countries and paying kickbacks to Iraq to illegally obtain business."
May 2011
Find out the difference between major depression and minor depression and why antidepressants, which are effective with precautions for the former, are not effective for the latter.
May 2011
Previous studies have shown cranberries to have some effectiveness in preventing urinary tract infections. However, in these studies the researchers and subjects knew what they were receiving, which almost always guarantees a biased result favoring the treatment.
Find out what a new study, where both patients and doctors were not aware of whether they were using cranberry juice or fake cranberry juice, concluded.
May 2011
This article reviews recent studies showing significantly increased risk of blood clots in high-selling contraceptives containing drospirenone, compared to the lower risk of blood clots with older contraceptives containing levonorgestrel. Drospirenone is an ingredient in the contraceptive pills Yaz and Yasmin, which are sold in the U.S.
May 2011
This article, adapted for U.S. patients from an excellent review of the topic in the U.K., gives answers as to what course of action to follow if you miss a dose.
May 2011
Find out why Johnson & Johnson was recently criminally prosecuted for illegally promoting an epilepsy drug that clearly causes birth defects.
April 2011
The article lists 27 drugs that can cause akathisia, a condition characterized by muscular quivering and the inability to sit still. Other signs of the condition include fidgety movements, leg swinging while sitting, rocking from foot to foot or pacing and motor restlessness.
April 2011
This article reviews the safety and efficacy of liraglutide (VICTOZA), a new medication used to treat type-2 diabetes.
April 2011
Find out what the latest study of the effectiveness of the shingles vaccine reveals.
April 2011
The pharmaceutical industry has now surpassed the defense industry as the largest defrauder of the federal government, as determined by payments it has made for violations of the False Claims Act (FCA).
March 2011
The article reviews a study on the potentially dangerous, inappropriate prescribing of 77 drugs that pose a high risk to older adults. Of the 67 of these drugs that we had previously reviewed in Worst, Pills, Best Pills News, we had classified 60 (90 percent) of them as “Do Not Use,” and the other seven as "Limited Use."
March 2011
The article details how you should review all of the medications you are using with your doctor. It also provides a drug worksheet for you to fill out with him or her. The worksheet, when shown to your doctors, may save you from being prescribed drugs that interact with each other or have other side effects that you might not have recognized as being drug-related.
March 2011
We discuss the controversy about the role of the FDA in approving the use of prescription drugs used to execute prisoners.
February 2011
This article discusses why certain homeopathic teething tablets should not be used and lists symptoms of their toxicity that parents and other child caregivers can look for.
February 2011
We discuss nine safety rules you need to know when using medications. The tenth, equally important rule will be discussed in detail in next month's issue.
February 2011
This article discusses why you should not use this newly approved diabetes drug until more is known about its safety.
February 2011
This article discusses the results of a new study involving more than 11,000 people who were given vitamin E, vitamin C, vitamin E and C together, or placebos and followed them to see if they developed new cataracts. The article also includes a review of older studies of the effects of these vitamins on colds, kidney stones, cancer, heart disease and other diseases.
February 2011
Find out how to see if your doctor is one of more than 32,000 who have taken money from pharmaceutical companies, mainly for acting as drug company speakers or as consultants. Three hundred eighty-four of these physicians have gotten more than $100,000 in little more than one year. Does this affect the way they treat you?
January 2011
This article lists 11 of the prescription drugs that we warned Worst Pills, Best Pills News subscribers not to use before they were banned by the FDA. Subscribers knew an average of 3.3 years before the FDA acted that these medications were unsafe to use.
January 2011
Learn about all of the diseases for which chelation products are illegally promoted, the products' lack of effectiveness for treating any of these diseases, and some of the products' serious risks.
January 2011
This article discusses the dangerous interactions that can occur when using methotrexate (TREXALL) with certain other drugs. See our list of 27 drugs you should never take with methotrexate.
January 2011
Learn about our efforts to ban Darvon and our warnings about the drug going back 32 years. Why did the FDA take so long to ban it compared to the United Kingdom and Europe?
December 2010
Find out why you should not use the newest entry into the crowded statin market.
December 2010
The article describes the symptoms of the life-threatening neurological disorder neuroleptic malignant syndrome (NMS) and lists 40 different prescription drugs that have been found to cause it.
December 2010
Find out how simvastatin (ZOCOR) can interact with another widely used drug to greatly increase the chance of life-threatening muscle damage that can lead to kidney damage.
December 2010
The article describes evidence that sudden hearing loss can occur in people using certain erectile dysfunction drugs, and tells you which drugs can cause this problem. It also describes other symptoms that can accompany the onset of this drug-induced hearing loss.
December 2010
Two recent studies found that indiscriminate prescribing of drugs to U.S military troops has been associated with an increase in drug-associated suicides and drug-induced deaths, probably related to interactions between drugs.
November 2010
This article discusses the potential risks to children and pets when they come in contact with the skin of someone who has used estrogen sprays for hot flashes.
November 2010
This article discusses 36 drugs that, when used by people also using a corticosteroid, can either cause toxic interactions with the steroid or decrease the steroid's effectiveness.
November 2010
Non-bacterial (aseptic) meningitis has been found in some people using the anti-convulsant drug lamotrigine (LAMICTAL), which is also used to treat bipolar illness. This article explains the symptoms of meningitis, what to do if these symptoms occur and how to prevent drug-induced meningitis.
November 2010
Find out how many deaths, hospitalizations and emergency room visits are caused by adverse drug reactions, many of which could have been prevented.
October 2010
A study discovered that more than 1 out of every 10 people who went to a Parkinson’s disease center was found to have drug-induced Parkinsonism. These people were misdiagnosed as having the more common illness, Parkinson’s disease, which is irreversible and has unknown causes.
October 2010
The lipodissolve procedure involves a series of injections that purport to selectively melt away pockets of fat in the body. On April 7, 2010, the Food and Drug Administration (FDA) issued warning letters to companies selling lipodissolve products and alerted consumers about the products’ risks.
October 2010
Bupropion is used to treat depression (brand name: WELLBUTRIN) and to aid smoking cessation (brand name: ZYBAN). The drug has a number of potentially dangerous interactions, some of which are quite different from typical antidepressant interactions.
October 2010
On July 13, 2010, the Food and Drug Administration (FDA) announced that the black-box warning for the arthritis drug leflunomide (ARAVA) will be updated to highlight the risk of severe liver injury with the use of this drug and to explain how this risk may be reduced.
September 2010
The article list 34 other medications that can harmfully interact with sleeping pills, increasing their sedative properties and causing excessive sedation. Excessive sedation at night could increase the risk of falls, should the person get up in the night for some reason. Moreover, excessive sedation causing respiratory depression could be dangerous for people with certain disorders, such as lung disease.
September 2010
Yet another problem has arisen with this drug which we have listed as DO NOT USE for a long time. There are a growing number of people who have unintentionally overdosed with the EXELON patch, leading to symptoms of toxicity described in the article. We also discuss ways of avoiding this dangerous overdose.
September 2010
Quinine is only approved to treat malaria but most of the use is for treating or preventing nighttime leg cramps, a purpose for which there is no evidence of effectiveness. Among 38 reports of serious side effects, including two deaths and two dozen cases of serious blood reactions, almost all occurred in people using the drug for purposes other than malaria.
September 2010
Another blow for Crestor occurred when a French court upheld the right of health insurers to state that the drug does not provide any significant added benefit compared to other medicines and recommended that doctors should only prescribe it in serious cases.
September 2010
Many women are using so-called bioidentical hormones, "natural" and implicitly safer versions of prescription drugs such as Premarin, because the latter drugs have been found to cause breast cancer, heart disease and many other serious health problems. The article discusses the fact that these products can be expected to have the same serious adverse effects that conventional preparations have and that they have the added disadvantage of not being regulated and thereby having unpredictable amounts of ingredients.
August 2010
The article explains why you should not use the new drug for schizophrenia, FANAPT.
August 2010
The article reviews evidence that patients 50 years old or older who take proton pump inhibitors (PPIs -- a list of the six approved ones is in the article) or use them for a year or more may be at increased risk of fractures of the hip, wrist and spine. Since much of the use of these drugs is inappropriate and unnecessarily dangerous, the article discusses pharmacologic and non-pharmacologic alternatives to PPIs.
August 2010
Vitamin and mineral supplements are a booming business in this country. Many people are misled by advertising into thinking that taking a supplement will help get rid of many of their health problems. But this is not the case.
August 2010
The article lists 34 prescription drugs that can have harmful interactions with vincristine. Recognizing signs of toxicity from vincristine early, as described in the article, is urgent because most of the side effects are reversible when the interacting drug is stopped and the patient receives corrective treatment.
July 2010
Learn more about zolpidem sublingual tablets (EDLUAR), a newly approved drug for the short-term treatment of difficulty falling asleep.
July 2010
This sixth drug for treating "heartburn" has no advantage for patients over older drugs such as PREVACID, generic name lansoprazole. Any advantage is for the industry because the manufacturer of DEXILANT charges three times more for this drug than the cost of generic lansoprazole, sold by another company and just as effective for patients.
July 2010
It appears likely that patients who take bisphosphonates (such as FOSAMAX) and NSAIDs at the same time have an increased risk of gastrointestinal ulcers as opposed to taking either drug alone. The article reviews the studies demonstrating this and offers some practical advice on what the cautious drug user should do.
July 2010
New evidence of severe liver failure, sometimes fatal, caused by orlistat (over-the-counter as ALLI, prescription version, XENICAL) adds to the many other reasons why no one should use this drug. They include Do not use orlistat. This drug has a meager effect on weight, but its potential to cause serious side effects, including pre-cancerous lesions of the colon (aberrant crypt foci), liver damage and pancreatitis, is significant. The most common side effects of orlistat include oily spotting, gas with discharge, fecal urgency, fatty/oily stools and frequent bowel movements. The article lists symptoms of liver failure.
July 2010
Experts in sleep and aging have stated, “It’s extraordinarily rare to find an old person who actually requires sleeping pills." This article lists many over-the-counter and prescription drugs that can actually cause difficulty with sleeping and also discusses a variety of non-pharmacologic alternatives to sleeping pills. Sleep experts have also said that “Nonpharmacological treatments not only cause fewer side effects, but they can sustain long-term improvements more successfully than pharmacological treatments.”
June 2010
Increasing knowledge about the risks and, in some cases, lack of benefits of vitamins suggests that by classifying vitamins as drugs, companies would be forced to give patients much more information than they now provide and would have to back medical claims for efficacy and safety with evidence. The article also provides recent evidence of previously unknown harms from certain vitamins and updates on current knowledge about the 13 most commonly used vitamins.
June 2010
Find out why you should not use cough products such as ROBITUSSIN DM that contain dextromethorphan. Also view a list of 22 other drugs that can have harmful interactions with dextromethorphan.
June 2010
For these drugs, approved only for people who have had organ transplants, there are more than one million prescriptions a year filled at a cost of more than $700 million dollars. There is clearly some prescribing for medical conditions for which the drugs are not approved. This has serious implications since the drugs can cause several kinds of life-threatening toxicity, described in the article.
May 2010
After explaining the symptoms of low blood sugar (hypoglycemia) the article lists 42 prescription drugs that can interact with one or more diabetes drugs to increase the chance of hypoglycemia.
May 2010
The article reviews 12 prescription drugs, many of which are top-sellers, all of which are greatly overpriced in comparison to older "versions" of the same drugs. The patents on the old drugs expired so the "innovative" companies patented these new products, gaining a patent on them, and, for all practical purposes, using them as a license to print money. There is no evidence that any of the new ones are better than the now less-expensive, old versions.
May 2010
The article reviews the dangers of testosterone gels and gives recommendations that adults who use testosterone gels should follow.
May 2010
The article reviews studies showing that widely-sold prescription drugs for treating cold sores, such as ZOVIRAX, DENAVIR, FAMVIR, and VALTREX and ABREVA have significant side effects, are expensive and, on the average, only reduce the duration of the cold sore by less than one day. The article describes other non-drug methods to treat cold sores that make more sense.
April 2010
This article discusses the greatly increased risk of bleeding with some widely-used antidepressant drugs and provides information that the FDA has not yet required be included in the patient Medication Guides for these drugs.
April 2010
The article lists 53 drugs that can interact with the psychiatric drug ABILIFY to either increase the amount in the body, which can lead to toxicity, or decrease the amount rendering the drug less effective.
April 2010
Learn how to report dangerous side effects of drugs and dietary supplements to the Food and Drug Administration (FDA).
March 2010
The article lists 35 different interacting drugs that can either increase blood levels of digoxin, leading to the serious problem of digitalis toxicity or decrease blood levels, causing the drug to be less effective.
March 2010
Find out how Pristiq and the older antidepressant drug, Effexor are, essentially, the same and why not to use the new one.
March 2010
Although skin application of drugs usually results in lower blood levels than oral use, cases of liver toxicity have been found with topical diclofenac Sodium (VOLTAREN).
The article lists other names of these products and explains the warning signals that may indicate liver toxicity.
March 2010
In the first study to examine the long-terms consequences of using any diet drug, sibutramine (MERIDIA) actually increased the risk of stroke, heart attack, resuscitated cardiac arrest or cardiovascular death in patients taking the drug, compared to those taking a placebo. The results of this study properly caused European drug agency to recommend banning the drug. In this country, the FDA recklessly decided to leave it on the market for now.
February 2010
Quetiapine (SEROQUEL) can interact with 26 different drugs, increasing its blood levels and causing dangerous side effects such as slowed breathing, dizziness and fainting. The article also lists 10 other interacting drugs that can result in lower blood levels, rendering the drug less effective.
February 2010
The newest FDA-approved drug for treating overactive bladder, TOVIAX (fesoterodine) is no more effective than the older five drugs, reducing the number of urinations a day by only one. In addition, since it is a new drug, we recommend not using it now because more will be known about its dangers after it has been on the market for a longer time.
February 2010
New warnings are being required on CIMZIA, ENBREL, HUMIRA, EMICADE and SIMPONI because of evidence that lymphoma (tumor of lymph tissue) and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers.
February 2010
The article discusses why all of these 16 diabetes drugs carry a label stating: "There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction [heart attacks, strokes, etc] with oral antidiabetic drug[s]." The article also explains why lifestlyle changes such as diet and exercise to prevent or even treat type II diabetes are not heavily promoted or usually reimbursed.
January 2010
The FDA has belatedly required a black box warning that treatment with metoclopramide (a drug for heartburn unresponsive to conventional therapy and for the symptoms of gastroparesis, a condition in which the stomach takes too long to empty its contents) can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with duration of treatment and total cumulative dose. We have warned Worst Pills readers about this for 21 years.
January 2010
We list this amphetamine-like drug as DO NOT USE because it is more expensive than (and does not treat ADHD better than) older, safer alternatives (such as methylphenidate [RITALIN]).
January 2010
This article lists a large number of drugs, used to treat high blood pressure and other carediovascular disease, that can interact harmfully with lithium (ESKALITH; LITHOBID; LITHONATE;generic lithium carbonate), drugs used to treat bipolar (manic/depressive) disorder. This may result in a dangerous condition known as lithium toxicity because these drugs stop the body from getting rid of lithium and lithium blood levels are increased; in severe cases, this can cause seizures, coma and even death. The article also lists other symptoms of lithium toxicity.
December 2009
Two large new studies shed light on the increased risks of so-called "third generation" oral contraceptives containing desogestrel as well as oral contraceptives containing drospirenone (such as YASMIN and YAZ) compared to older, "second-generation" oral contraceptives. This study also discusses newly discovered risks associated with YASMIN and YAZ.
December 2009
Many people believe that drinking caffeine with or after drinking alcohol will sober them up, but there is no evidence to support this.
December 2009
As the H1N1 influenza continues to spread, we review the best ways to prevent the flu. We also discuss over 100 products that the Food and Drug Administration reprimanded for selling unapproved flu treatments online.
December 2009
In mid-October, Supreme Court Justice Ruth Bader Ginsburg was kept at a hospital overnight after she became drowsy, fell from her airplane seat and had to be taken off the plane before it departed. What common drug interaction was to blame?
December 2009
When pharmaceuticals are intent on proving that one of their products is safe and effective, they may engage in practices that are professionally suspect and morally unethical. The recent news on Neurontin is a case in point.
November 2009
Because exenatide (BYETTA) is a new drug with increasing reports of severe, hospitalization-requiring pancreatitis and offers no significant breakthrough compared to other diabetes drugs, we urge readers not to use it until 2012--seven years after its approval, by which time much more will be known about its dangers.
November 2009
The article explaions how parents, in consultation with their doctors, in certain circumstances can safely avoid using antibiotics for treating children's middle ear infections.
November 2009
The article explains why febuxostat (ULORIC) should not be used because of problems with both its safety and effectivness.
November 2009
The article updates our previous information on the benefits and risks of this important vaccine.
October 2009
Antacids can interact with a number of medications, either increasing or decreasing drug effect.
October 2009
This article reviews how homeopathy is said to work and concludes that there is no condition for which its effectiveness has been convincingly demonstrated.
October 2009
We review recent studies potentially implicating one form of insulin in cancer and conclude that there is insufficient evidence to link the drug to cancer at present.
October 2009
The use of anti-depressants in the U.S. nearly doubled in a 10-year period as drugs displaced "talk therapy" and the drugs came to be used for an ever-widening set of disorders.
September 2009
This article raises serious questions about the the limited effectiveness of SAVELLA and reviews evidence of serious toxicity.
September 2009
The article lists 24 drugs that can increase the toxicity of oxycodone if taken together with the drug and 11 other drugs that can weaken its effectiveness as a painkiller if they are simutaneously used.
September 2009
The article reviews the benefits and risks of the new shingles vaccine and discusses who should and who should not get the vaccine.
September 2009
Common myths, often spread via the brand name drug companies who lose as a result of competition from lower-priced generic drugs, are discussed and rebutted in this article.
September 2009
The article describes how many noted physicians lent their name to articles they had not actually written resulting in much more prescribing of hormones to post-menopausal women. As a result, this misinformation caused thousands of cases of breast cancer and heart disease. Some doctors received medical school tenure on the basis of their "literary production" when they had merely agreed to stake their names (and, by extension, the reputations of their institutions) to enhance pharmaceutical company's profits and line their own pockets.
August 2009
We review evidence from a recently-published medical journal article that syncope (fainting), often leading to falls, can be a serious side effect of the Alzheimer’s disease drugs donepezil (ARICEPT), rivastigmine (EXELON) and galantamine (REMINYL). In addition, hospitalizations for slow heart rhythms, pacemaker insertions and hip fractures — all of which can be related to syncope — increased in patients using these Alzheimer’s drugs. This, along with their questionable effectiveness, further increases the evidence underlying our recommendation not to use these drugs.
August 2009
Many doctors and pharmacists use computerized drug interaction screening systems to prevent the prescriptions for drugs that may have a harmful interaction with drugs already being used by the patient. This article points out several significant weaknesses of these systems and provides five common sense suggestions as to how patients can avoid dangerous drug interactions despite the weaknesses of these computerized systems.
August 2009
The article reviews published evidence of safety and effectiveness for five herbal supplements widely used for treating menopausal symptoms. There is no convincing evidence that any of the herbal supplements promoted for relief of menopausal symptoms is beneficial. In addition, as discussed in the article, many of them have serious safety problems.
August 2009
The FDA has just warned about about mood and behavior changes for three drugs used to treat asthma: montelukast (SINGULAIR), zafirlukast (ACCOLATE) and zileuton (ZYFLO, ZYFLO CR). The article describes these side effects and urges that patients talk with their health care providers if these events occur.
However, we advise that patients should not stop any asthma medication without first consulting your physician. Abruptly stopping a medication may result in acutely deteriorating asthma control.
August 2009
Many drugs, devices, and procedures that are found to be ineffectual or even dangerous have seemed to work when initially introduced, or seemed to prove useful for selected populations. Consumers are therefore often puzzled when some therapies that are initially hailed as breakthroughs are later pronounced useless, even hazardous.
July 2009
The article discusses a variety of reasons why it is neither in the best interests of doctors to prescribe or patients to use free samples. The truism that "there is no such thing as a free lunch" rings true once again.
July 2009
This article documents how long it has taken the FDA to fully implement a recommendation from its own advisory committee 32 years ago stating that: "Do not exceed the recommended dosage [acetaminophen--as in Tylenol] because severe liver damage may occur." Other countries have done more.
July 2009
The article lists 38 prescription drugs that can harmfully interact with statin drugs. The article also advises that No matter what statin you are taking and regardless of any interacting drugs, you should notify your prescriber immediately if you develop muscle pain, weakness or a darkening of your urine.
.
June 2009
Do not use lubiprostone. There are safer and equally or more effective treatments for both chronic constipation and for the constipation variety of irritable bowel syndrome.
We have just asked the FDA to place a black box warning on this drug because it may cause abortions in women using it who are pregnant.
June 2009
The article explains why it is not a good idea to start treatment with thyroid hormone replacement without confirmation with laboratory tests that you actually have hypothyroidism. It also discusses the kinds of symptoms that should lead you to have your thyroid level checked.
June 2009
Sixteen months after we petitioned the FDA to greatly increase warnings to doctors and patients about BOTOX, the agency has agreed to do so. The article discusses some of the life-threatening side effects of the drug such as swallowing and breathing problems and points out that much of its use is for conditions for which it has not been approved by the FDA.
June 2009
Taking alpha-blockers in combination with drugs for erectile dysfunction and with other drugs can cause dizziness and fainting.
In this article we will discuss alfuzosin (UROXATRAL), doxazosin (CARDURA), tamsulosin (FLOMAX) and terazosin (HYTRIN) and drugs with which they can have harmful interactions.
June 2009
A new Vermont law is the most extensive state law requiring the reporting of payments from drug and device companies to physicians.
June 2009
Comparative effectiveness research permits comparisons between existing therapies to establish whether they are safer or more effective than one another. The pharmaceutical industry opposes these studies because it doesn't want you to know the truth about these therapies.
May 2009
Patients taking a non-selective beta blocker should make sure the provider is aware of this before they receive an injection of epinephrine, as your physician or other health care provider may not be aware that a systemic dose of epinephrine may produce a dangerous spike in blood pressure. The article lists the selective beta blockers that do not cause this problem because they do not interact with epinephrine.
May 2009
This article discusses the fairly narrow range of daily aspirin doses most safe and effective for preventing heart disease.
May 2009
The article lists 72 weight loss dietary supplements that have recently been found to have been spiked with one of nine different prescription drugs, often at dangerously high concentrations. If you have used any products containing these ingredients, you should stop taking them and consult your health care professional immediately.
May 2009
On March 5, 2009, the FDA sent a public health warning to patients and doctors that transdermal drug patches containing metal may overheat during a MRI scan, causing skin burns. The article discusses several precautions you can take to prevent this from happening.
April 2009
This article adds other substances, cranberry products, to the long lists of drugs we have previously stated should not be used with the important blood thinner, warfarin (COUMADIN).
April 2009
The article reviews a widely-prescribed drug that contains a specific formulation of purified fish oil that is only approved for lowering very high levels of one type of fat, triglycerides, because these high levels can increase the risk of pancreatitis. The article explains why there should only be limited use of this drug.
April 2009
This second article about drug-induced dementia or delirium lists and discusses an additional 79 drugs that can cause these reversible kinds of mental deterioration. The two articles collectively review 136 drugs that can cause these serious side effects, especially in older people.
March 2009
Tamoxifen (NOLVADEX) is still widely and successfully used for treatment of breast cancer. However, when used along with certain other drugs, its effectiveness can be significantly reduced. The article explains how this can happen and lists 19 different drugs that can cause this serious problem if used with tamoxifen.
March 2009
The article lists 57 different drugs that can cause dementia if used. This can be even more problematic if more than one of these drugs is being taken. These drugs are only one class of drugs that can cause mental deterioration and next month's issue will discuss additional drugs that can also impair thinking.
March 2009
This article describes how and why people using both PLAVIX, a drug that prevents blood clotting, and heartburn drugs such as NEXIUM had a 27 percent increased risk of heart attacks compared with people using PLAVIX alone.
March 2009
The article explains how certain commonly-used prescription and over-the-counter drugs can cause kidney damage when used as bowel preparation for colonoscopy. The article also list alternative drugs for this important screening procedure that do not cause kidney damage.
February 2009
Twenty different NSAIDS (nonsteroidal antiinflammatory drugs) are listed in this article that can adversely affect your blood pressure control. The article discusses the way in which this happens and what you can do about it.
February 2009
The article discusses evidence from a large, new study finding that neither Vitamin C nor E had an effect on prostate cancer, a number of other cancers total cancer. The article also reviews older evidence concerning the effects of these vitamins on cardiovascular disease and other diseases.
February 2009
The sooner the Food and Drug Administration (FDA) finds out about serious side effects of drugs, the more quickly it can warn the public. The article explains you can easily report suspected side effects of drugs or other medical products to the FDA.
February 2009
Despite a 2006 Food and Drug Administration decision to make the morning-after contraceptive Plan B over the counter, 31% of pharmacies in Los Angeles do not carry the product.
January 2009
The article lists 56 drugs that can interact with the three drugs for erectile dysfunction (ED): sildenafil (VIAGRA), tadalafil (CIALIS) and vardenafil (LEVITRA). Eight of the drugs are either nitrates such as nitroglycerin or a certain group of high blood pressure drugs.In combination with ED drugs, these drugs can cause a dangerous fall in blood pressure that could lead to a heart attack or stroke. Thirty-two other drugs can inhibit the enzyme that helps the body to eliminate the ED drugs, resulting in abnormally high blood levels of the drugs and a potentially harmful "overdose" even though you are actually taking the recommended amount. The other 16 drugs speed up the metabolism of the ED drugs, thereby lowering the blood levels and reducing the effectiveness of the ED drugs.
January 2009
In a recent survey of U.S. doctors, 55 percent of those responding stated that, in the past year, they had used a placebo, defined as “a treatment whose benefits derive from positive patient expectations and not from the physiological mechanism of the treatment itself.”
However, the prescribing of these "placebos" was not limited to the traditional inert "sugar pill" but also included actual drugs such as over-the-counter analgesics,sedatives and antibiotics, products that can have serious side effects even though, for the illnesses they were being used to treat, they would not be expected to have benefits beyond the patient expectation level.
The article concludes with a discussion of the basis of our opposition to the use of placebos.
January 2009
Emerging reports of a rare but unique type of fracture in patients receiving bisphosphonates for many years point toward the drug as a possible culprit. Unlike most drugs, bisphosphonates remain in your body for many years after you stop taking them.
Further investigation into the risks, as well as benefits, of long-term bisphosphonate use is needed. But, because there is little evidence of benefit after five years and the long-term risks remain largely unknown, it is reasonable to discuss with your doctor discontinuing these drugs after five years. However, you should continue to take calcium and vitamin D supplements at currently suggested doses (discussed in the article) regardless of whether or not you are on bisphosphonates.
December 2008
On Oct. 30, Public Citizen formally petitioned the Food and Drug Administration (FDA) to immediately ban the dangerous diabetes drug rosiglitazone (AVANDIA) because the drug causes multiple types of serious toxicity.
December 2008
The article discusses the difference between the benefits of drugs to prevent a first fracture (primary prevention) and to prevent further fractures in people who have already experienced a fracture (secondary prevention).In addition to discussing when it may or may not be appropriate to use drugs such as Fosamax (alendronate) or Actonel (risedronate) the article discusses ways of preventing falls and other non-pharmacologic approaches to preventing fractures.
December 2008
This article lists 27 drugs that can have life-threatening interactions with the widely-used gout drug, colchicine, resulting in dangerously elevated levels of colchicine.
Too much colchicine in the body leads to toxicity such as fever, vomiting, diarrhea, abdominal pain and muscle pains.
Even worse, it can impair the bone marrow’s ability to make red and white blood cells, causing severe anemia and dangerously low numbers of white blood cells. When the number of white blood cells is reduced, your body may have difficulty fighting infections. Most people who have died from colchicine toxicity have had bone marrow toxicity or had preexisting kidney problems.
Every patient on colchicine — whether on other drugs or not — should be alert for evidence of colchicine toxicity as described above.
December 2008
This article lists 68 drugs that can cause high blood potassium (hyperkalemia) that can result in nausea, fatigue, muscle weakness or tingling sensations, as well as heart abnormalities (showing up as an abnormal electrocardiogram). In some cases it can be fatal.
If you are taking any of these drugs, be especially careful if you have diabetes or kidney disease. If so, you are at increased risk, and your doctor will have to weigh the risk of giving you these drugs. Also, the older you are, the more likely you are to develop hyperkalemia. Also, make sure you are receiving appropriate laboratory monitoring.
November 2008
One of the most common drug interactions occurs when patients take two or more drugs that can each increase blood potassium levels. The resulting condition, hyperkalemia (increased blood potassium levels), can cause nausea, fatigue, muscle weakness or tingling sensations, as well as heart abnormalities, showing up as an abnormal electrocardiogram. In some cases it can be fatal. The article lists 50 drugs which, especially when used in combination, can cause hyperkalemia.
November 2008
Despite the dangers of this combination--risk of severe muscle injury, rhabdomyolysis, which can lead to kidney failure or death--many clinicians continue to prescribe them together and cases of life-threatening adverse reactions from continue to be reported to the FDA. Patients taking simvastatin at a dose greater than 20 milligrams a day in combination with amiodarone should let their physician know that this combination puts them at high risk of muscle injury. There are other statins that do not appear to interact with amiodarone that are discussed.
November 2008
Among patients taking antiepileptic drugs for epilepsy, the risk of suicidal thinking and behavior was 3.5 times greater compared to placebo. These drugs are also used to treat pain and as mood stabilizers in people with manic-depressive disorders.
Pay attention to common warning signs that may indicate an increased risk of suicide, including: talking or thinking about hurting oneself or ending one’s life; withdrawal from family and friends; worsening depression; increased preoccupation with death and dying; giving away prized possessions. Do not make any medication regimen changes without consulting your provider. Unsupervised sudden changes in prescription drugs can have dangerous adverse effects
November 2008
The article lists 13 risk factors for fractures. But it points out that in deciding whether to use drugs, several important risk factors other than bone mineral density are often omitted which can result in inappropriate drug treatment for people who may not necessarily need it. Examples are given of patients who are really at low risk of a fracture but who often get treated.
November 2008
Dr. Nortin Hadler discusses the causes of and solutions to fibromyalgia.
October 2008
The article reviews what former Olympians — swimmer Mark Spitz and gymnast Nadia Comaneci - have in common with Botox. Instead of tens of millions of people watching these athletes’ performances in the past as they strived for their personal best, people will now be able to watch videos of doctors’ performances as they inject Mark Spitz and Nadia Comaneci with BOTOX. Read about the new definition of "personal best".
October 2008
Tizanidine (ZANAFLEX) is a muscle relaxant for which more than 3.8 million prescriptions were filled in the U.S. last year. The article lists more than 64 drugs with which it can have dangerous interactions resulting in excess sedation, difficulty breathing or dangerously low blood pressure that can result in falling.
October 2008
After a petition and lawsuit by Public Citizen's Health Research Group, the FDA announced in July that it will require a “black box” warning concerning tendon rupture and tendinitis caused by fluoroquinolone antibiotics, as well as an FDA-approved medication guide to be dispensed when prescriptions are filled. Although this accomplishes two of the three steps Public Citizen has urged the agency to take for nearly two years, we are troubled that the FDA is not doing everything within its power to prevent more people from needlessly suffering disabling tendon ruptures. Nothing could be simpler and more effective than a letter to doctors in addition to what the FDA has already agreed to do.
October 2008
The European Medicines Agency (EMEA) has recently proposed removing the widely prescribed, dangerous muscle relaxant carisoprodol (SOMA, SOMA COM- POUND and SOMA COMPOUND with CODEINE) from the market in all European Union countries because “the risks of these medicines outweigh their benefits.”
September 2008
A nationwide study published in spring 2008 in the Journal of Hospital Medicine showed that nearly half (49 percent) of almost 500,000 hospital patients older than 65 have been prescribed one or more of 92 drugs known to be unnecessarily unsafe for older patients. 10,000 of these patients had four or more of these inappropriate medicines prescribed during their hospitalization.
Among the most common categories of adverse drug reactions these inappropriately prescribed drugs can cause are excessive sedation, abnormally low blood pressure and bleeding. We list the 92 drugs in the article and give further details about the kinds of side effects these drugs can cause.
September 2008
Thyroid medications are among the most widely-prescribed drugs in the U.S. In this article, we review 29 different medications that can have harmful interactions with thyroid medicines such as levothyroxine (Synthroid). There are four major kinds of interaction problems that can occur:
• Certain medications can decrease the absorption of levothyroxine resulting in lower levels in the blood.
• Other medications can increase the rate at which the body gets rid of levothyroxine, also resulting in lower thyroid levels in the blood.
• Other medications can cause changes of levothyroxine binding in blood, decreasing the body's ability to use levothyroxine.
• Levothyroxine can affect the safety or effectiveness of other medications by raising or lowering the levels of these other drugs in the blood, causing them to be either infective (lower levels) or dangerous (higher levels).
September 2008
Athletes once were rewarded for their prowess by appearing on a box of Wheaties, but now promote drugs in frequently played commercials during the Olympics.
August 2008
With the imminent demise of CFC-propelled albuterol asthma inhalers and the substitution of HFA (hydroflouroalkane)as a more environmentally-friendly propellant, two sets of problems arise. First, and the main subject of this article, are differences between the old and new propellants that require special attention by asthmatics using the new HFA asthma inhalers because they may clog more easily than the older CFC-containing ones. The second problem is cost in that less expensive generic versions of the HFA inhalers will not be available until 2010 and the half-as-expensive generic CFC albuterol inhalers will not be manufactured or sold after December 31, 2008.
August 2008
The article discusses 273 drugs that can have harmful interactions with alcohol. Also reviewed are several ways in which these harmful interactions can occur:
1/ Medications Can Increase Alcohol Blood Levels
2/ Additive effects of medications and alcohol. One of the best- known drug-alcohol interactions is when alcohol, a depressant, is taken with other sedative medications, and excessive sedation or depression of respiration can occur
3/Alcohol can increase the blood levels of some medications leading to toxicity of these drugs.
4/ Alcohol also can reduce blood levels of some medications causing them to be less effective.
Although some of the interactions between alcohol and medications mainly occur in people who drink heavily (three or more drinks on one occasion), many of these interactions may occur with much lower amounts of alcohol use, such as one to two drinks on an occasion.
We strongly urge you to tell your physicians and other health care providers how much alcohol you are drinking so they can effectively assess the risks and advise you about the safe use of alcohol and medications.
August 2008
Growth hormone is only approved for three relatively rare conditions in adults: AIDS Wasting Syndrome, Short bowel syndrome involving malabsorption of food and Growth Hormone Deficiency. Experts in the care of patients with hGH-related problems clearly state that giving hGH for antiaging, age management or bodybuilding is not medically appropriate particularly when weighing the potential benefits and risks. The article discusses known risks including soft tissue swelling, joint pains, carpal tunnel-like syndrome, breast enlargement and diabetes. Other side effects include liver and heart enlargement, increased pressure around the brain and high blood pressure.
Do not use growth hormone unless you have one of the three medical conditions for which there is actually evidence that the benefits outweigh the risks.
July 2008
An increasing body of evidence documents both the risks and lack of evidence of clinical benefits associated with sitagliptin, and several reviews have cautioned against its use.
July 2008
Low levels of sodium in the blood are one of the most common laboratory abnormalities and the consequences range from mild and non-specific to life-threatening. The article discusses the symptoms of low blood sodium and lists 53 prescription drugs that can cause it. We urge that both patients and health professionals be alert for symptoms that may signal the onset of hyponatremia if the patient is predisposed to this disorder as a result of their drug therapy or diseases.
July 2008
A recent study has found large numbers of reports of psychiatric adverse effects with varenicline (CHANTIX) including hundres of reports of suicidal acts, thoughts or behaviors; possible psychosis; and hostility or aggression.
July 2008
Enter Abstract Here
June 2008
Etanercept, an effective disease-modifying anti-rheumatic drug (DMARD), now joins adalimubab (HUMIRA) and inflixamib (REMICADE) to be the third of the arthritis disease-modifying drugs (see discussion on the following page about disease-modifying drugs) to receive a black box warning concerning infections, calling for TB testing and, if positive, TB treatment before starting these drugs. For some people, the potential benefit of etanercept outweighs the risk of infections, including the very small risk of TB infection. The article also discusses a fourth DMARD and the precautions we advise for its use.
June 2008
Codeine is routinely converted to morphine in the body in order for it to be an effective painkiller. The metabolism of codeine to morphine takes place through the actions of an enzyme in the liver. The article explains how various drugs and or a person's genetic makeup can greatly influence the conversion of codeine to morphine, making its pain-relieving properties too week if not enough conversion occurs and resulting in what amounts to an overdose at the recommended dose if the conversion to morphine is too rapid. Fourteen drugs that inhibit the conversion to morphine are listed in the article.
June 2008
The American Heart Association (AHA) has just recommended specific screening for heart problems for children and adolescents before they get stimulant drugs for treating attention deficit hyperactivity disease (ADHD). The recommendations include a thorough history, a physical exam focussing on the heart and, according to the American Heart Association, that it is reasonable to obtain an electrocardiogram. The article lists the components of an adequate history and physical exam to look for the presence of pre-existing heart disease in children.
June 2008
Last year, US women filled 2.7 million prescriptions for a contraceptive that has, compared to the pill: significantly higher estrogen levels; a possible two-fold increase in the risk of blood clots; increased painful side effects such as breast discomfort, severe menstrual pain, nausea and vomiting; an increased likelihood of discontinued contraceptive use; and no improvement in contraceptive outcomes. The article gives more details about why we want this product banned.
June 2008
More and more Americans are choosing not to have their children vaccinated, and as a result, obsolete diseases are making a come-back.
June 2008
The drug industry uses for-profit human experimentation companies to obtain faster results, to the detriment of the consumer.
May 2008
This article lists more than 60 prescription drugs that can interact with calcium channel blocking drugs such as amlodipine (NORVASC),diltiazem (CARDIZEM, DILACOR XR TIAZAC)or nifedipine (PROCARDIA)to either cause toxicity or to lessen the effectiveness of the calcium channel blocking drugs. Included in the lists are a number of drugs that we list in Worst Pills, Best Pills as DO NOT USE or LIMITED USE drugs. The article also explains the different kinds of toxicity that can ensue from these interactions.
May 2008
Older patients are especially at increased risk for adverse drug reactions because of age-related factors.The article reviews nine reasons why this is the case and discusses what you can do about these often-preventable adverse reactions. Increasing awareness of this problem should result in the prescription of far fewer drugs to older adults, and those that are prescribed will be given at lower doses in most instances.
May 2008
PROVIGIL, an amphetamine-like drug, has been illegally promoted by its manufacturer for treating many conditions for which there is no evidence that its benefits outweigh its risks. Thus, a large proportion of prescriptions for this top-200 selling drug are for off-label or unapproved uses.
April 2008
The article lists more than 30 prescription drugs that can cause the serotonin syndrome.
April 2008
This article, based on a recent review in Drug Safety, lists 62 prescription drugs that can cause eye disease. The range of drug-induced eye diseases includes diseases of the eyelids, glaucoma, cataracts, retinal damage and optic nerve damage. As is true for drug-induced diseases in other parts of the body, you should consider newly developed eye symptoms beginning shortly after starting a new medication to be possibly drug-induced and consult a physician.
April 2008
Allergic reactions to a component of denture cleansers - persulfates - can occur with both proper and improper use of denture cleansers and can be delayed. Symptoms of an allergic reaction may include: irritation, rash, hives, gum tenderness, breathing problems and low blood pressure.
March 2008
This article reviews evidence for the international epidemic of overuse of proton pump inhibitors (PPI),
drugs used to treat ulcers and gastroesophageal reflux disease (GERD). There were 70 million prescriptions filled in U.S. pharmacies in 2006 for the four leading PPI drugs: esomeprazole (NEXIUM), lansoprazole (PREVACID), pantoprazole (PROTONIX) and rabeprazole (ACIPHIX). Find out about several serious side effects of these drugs such as increased community-acquired pneumonia, increased hip fractures and acute kidney inflammation. Learn about alternatives to using PPIs.
March 2008
This article explains what autism is and analyzes the latest evidence concerning its alleged link to mercury from childhood vaccines.
March 2008
Find out why Worst Pills warned against the use of VYTORIN more than three years ago. Also, learn about new evidence showing that despite the fact that this drug lowers cholesterol, there is no evidence that it prevents heart attacks or strokes (though massive misleading advertising would have you believe otherwise).
March 2008
This article explains the dangers of using ibuprofen (MOTRIN, ADVIL) because it interferes with the protective effect of low-dose aspirin to prevent blood clots and protect against heart attacks or strokes. Find out how these two widely-used therapies have a harmful interaction and what you should do.
March 2008
This article reviews such topics as: Why should I have my medical record? Am I entitled to my medical record? Who has access to my medical record? Can a provider deny me access to my record? What if I change health care providers, or my provider has moved or gone out of business? What happens to my record if my provider dies?
March 2008
Public Citizen’s communications office launched “Citizen Vox” in February as the organization’s latest tool in spreading the word about its mission of protecting health, safety and democracy. Check out www.CitizenVox.org.
February 2008
We review a recent study suggesting that very low cholesterol levels may be linked to an increased risk of cancer. The related issue discussed in the article is whether the current U.S. thinking that "lower is better," especially for those who have not yet had a heart attack or stroke or angina, is correct. There is also a discussion about the difference between primary and secondary prevention.
February 2008
Recent updates on this diabetes drug that we have urged our readers not to use for three years are reviewed, including the delisting of the drug by the Veterans Administration because of its dangers and warnings by the Canadian government. We are renewing our call for a ban on the drug in the U.S.
February 2008
The article discusses the adverse drug interactions between either of two widely-prescribed macrolide antibiotics, erythromycin (as in ERYTHROCIN) and clarithromycin (BIAXIN)and more than 40 other drugs that are listed in a table in the article. It also describes the nature of the adverse interactions that can occur.
February 2008
A recent study examined the ways the drug industry spends an average of $61,000 per physician each year trying to convince them to buy certain drugs. The findings provide a well-documented reminder that the industry is much more financially committed to massive promotional expenses than to research and development of drugs.
January 2008
Why is this big-selling, extremely dangerous, not very effective narcotic painkiller still on the market in the U.S. despite haveing been withdrawn in the U.K.? Learn about how it kills more than 200 people a year.
January 2008
More than 70 million prescriptions a year are filled for these popular antidepressants, including Prozac, Paxil, Zoloft, Luvox, Celexa and Lexapro. This article gives details about more than 60 other widely prescribed prescription drugs that can have harmful interactions if used with these antidepressants. The two different kinds of interactions are also discussed.
January 2008
Learn how you can easily report to the FDA an adverse reaction you have had to a drug or dietary supplement. The basis for most drugs being taken off the market or being required to have a black box warning are such reports. Do your part!
January 2008
This article reviews an example of the growing trend of paying doctors more for "better" performance. Referring to doctors getting financial kickbacks for prescribing generic drugs, the article points out that doing the right thing for the wrong reason is not acceptable. Having doctors increasingly basing their decision-making on financial conflicts of interest is not in patients' interests.
December 2007
A recent drug industry-funded study was widely hailed as showing that TOPAMAX, a drug approved for seizures and migraines, worked well in treating alcoholism in heavy drinkers. However, upon closer inspection, the study does not convincingly prove the safety or effectiveness of the new suggested use of topiramate. The use of the drug produced only a modest decrease in the percentage of days of heavy drinking, compared to placebo. Topiramate can be unsafe if mixed with alcohol. Current FDA labeling for the approved uses of the drug states, “You should avoid drinking alcohol while taking [topiramate]. Alcohol with [topiramate] can make side effects such as sleepiness and dizziness worse.” In addition. the drug can cause metabolic acidosis, a condition that occurs when there is too much acid in your blood. Metabolic acidosis can cause symptoms such as tiredness, loss of appetite, irregular heartbeat and impaired consciousness.
December 2007
This article explains how to understand the International Normalized Ratio (INR), a test applied to a sample of a patient’s blood to determine how “thin” it is when you are using the blood thinner COUMADIN (warfarin). In addition, the article lists more than 50 drugs or dietary supplements that can interact harmfully with COUMADIN to cause the blood to be too thin (abnormal bleeding) or not thin enough which could result in lessening the effect of COUMADIN in stopping blood clot formation.
December 2007
This article summarizes 14 important health events that occurred in 2007, including seven that involve the pharmaceutical industry or its increasingly close financial partner, the FDA. Seven other reviews involve our so-called health care system.
November 2007
The European Medicines Agency (EMEA) has issued new warnings for the painkiller/arthritis drug piroxicam (Feldene). The drug "was singled out for special review because piroxicam-containing medicines are associated with more gastro intestinal side effects and more serious skin reactions than other non-selective NSAIDs." In a series of published studies, in comparison to ibuprofen (ADVIL, MOTRIN), piroxicam was between 2.8 and 7.1 times more likely to be associated with severe gastrointestinal toxicity, defined as bleeding, ulceration or perforation. No other NSAID was as consistently as high in gastrointestinal risk as piroxicam. We continue to recommend that this uniquely dangerous drug be classified as Do Not Use.
November 2007
Something never mentioned on cigarette warning labels is that smoking can affect the way a number of medications work, in some cases resulting in significant, dangerous adverse outcomes. Smokers should be aware that a number of medications may not work as well because of smoking cigarettes. The article lists 16 drugs whose levels in the blood become lower, making the drugs less effective, if the patient is also smoking.
November 2007
This month marks the beginning of an important addition to every issue of Worst Pills, Best Pills News concerning drug interactions. The articles are being written by one of the world’s top authorities on interactions, Dr. Philip Hansten of the University of Washington. This introductory article explains how to understand different types of interactions and every month, starting now, there will be a specific article on the adverse interaction of the month.
November 2007
A September 2007 report by the Inspector General (IG) of the Department of Health and Human Services suggests that there has been inadequate oversight of clinical trials in which experimental drugs are used, to the possible detriment of the patients in these studies.
People who are willing to take risks to benefit science and society deserve respect, even honor and certainly protection. They are entitled to a system that can monitor clinical trials and that can correct deficiencies before it is too late. What they have instead is a system that is more interested in the data they generate than their well-being.
November 2007
The authors of a recent British Medical Journal article plead for physicians to take a more global look at their patients, not to focus on individual diseases, and especially not to turn healthy patients into “sick” ones by the inappropriate use of certain prescription drugs. Rather than putting people on drugs for prevention of a disease they might never have, they recommend using the available money to improve the quality of life of their patients (e.g., provide cataract operations, joint replacement surgery, and personal care of those with dementia). Physicians should not turn the elderly population into patients worried about disease. Instead, they should provide them with the care needed to increase their enjoyment of day-to-day life.
November 2007
At present, facing increasing competition and dwindling sales, Pfizer has launched a “reminder” ad for Viagra that skirts FDA requirements. Because any ad that mentions the product’s name and the condition that it treats must also disclose its side effects, Pfizer has eclipsed its message with a song and an image. The song is “Viva Viagra” (to the tune of “Viva Las Vegas”) and the image is that of a jam session of guitar-playing 40-something-year-old men singing about their “not straying” and their devotion to an unseen “she.” The ad omits a caution against sexually transmitted diseases (STDs) and HIV, although this is flashed briefly on the screen. The result is an undermining of the pharmaceutical manufacturers’ original rationale for direct-to-consumer advertising: that it would be a tool to provide important information to patients who would benefit from the knowledge.
November 2007
The U.S. is essentially isolated when it comes to permitting Direct-to-Consumer (DTC) ads. Other than the U.S., only New Zealand has ever permitted such ads – and health authorities there have been recently struggling valiantly to put an end to them. Here in the U.S., the problem is more intractable. A veritable army of drug companies and advertisers, to say nothing of their now DTC-dependent counterparts in the print and electronic media, now exists to resist any challenge to the primacy of these ads. But the ultimate culprit is the government. By failing to provide objective information on medications, the FDA, in particular, has ceded its authority and delivered a massive nest egg to industry – with the usual, predictable results. The best we can hope for is that no other countries follow us down this garden path.
November 2007
Consumers are bombarded with claims about new medications, diets and devices. These claims promise much, and there is no guarantee that they will deliver. In fact, there are usually indicators that they will not deliver. In order to alert consumers to some of the tell-tale signs of questionable products, we have devised a quack-o-meter to assess these products. The article lists 10 different sorts of "quacks" that should alert people to the possibility/probability of fraudulent health products.
October 2007
The European Union has warned that Botox can travel from the site of injection and cause muscle paralysis at other sites. The consequences can include difficulty swallowing and inhaling of food into the lungs. The US FDA has not issued similar warnings.
October 2007
Hoodia is a Southern African succulent that is claimed to reduce the craving for food. In fact, it is just the latest in the long line of dietary supplements making unproven weight-loss claims.
October 2007
This article describes patients who have had side effects of drugs, in some cases leading to years of misdiagnosis. It also provides a list of common conditions that can be caused by drugs and some drugs that cause them.
October 2007
Because of evidence from a number of studies, the Food and Drug Administration (FDA) recently required a “black box” label for all SSRI (selective serotonin reuptake inhibitor) antidepressants indicating that use in children could lead to an increased risk of suicidal behavior. Now comes a study published in the prestigious American Journal of Psychiatry (Volume 164, pp. 1356-1363) purporting to show, in effect, the opposite: the FDA warnings had caused the rate of pediatric SSRI prescriptions to plummet and as a result young people are killing themselves due to lack of treatment. If this were true, it would be a clear example of the unintended consequences of regulation.
The paper and its subsequent publicity appear to be little more than a public relations ploy. The editors of the AJP should not have allowed such gross misrepresentations to pass into print unscathed, and journalists who cited this study as if it deserved equal credence to the RCTs are just as guilty.
September 2007
Varenicline was approved by the FDA in May 2006 for use as an aid in smoking cessation treatment. It belongs to a new family of drugs, not containing nicotine, but thought to work by stimulating nicotine receptors in the brain, just as nicotine does.
September 2007
This is the first of two articles discussing drug-induced diseases, often mistaken for these diseases that commonly occur even if you are not taking drugs. Examples include drug-induced depression, hallucinations, confusion, delirium, memory loss, impaired thinking as well as neurologic problems such as parkinsonism, involuntary movements of the face, arms, legs (tardive dyskinesia), and sexual dysfunction.
September 2007
This article describes Pfizer's attempts to promote Viagra for erectile dysfunction by targeting Latinos, in part through support to a Latino physicians association.
September 2007
Clinical trials databases can disclose that a trial is taking place and the results of the trial once it is completed. Our international study of such databases shows that only a government-run database is likely to produce a comprehensive, consumer-friendly database.
August 2007
Patients currently taking drugs approved for the treatment of ADHD who experience any of the cardiac or psychiatric side effects mentioned in this article are advised to seek medical attention immediately.
August 2007
The muscle spasm drug tizanidine (ZANAFLEX) combined with certain other drugs could cause serious complications such as drowsiness and can dramatically lower blood pressure, according to the Food and Drug Administration (FDA). The article lists 20 drugs to avoid if you are using Zanaflex so that you avoid these potentially dangerous interactions.
August 2007
Patients over the age of 65 taking or considering taking venlafaxine (EFFEXOR) should ask their provider to check for low blood sodium levels within three to five days after treatment is started.
Patients taking venlafaxine who are experiencing the symptoms of low blood sodium levels listed in the article should contact the prescriber as soon as possible.
Patients should not discontinue taking venlafaxine without first consulting with their prescribing health care provider. Other antidepressants in the SSRI family such as PROZAC and PAXIL have also been found to cause low sodium levels.
August 2007
There is no medical reason that you should be taking levocetirizine (XYZAL) rather than one of the many other prescription and non-prescription antihistamines that are available in the market. The article discusses alternatives.
August 2007
The article answers 18 commonly asked questions about the new vaccine for preventing cervical cancer such as:
Won’t the HPV vaccine cause an increase in teen sexual activity?
While this has also not been studied, this seems very unlikely to us. Of all the factors young women (and men) take into consideration when deciding whether to have sex, a vaccination, years previously, against an infection they may not have heard of seems unlikely to rank high.
August 2007
The article explains 15 of the most commonly used terms involving types of health insurance now being debated nationally, such as the difference between a market-based, pay-or-play, Medicare-for-all and single payer systems.
July 2007
In addition to years-old information about increased heart failure in patients using AVANDIA, that Worst Pills readers have been warned about for years, new evidence has emerged about increased heart attacks as well. The article reviews the evidence for both of these serious problems and why we continue to advise people not to use either AVANDIA or the related drug, ACTOS.
July 2007
Yet another reason has arisen to support our several years-old warning not to use the diabetes drugs AVANDIA or ACTOS. Randomized trials of both drugs, compared to other diabetes drugs, showed an increase in fractures in women (not men) using them.
July 2007
The harms of human growth hormone outweigh any benefit when used in healthy elderly individuals, according to a systematic review of randomized controlled trials. The article lists a number of side effects caused by growth hormone in otherwise healthy elderly people. The antiaging industry has established a new low in disease mongering by turning the normal aging process into a disease that can be treated by growth hormone.
July 2007
Because of new information about increased risks of suicidal thoughts associated with the use of a variety of antidepressants, people of all ages should be monitored closely with all antidepressants after the drugs are first prescribed, switched or when the dosage is changed.
Do not stop using any antidepressants without first consulting the prescriber.
July 2007
The government in the UK has removed the approval of desmopressin nasal spray for bedwetting because it can cause low sodium and life-threatening swelling of the brain. In the US, however, the drug is still approved for this purpose. The article discusses symptoms of low sodium induced brain swelling that should lead to seeking emergency medical help.
June 2007
Worst Pills, Best Pills reviews side effects and long-term effects of type-2 diabetes drug sitagliptin (JANUVIA) in this article.
June 2007
On March 29, 2007, the Parkinson’s disease drug pergolide (PERMAX) was withdrawn from the market. This follows the publication of two studies which show an increased risk of heart valve damage in patients taking pergolide compared to those not taking the drug. You should contact your health care professional immediately if you are taking pergolide to discuss other treatments. Do not discontinue taking pergolide abruptly. The dosage of the drug must be gradually decreased.
June 2007
Yet another problem has been detected with this diet drug whose approval we opposed and that we have been attempting to get banned. The FDA found 37 cases of gall stones in patients using orlistat. This, in addition to inhibiting the absorption of important vitamins such as A, D, E and K as well as evidence that the drug can cause pre-cancerous abnormalities in the colon of animals, further emphasizes why this barely effective drug should not be used, either in the prescription version called Xenical or the about-to-appear over-the-counter version, Alli.
June 2007
If you experience one or more of the signs of liver toxicity listed in the article, you should stop taking telithromycin and call your physician immediately. Do not take another dose of the drug unless instructed to do so by your physician.
June 2007
The Food and Drug Administration (FDA) removed tegaserod (ZELNORM), a widely prescribed constipation drug, from the market on March 30, 2007. Public Citizen wrote a letter to the FDA opposing the approval of this drug in March 2001 because studies showed it to be only marginally effective. Further, the drug exhibited serious safety problems in clinical trials before it was approved, including an increased incidence of non-cancerous ovarian cysts and a five-fold increase in fainting compared to patients receiving a placebo. For the past three years, we have urged readers of Worst Pills not to use the drug. If you are currently taking tegaserod, you should contact your physician right away to discuss alternative treatments.
May 2007
A few months ago the FDA warned about the potential of methadone - when used to treat pain - to cause life-threatening breathing problems and heart rhythm disturbances. When it made this safety announcement, however, the FDA negligently failed to point out that they had recommended a drastic reduction in the starting dose for pain to prevent some of these life-threatening adverse reactions. The new recommended starting dose is more than a 2.5 fold reduction in the dosage for the initial treatment of pain. Symptoms of overdose with the older, higher doses are discussed in the article.
May 2007
Not only does this study find that consumer drug ads are not educational, it also says that the ads may oversell the benefits of the drugs and could put the public health in danger. For example, of the 24 drugs included in this advertising study, seven are listed as Do Not Use in Worst Pills, Best Pills publications. You should not rely on direct-to-consumer television advertisements as a source of drug information.
May 2007
Patients taking sleep medications could be at risk of severe allergic reactions and complex sleep-related behaviors, which may include sleep driving, driving while not fully awake after ingestion of a sleeping pill, with no memory of the event, according to the FDA. DO NOT suddenly stop taking sleeping pills without consulting your physician because of the possibility of withdrawal reactions.
April 2007
Public Citizen's Health Research Group filed a petition with the Food and Drug Administration (FDA) on February 6, 2007, to ban the sale of all third-generation oral contraceptives (OCs), which double the risk of potentially life-threatening blood clots compared to second-generation birth control pills. A list of these oral contraceptives that contain desogestrel accompanies this article.
April 2007
The long-term safety of lubiprostone is unknown. Because lubiprostone is the first in a new class of drugs that works in a new way, it is possible that unknown and unpredictable side effects may occur after the drug is used in large numbers of patients.
April 2007
Roche Laboratories Inc., announced on November 14, 2006, that new precautions have been added to Tamiflu's professional product label (also known as a package insert) about the possibility of abnormal behavior in children and adolescents that, in extreme cases, has resulted in deaths. Oseltamivir should be stopped immediately if the person taking this drug develops abnormal behavior, delirium, hallucinations, delusions, aggression, suicidal ideation and/or other mental status changes while taking the drug to treat the flu.
March 2007
Prescription and over-the-counter cough and cold medications should not be used in children younger than 2 years of age. For example, the American Academy of Pediatrics issued a policy statement advising that parents should be told that efficacy of the cough suppressants codeine and dextromethorphan in young children was unproven, and that there is a potential for adverse drug reactions.
March 2007
Although the FDA medical officer in charge of reviewing ranolazine recommended that ranolazine's professional product labeling display a black box warning about potential disruption in the heart's electrical cycle, the drug does not have a black box warning.
March 2007
There is reliable evidence that products containing black cohosh do not help menopausal symptoms compared to no treatment at all and there is growing evidence of substantial harm, such as liver toxicity, with the use of this dietary supplement.
February 2007
Some of the names used for these products are: Anesthetic Skin Lotion (containing lidocaine and prilocaine), Tetracaine in DMSO Gel (tetracaine and dimethyl sulfoxide) and Triple Kwick Anesthetic Gel (benzocaine, lidocaine and tetracaine), N*E*W* topical anesthetic (lidocaine, prilocaine and tetracaine), Kwick Anesthetic Gel (benzocaine, lidocaine, tetracaine and dimethyl sulfoxide), Lidocaine and Tetracaine Demi Gel and Anesthetic Skin Gel 3+ (lidocaine, prilocaine and tetracaine). The article explains the risks of each.
February 2007
Deaths, cardiac and respiratory, have been reported during initiation and conversion of pain patients to methadone treatment from treatment with other opioid agonists. Because methadone has some of the effects of other narcotics, do not stop the drug without consulting the prescriber because of the possibility of serious and uncomfortable withdrawal symptoms.
February 2007
The use of unapproved quinine-containing drugs to prevent nocturnal leg cramps poses serious safety concerns, including the risk of death, according to a December 11, 2006, warning from the Food and Drug Administration (FDA). The risk associated with the use of quinine sulfate in the absence of evidence of its effectiveness for treatment or prevention of nocturnal leg cramps, outweighs any potential benefit in treating and/or preventing this benign, self-limiting condition.
February 2007
If you are presently using albuterol and your asthma is adequately controlled, there is no medical reason why you should be switched to levalbuterol. There is no convincing evidence that it is any safer or more effective than the older, much less expensive short-acting beta agonist, albuterol.
February 2007
The Food and Drug Administration (FDA)is proposing that the Prescription Drug User Fee Act (PDUFA) be reauthorized by Congress this year and that under the act, drug companies give the agency nearly $400 million a year. The FDA's crucial drug regulatory functions are too important to be tainted and compromised by direct funding from the very companies whose drugs the agency reviews for safety.
February 2007
Recent data confirm that drug manufacturers are also savvy marketers, and that they consider physicians to be a prime target. In 2004 drug companies spent a total of $7.8 billion influencing physicians. This computes to an average of $10,000 for every practicing doctor in the United States. If these companies gave each doctor a check for this amount, we would be duly outraged.
February 2007
Imagine the following: You are involved in a lawsuit against a manufacturer whose product you say caused you injury. During the trial, you get the impression that the judge is favoring your opponent; ruling to his or her advantage on motions, objections, evidence and the like, and you end up losing. Later, you learn that the judge had a significant financial interest in the form of stocks and stock options in the company you sued. Would you suspect that you had been had by a biased judge? You bet!
January 2007
An estimated 701,547 patients were treated for adverse drug reactions in emergency rooms each year in 2004 and 2005, totaling 1.4 million visits to the emergency room. Of these, an estimated 117,318 patients were hospitalized each year. According to the study. 18 drugs were each, either independently or in combination with other drugs, implicated in one percent or more of the estimated adverse drug events. These drugs are listed in the table that accompanies this article along with the annual estimates of adverse drug events.
January 2007
The seizure and depression drug lamotrigine (LAMICTAL) may cause birth defects when taken during the first trimester of pregnancy. Specifically, the drug may cause either or both cleft lip (a gap in the upper lip) and cleft palate (a gap the roof of the mouth) in babies. If you are taking lamotrigine and become pregnant, consult the prescribing physician immediately. DO NOT discontinue any seizure medication without first consulting the prescriber.
January 2007
Serious health complications involving toxicity to the bone marrow have been reported in association with the drug terbinafine (LAMISIL), according to the August 2006 edition of the Australian Adverse Drug Reactions Bulletin. This is in addition to the hundreds of cases of liver toxicity that were the cause of our listing this drug as Do Not Use.
January 2007
Cognitive behavioral therapy is a safer, more effective alternative to taking sleeping pills such as zopiclone or eszopiclone (Lunesta).
DO NOT ABRUPTLY DISCONTINUE ANY SLEEP MEDICATION BECAUSE OF THE POSSIBILITY OF WITHDRAWAL REACTIONS.
January 2007
The article describes, in detail, a safe, sustainable combination of diet and exercise that enables people to lose one pound per week.
January 2007
New evidence indicates that conflicts of interest permeate much of what passes as unbiased scientific judgment, and that three gatekeepers of medical knowledge the National Institutes of Health, institutional review boards monitoring human experimentation, and major medical journals are part of the problem.
December 2006
The Food and Drug Administration (FDA) announced October 10 that an agency-approved Medication Guide, which provides information about drug safety, will now be required to accompany all new and refill prescriptions for the blood thinner warfarin (COUMADIN). Warfarin can interact dangerously with a number of other drugs, dietary supplements and vitamins, but these products are inexplicably not listed in the Medication Guide. The details of these serioius interactions can be found at Worstpills.org or in our book, Worst Pills, Best Pills.
December 2006
In addition, there was an almost significant 37 percent excess in the rosiglitazone group of what the authors called cardiovascular events composite, comprised of heart attacks, strokes, cardiovascular deaths, heart failure, the appearance of new angina attacks, and the need for heart surgery such as bypass or angioplasty. You have a greater likelihood of preventing type 2 diabetes by improving your diet and getting a moderate amount of exercise than by taking a prescription drug. The effects of such a change in lifestyle can last a lifetime.
December 2006
Consumers can play a vital role in protecting the public health by reporting to the Food and Drug Administration the often serious health problems they experience while taking prescription drugs and dietary and herbal supplements or while using medical devices. The article details different ways to report to the FDA.
November 2006
If you are considering treatment with a stimulant ADHD drug for yourself or your child, become familiar with the new warnings for these drugs that are presented in this article. The new warnings do not tell patients that the drugs can also cause sudden death in those using the medication properly, not just in those abusing the drugs.
November 2006
You should not use beta blocker eye drops to treat glaucoma if you have pre-existing breathing or certain heart conditions.
November 2006
You should stop taking fluoroquinolones(listed in the article) and immediately contact your physician if you experience pain in any tendon while taking one of these antibiotics so you can be switched to another antibiotic.
November 2006
A study published in the Journal of the American Medical Association found an increased risk of death in patients using l-arginine after a heart attack. L-arginine is widely promoted on the Internet for a number of conditions, including protecting the heart.
November 2006
A joint effort of the Food and Drug Administration (FDA) and the Federal Trade Commission(FTC) has resulted in recent warning letters to a large number of companies who are illegally marketing unproven diabetes treatments online. The article lists many of these products.
October 2006
The FDA analysis found that some of these products illegally contained sildenafil (VIAGRA), which is FDA-approved for erectile dysfunction. Others contained chemicals similar to sildenafil.
October 2006
If you are taking triptans, SSRIs or SNRIs and experience the symptoms of serotonin syndrome listed in this article, you should seek medical attention immediately. This is because of the possibility of life-threatening reactions such as nausea, changes in blood pressure or hallucinations that may be caused by the interaction of migraine headache drugs, called triptans, and certain antidepressants.
October 2006
Although this osteoporosis drug has been shown to decrease vertebral fractures, which involve the bones that make up the spine, the drug did not show any decrease in nonvertebral fractures, such as hip fractures, in postmenopausal women. We know more about the older, alternative drugs for osteoporosis.
October 2006
Women who are pregnant and taking certain antidepressants take note: a recent study finds that you are more likely to have a recurrence of depression if you stop treatment during pregnancy, but another recent study suggests that taking certain antidepressants may harm your baby. Find out about this dilemma.
October 2006
Placebos are very powerful. Beyond yoga for lower back pain and acupuncture for analgesia, there has not been a study showing an unequivocal benefit of an alternative therapy when subjected to the rigor of an NIH trial. This negative outcome should not be greeted smugly, because most experimental drugs developed by pharmaceutical or biotechnology companies fail to fulfill their promise.
September 2006
The authors of the study commented that their review of previously published medical studies supports their observations that some healthy adult patients in clinical trials developed ALT elevations when repeatedly treated with four grams of acetaminophen daily,which is within the recommended dosage range for the drug.
September 2006
The typical signs and symptoms of osteonecrosis of the jaw may include pain, swelling or infection of the gums, loosening of the teeth, poor healing of the gums, numbness or a feeling of heaviness in the jaw, drainage and exposed bone. Patients taking a bisphosphonate (including Fosamax) should carefully monitor themselves for any sign of jaw problems resembling those described in this article.
September 2006
The Food and Drug Administration (FDA) announced that new warnings about liver toxicity, including the possibility of death, have been added to the package insert for the antibiotic telithromycin (KETEK).
September 2006
Ophthalmologists consulting for the Medical Letter generally agree that all eye drops should only be used in a dose of one drop because there is a smaller chance of an overdose with one drop. Also, using one drop instead of two makes more efficient use of the medicine.
September 2006
Promoting a particular body image or behavior pattern as the preferred one and then selling medicines or products to help people attain the particular ideal may be regarded as disease mongering. Fairness cream manufacturers have exploited the preference for fair skin, portrayed it as a necessary prerequisite for success, and promoted the use of their product to achieve the ideal. Controlled studies on the efficacy and safety of fairness creams are lacking.
August 2006
Because of the risk of birth defects, you should contact your physician immediately if you are pregnant and are taking either an ACE or ARB inhibitor at any stage in pregnancy. DO NOT discontinue a blood pressure-lowering drug without first consulting the prescriber.
August 2006
Two industries peddling hormone replacement drugs became involved in a conflict with one another on October 6, 2005, when the pharmaceutical company Wyeth filed a petition with the FDA urging the agency to counter flagrant violations of the law by pharmacies compounding Bioidentical Hormone Replacement Therapy Drugs. Both sides have been very culpable in assaults on women's health.
August 2006
PHENERGAN should not be used in pediatric patients less than two years of age because of the potential for fatal respiratory depression. It is also advisable that the drug not be given to children less than 16 years of age.
August 2006
49 cases of liver toxicity worldwide have been associated with the use of the dietary supplement black cohosh.
August 2006
An anthropologist comments insightfully on the pharmaceutical industry's exploitation of medical consumers. He concludes that "[I]n our pursuit of a near-utopian promise of perfect health, we have, without realizing it, given corporate marketers free reign to take control of the true instruments of our freedom: objectivity in science, ethics and fairness in health care, and the privilege to endow medicine with the autonomy to fulfill its oath to work for the benefit of the sick."
July 2006
You should wait to use raloxifene for reducing the risk of breast cancer until the drug is FDA approved for this use.
July 2006
21 percent of the prescriptions written in 2001 in the United States were for drugs that were not deemed to be safe and effective to treat the diseases or symptoms for which they were prescribed. If you have been prescribed a drug for an off-label (unapproved) use, ask your physician about the science supporting the use of the drug and ask if a drug that is approved for that use could be substituted.
July 2006
The article discusses numerous recent examples of the harm that has been caused by off-label prescribing, including the heart drugs amiodarone (Cordarone), many antipsychotic drugs, topiramate (Topamax)and several antidepressants.
July 2006
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo...The percentage of patients using antipsychotic drugs in the six nursing homes receiving training and support was significantly lower (23 percent) than that in the nursing homes whose patients received usual care (42.1 percent).
June 2006
Public Citizen petitioned the Food and Drug Administration (FDA) on Apr. 10, 2006 to immediately remove the diet drug orlistat (XENICAL) from the market. The basis for the petition is the fact that orlistat can cause pre-cancerous changes in the lining of the intestines called aberrant crypt foci (ACF). You should not take orlistat. There is no evidence that this drug can reduce the health risks associated with obesity and inactivity, and the drug's minimal effectiveness for weight loss-coupled with both the real and theoretical risks of orlistat-outweigh any known benefit for the drug.
June 2006
On Feb. 28, 2006, the Health Research Group petitioned the Food and Drug Administration (FDA) to immediately begin phasing out the sale of the dangerous painkiller propoxyphene (DARVON). The reason for the petition is that propoxyphene has been associated with over 10,000 confirmed deaths and 2,110 reported accidental deaths in the U.S. from 1981 through 1999. There are many generic versions of propoxyphene on the market, as well as a number of products that combine propoxyphene with acetaminophen (TYLENOL). These products are sold as DARVOCET and are also widely sold as generic drugs. A phased withdrawal, instead of an immediate ban, is necessary because of the addicting properties of the drug and the need to switch patients to other painkillers.
June 2006
Assume that any new symptom you develop after starting a new drug may be caused by the drug. If you develop a new symptom after starting atorvastatin or other statins (such as nightmares), report it to your doctor. The drug may be responsible.
June 2006
You should not use combinations of folic acid and B vitamins to lower blood levels of homocystine with the goal of preventing heart attacks, strokes, or sudden death. There is no evidence of a beneficial effect of these vitamins, and there is a possibility that they may cause harm.
June 2006
There is increasing evidence that the arthritis drug leflunomide (ARAVA), taken alone or in combination with another drug, methotrexate, can case serious lung inflammation called pneumonitis. If you are taking leflunomide, either alone or in combination with methotrexate, and you experience difficulty breathing, a dry cough, and dizziness, you should contact your physician immediately.
June 2006
A Harris poll released on May 24th found that 58 percent of 2,371 people surveyed last week thought that the Food and Drug Administration (FDA) does only a fair or poor job ensuring the safety and efficacy of new prescription drugs, a significantly worse assessment than as recently as two years ago. This shows that the public has caught on to the systemic problems at the FDA — problems that jeopardize the health of millions of prescription drug users in this country.
June 2006
Every other substantial country in the world has some kind of government price controls on pharmaceutical manufacturers. This policy assures that any savings realized go to the government and taxpayers rather than being diverted to profits of a middleman.
May 2006
If you have had a previous heart attack or stroke or have blood vessel disease, you should be on aspirin treatment rather than clopidogrel with or without aspirin. You should only take clopidogrel if you cannot tolerate aspirin.
May 2006
New research published in the March 2006 edition of the Journal of the Royal Society of Medicine indicates that the popular arthritis and painkilling drug celecoxib (CELEBREX) may double the risk for heart attacks compared to older arthritis medications.
May 2006
In the most rigorous study to date, there was no evidence of effectiveness for glucosamine, chondroitin or the two together. We continue to recommend against the use of these unregulated supplements.
May 2006
ADVAIR DISKUS is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled, short-acting beta2-agonists.
May 2006
If you are taking venlafaxine (Effexor XR)and experience an episode of increased blood pressure you should talk to the prescribing healthcare provider about lowering the dose or stopping the drug.
May 2006
In comments about the benefit risk ratio of the testosterone patch for women, the question was asked, "Is an increase in approximately one sexually satisfying encounter a month (not from zero to one, but from approximately four to five times per month) worth the possibility of an increase in breast cancer or coronary artery disease?"
May 2006
The desire to take medicine," wrote Dr. William Osler, "is perhaps the greatest feature which distinguishes man from animals." This desire, however, is neither innate nor stable over time. At present, it is actively promoted by direct-to-consumer advertising on TV and pop-up ads on the Internet as well as by industry-funded disease-awareness campaigns. New diseases may result from new pathogenic agents, of course. But they are most often the result of three deliberate processes: the medicalization of aspects of everyday life (e.g., menopause), the portrayal of mild problems as serious illnesses, and the framing of risk factors (high cholesterol, obesity, osteoporosis) as diseases. The recent issue of PLoS Medicine cited elsewhere illustrates how these processes have affected the diagnosis and treatment of a number of relatively new disease entities
April 2006
If you experience visual deterioration while taking rosiglitazone (AVANDIA)or the combination of rosiglitazone with metformin (AVANDAMET), report this potential adverse drug reaction to your physician as soon as possible.
April 2006
Saw Palmetto was found to be no more effective than sugar pills in treating urinary symptoms from an enlarged prostate.
April 2006
A study has shown that patients given l-arginine after a certain type of heart attack were more likely to die than similar patients given a placebo (sugar pill).
April 2006
Mallinckrodt Inc. has agreed to remove the diagnostic drug technetium 99m Tc fanolesomab, a drug to help diagnose appendicitis, from the market because of potentially fatal adverse drug reactions, according to a Dec. 19, 2005 Food and Drug Administration announcement. This is the 17th new drug safety withdrawal since 1992.
April 2006
If you are taking lovastatin to lower your cholesterol and also take any of the 13 drugs discussed in this article, consult with your physician as soon as possible. Dose alterations may be necessary to avoid drug-induced muscle damage.
April 2006
Among the reasons not to trust prescription drug advertising is that the FDA has admitted that 82 percent of drug advertising violations were because inadequate risk information was presented in the ads. The article discusses the importance of using reliable sources for this important information.
March 2006
There is no reason to take telithromycin.(KETEK) There are safer and equally effective antibiotics available that are approved to treat the same illnesses. If you or a family member experience the symptoms of potential liver toxicity listed in the article, contact the prescriber immediately. Do not stop taking this antibiotic without an urgent call to your physician so you can be placed on a different, safer antibiotic.
March 2006
You should talk to your physician prior to a colonoscopy or other procedure that requires a sodium phosphate bowel cleansing drug about the possibility of phosphate-induced kidney toxicity. There are alternative methods of pre-colonoscopy bowel cleansing, discussed in the full article, that are effective but are safer because they do not involve the use of sodium phosphate.
March 2006
Because of the possibility of an increased risk of potentially fatal blood clots with the use of this product, there is no medical reason for women to use the more dangerous Ortho Evra patch rather than one of the older, better understood, and equally or more effective oral contraceptives.
March 2006
If you are now taking Avinza or Kadian, you should ask your doctor whether another painkiller such as immediate-release morphine might be more appropriate. If you decide to continue taking Avinza or Kadian, you should be sure never to consume alcohol or chew, crush, or dissolve the capsules.
March 2006
The Food and Drug Administration requested that additional new safety warnings be added to the professional product labels for the popular asthma drugs salmeterol (SEREVENT), salmeterol with fluticasone (ADVAIR), and formoterol (FORADIL). The new warnings concern the possibility that these drugs may increase the chance of severe asthma attacks and asthma-related death. DO NOT STOP ANY ASTHMA MEDICATION WITHOUT FIRST CONSULTING YOUR PHYSICIAN. ABRUPTLY STOPPING A MEDICATION MAY RESULT IN ACUTELY DETERIORATING ASTHMA CONTROL.
February 2006
Research published in the December 2005 issue of the medical journal Hepatology found that the annual percentage of potentially fatal acute liver failure (ALF) cases caused by acetaminophen (TYLENOL) rose from 28 percent in 1998 to 51 percent in 2003. The article discusses the problem of alcohol and Tylenol with recommendations.
February 2006
Clearly, the concern here is that the use of atypical and typical antipsychotic drugs to control the behavior of elderly nursing home residents who are not psychotic could be considered an unlawful chemical restraint.
February 2006
Antibiotic-associated diarrhea (AAD) is quite common and its incidence varies from 5% to 20% of patients depending on which antibiotic they are taking. The article lists some of the drugs most associated with this potentially life-threatening adverse reaction.
February 2006
On Dec. 21, 2005, the Canadian equivalent of the Food and Drug Administration (FDA), Health Canada, warned the public and healthcare professionals of serious cases of both low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia) with the use of the fluoroquinolone antibiotic gatifloxacin (TEQUIN).
February 2006
On January 23rd, an FDA advisory committee voted to recommend that the agency allow the weight-reduction drug orlistat (Xenical) to be marketed in an over-the-counter form that will be known by the brand name ALLI. However, the drug caused only a minimal increase (4-5 pounds) in weight loss compared to placebo, and studies showed that over time, weight could begin to return. There are also significant safety concerns including the possibility of drug-induced malnutrition and GI effects, including loss of bowel control. The drug is not useful and should not be made over-the-counter.
February 2006
Enter Abstract Here
January 2006
This drug is minimally effective and the long term safety effects of the increased prolactin levels caused by ramelteon are unknown.
January 2006
If you are considering starting HRT (hormone replacement therapy), the possibility of experiencing urinary incontinence should be taken into account along with its other potential harms, which are outlined in the black box warning accompanying this article.
January 2006
We have asked the Food and Drug Administration (FDA) to add black box warnings to the professional product labels, or package inserts, for the erectile dysfunction drugs sildenafil (VIAGRA), tadalafil (CIALIS), and vardenafil (LEVITRA). The warnings would alert prescribers to the possibility of irreversible vision loss with the use of these drugs.
January 2006
Enter Abstract Here
December 2005
Bacterial meningitis is a potentially life threatening condition that is characterized by fever, headache, vomiting, malaise, and a stiff neck. At this time, the FDA and the CDC do not know whether the five cases of Guillain-Barre Syndrome were caused by the Sanofi Pasteur vaccine or were merely coincidental to the administration of the vaccine.
December 2005
You should consult with your doctor immediately if you are taking paroxetine and are pregnant and particularly if you are in your first trimester. Suddenly stopping paroxetine and drugs like it may result in a withdrawal syndrome. See the warning statement above.
December 2005
The Food and Drug Administration (FDA) issued a Public Health Advisory on Sept. 29, 2005 to warn of suicidal thinking in children and adolescents being treated with atomoxetine (STRATTERA) for attention deficit hyperactivity disorder (ADHD). There is no convincing evidence that atomoxetine (STRATTERA) is as effective or as well tolerated as stimulants such as methylphenidate (CONCERTA, and others) for treatment of ADHD.
December 2005
Product problems should be reported to the FDA when there is a concern about the quality, authenticity, performance, or safety of any drug or device.The article tells how to report to the FDA.
December 2005
In the October 2005 issue of the Canadian Adverse Reaction Newsletter, 19 case reports of memory loss or impairment associated with the use of a cholesterol-lowering statin drug were analyzed. If you are taking a statin drug and you notice memory problems, talk to your doctor about stopping the drug or reducing the dose.
December 2005
Research published in the August 6, 2005 British Medical Journal found that the daily use of a multivitamin with a mineral supplement by people over 65 years of age did not did not affect numbers of infections, use of health care services, quality of life, number of antibiotic prescriptions, or hospital admissions compared to an inactive placebo.
December 2005
Enter Abstract Here
December 2005
Enter Abstract Here
November 2005
You should contact the prescribing physician as soon as possible if a family member with Parkinson’s disease who is being treated with a dopamine agonist suddenly changes behavior in regards to gambling. (see article for list of drugs)
November 2005
Echinacea dietary supplements are not more effective than placebo.
November 2005
Homeopathy does not provide a useful alternative to conventional medicine. It only provides an alternative method for wasting money on unproven treatments.
November 2005
Your best source of vitamins is a healthy balanced diet. Use the chart in this article for examples of vitamin-rich foods. Use vitamins only when they are necessary and in consultation with your physician.
November 2005
The Canadian ban was taken because manufacturers of the drug have failed to provide convincing evidence that thioridazine is safe to use. The questions about safety involve cases of heart rhythm disturbances that can be life-threatening.
November 2005
The committee’s report makes clear that reducing the influence of the industry would be good for everybody, including — paradoxically — the industry itself, which could concentrate on developing new drugs rather than on corrupting doctors, patient organisations, and others.
October 2005
Using the antibiotic clarithromycin (BIAXIN, BIAXIN XL) in combination with the gout drug colchicine at the same time increases the risk of death because of colchicine toxicity, a recent study shows. In the 88 patients who received the two drugs together, nine (10.2 percent) died. Only one (3.6 percent) of the 28 patients who received the two drugs sequentially died.
October 2005
A study appearing in the August 2005 Archives of Neurology provides important new data indicating that the risk of sudden sleep is considerable with certain drugs used to treat Parkinson's Disease(see list in article). You should not drive a car or engage in other potentially dangerous activities unless you have gained sufficient experience from taking any of these drugs while engaged in non-dangerous activities to gauge whether or not you are affected adversely.
October 2005
As the black box warning suggests, fentanyl skin patches should not be used in the following situations:in patients who have not previously been prescribed opioid painkillers, in the management of acute pain or in patients who require opioid pain killers only for a short period of time.
October 2005
There is no reason why you should use Lindane Lotion or Shampoo when safer and equally effective treatments for lice and scabies are available.
October 2005
This article outlines a recent systematic review of all published, gold standard clinical trials of the Alzheimers disease drugs donepezil (ARICEPT), rivastigmine (EXELON), and galantamine (REMINYL).
September 2005
Do not stop any asthma medication without first consulting your physician. Abruptly stopping a medication may result in acutely deteriorating asthma control.
September 2005
You should only be using BiDil for congestive heart failure in combination with other drugs for this condition. For one-fourth of the cost, with the cooperation of your physician, you can get prescriptions for the two generically-available drugs that comprise BiDil, isosorbide dinitrate and hydralazine.
September 2005
There is evidence that links the popular birth control patch containing a combination of norelgestromin with ethinyl estradiol (ORTHO EVRA) to an increased risk of blood clots and deaths (compared to older contraceptives) in some young healthy women.
September 2005
The Food and Drug Administration (FDA) asked the maker of the long-acting potent narcotic, or opiate, painkiller hydromorphone (PALLADONE) to remove the drug from the market because of a potentially fatal interaction with alcohol. If you are now taking Palladone, Avinza, or Kadian you should talk to your physician immediately to discuss alternative treatment.
August 2005
You should not use sildenafil Viagra), vardenafil(Levitra), or tadalafil(Cialis) for recreational purposes because there is no medical benefit to be gained. The possible harm from these drugs, no matter how small, will always outweigh a lack of medical benefit. If you experience any visual problems while using these drugs, notify your doctor immediately.
August 2005
The FDA Office of Drug Safety recommended that the professional product labeling for alendronate(Fosamax)and risedronate (Actonel) also be revised to warn of the possibility of osteonecrosis of the jaw (destruction of the jawbone). At this time, the FDA has not taken such action.
August 2005
If you are healthy, you should not undertake aspirin treatment for the primary prevention of cardiovascular disease without consulting your physician about whether you are at high enough risk to benefit.
August 2005
Even when fully operational, the site will not be very critical or have very many, if any, of the details about the listed drugs merited by the evidence of their dangers. For this, you will still need to consult the book Worst Pills, Best Pills or our web site www.worstpills.org.
August 2005
Merck aimed to re-formulate the arthritis drug Vioxx five years ago in order to reduce the potential for heart attacks, adding to previous evidence that the company was fully aware of the dangers of the drug well before it withdrew it from the market last year.
August 2005
"[T]ravel funds, honoraria for minimal consultant visits, lunch for students/residents/faculty, elegant dinners associated with product demonstrations, and guest lecturers with favorable views of donors' products are all suspect. They threaten our integrity and our ability to put patients first in our medical decisions."
July 2005
Further evidence that Crestor causes uniquely high rates of muscle and kidney damage
July 2005
FDA relabels these drugs due to an increased risk of death among patients taking the drugs off-label for dementia.
July 2005
This dietary supplement, often used as a substitute for ephedra, can cause stroke.
July 2005
This drug has no unique benefits, is costly and has caused cancer in an animal study.
July 2005
How the pharmaceutical industry has turned medical journals into an arm of their marketing operations.
July 2005
A new study shows how direct-to-consumer advertising can increase the use of antidepressants for minor conditions.
July 2005
How one doctor tried to resist the largesse of the pharmaceutical industry – and how the industry responded.
June 2005
Oxcarbazepine (TRILEPTAL) has been associated with life-threatening skin reactions. If you or a family member develop AN ALLERGIC reaction or a skin rash while taking oxcarbazepine (TRILEPTAL), contact the prescribing physician immediately.
June 2005
You should not use coenzyme Q10 in an attempt to prevent or treat the adverse reactions associated with the use of the cholesterol lowering statin drugs.
June 2005
If you are currently taking celecoxib (CELEBREX)you should contact your physician to consider alternative NSAID treatment.
May 2005
Both solifenacin or darifenacin are only modestly effective compared to a placebo, both carry the risk of significant harm to older adults, and both are overpriced.
May 2005
When studied for cardiovascular disease and cancer using the scientific "gold standard" method, a randomized controlled clinical trial, vitamin E offers only a cost without benefit and perhaps some harm.
May 2005
The Food and Drug Administration (FDA) issued a public health advisory on March 10, 2005 to inform patients and healthcare professionals about the potential risk of cancer with the use of two topical drugs, pimecrolimus (ELIDEL) and tacrolimus (PROTOPIC). If pimecrolimus or tacrolimus is the only treatment option for you or a family member for eczema, follow the advice given by the FDA carefully.
May 2005
The use of the heartburn drug metoclopramide (REGLAN) is increasing and that this fact may result in more cases of drug-induced movement disorders from metoclopramide (Reglan)that in some cases mimic Parkinson. If you or a family member are taking metoclopramide and uncontrollable movements develop, contact the prescribing physician immediately.
April 2005
Amiodarone has several potentially fatal toxicities, the most important of which is lung toxicity. This has resulted in clinically manifest disease at rates as high as 10 to 17 percent in some series of patients. This type of lung toxicity has been fatal about 10 percent of the time.
April 2005
The decision to remove this drug from the market is based on the fact that it is a poor pain reliever and that the risk of toxicity in overdose, both accidental and deliberate, is unacceptable.
April 2005
The warning concerns respiratory depression and death with its use in children less than two years of age. Antinausea drugs are also referred to as antiemetics.
April 2005
You should not be taking tiagabine for any use other than treatment of partial seizure. Tiagabine has not been shown to be safe and effective for any use other than treatment of partial seizure.
March 2005
There is no evidence that this drug leads to substantial functional improvement or prevents the progression of the disease, and new evidence indicates that it may increase the risk of death.
March 2005
If you are now taking clopidogrel and do not have a severe allergy to aspirin, contact your doctor and discuss switching from clopidogrel to low dose aspirin plus a PPI.
March 2005
If you must use a statin drug to control your cholesterol, you should use one that has an FDA health benefit claim in its professional product labeling.
(chart with these statins listed in the article)
March 2005
There is no medical reason why you should be taking meloxicam rather than an older, equally effective NSAID such as ibuprofen to manage arthritis.
February 2005
This article will look at the potential savings for the individual consumer if the alternative treatments recommended in Worst Pills, Best Pills were used for six DO NOT USE drugs. All six are listed in the Drug Topics Magazine Top 200 selling drugs in U.S. in 2003. The drugs are: celecoxib (CELEBREX) used for arthritis and pain; the Alzheimer’s disease drug donepezil (ARICEPT); drospirenone with ethinyl estradiol (YASMIN 28), an oral contraceptive; esomeprazole (NEXIUM) the “new purple pill” for heartburn; montelukast (SINGULAIR), a drug approved for both asthma and hay fever; and valdecoxib (BEXTRA), an arthritis drug very similar to celecoxib.The combined sales of these six DO NOT USE drugs was $8.1 billion with more that 75 million prescriptions dispensed in 2003.
February 2005
On December 17, 2004 the Food and Drug Administration (FDA) issued a new warning for atomoxetine (STRATTERA), a drug approved to treat attention deficit hyperactivity disorder (ADHD) in adults and children, to include a bolded warning about the potential for severe liver toxicity.
February 2005
The Food and Drug Administration (FDA) announced on November 17, 2004 that a black box warning is now required in the professional product labeling, or package insert, for the widely prescribed injectable long-term contraceptive medroxyprogesterone acetate (DEPO-PROVERA).
January 2005
An FDA reviewer wrote: In the event that unconfounded cases of severe liver injury or acute liver failure related to duloxetine treatment are identified and submitted early in the postmarketing period, the division will use the threshold of three “clean” cases to initiate additional regulatory action that could range from a more prominent warning to the withdrawal of the drug product.
January 2005
If you have had a previous heart attack, stroke, or have blood vessel disease you should be on aspirin treatment rather than clopidogrel unless you cannot tolerate aspirin, or aspirin treatment has failed.
If you are now taking ticlopidine and cannot take aspirin, talk to your doctor about clopidogrel.
January 2005
The FDA offers several ways for health professionals or consumers to submit MedWatch reports:
Online — Go to the MedWatch Web site at www.fda.gov/medwatch/ and follow the instructions for submitting a report electronically
By mail — Fill out and mail the MedWatch form on the next page to the FDA
By phone — The toll-free number for reporting to the FDA is 1-800-FDA-1088
December 2004
We are concerned about any new drug but are particularly concerned about the use of ZETIA together with statins.
December 2004
The letter was prompted by a new Public Citizen analysis of adverse drug reaction reports to the FDA. The analysis found that the rate of reports of kidney failure or damage among patients taking Crestor is 75 times higher than in all patients taking all other statin drugs.
December 2004
Belatedly, the Food and Drug Administration (FDA) announced on October 15, 2004 that it is taking steps to inform parents and physicians about the risks of antidepressants when these drugs are used to treat major depressive disorder in children and adolescents.
December 2004
The Food and Drug Administration (FDA) now requires that the professional product labeling, or package inserts, for all fluroquinolone antibiotics must warn about the possibility of peripheral neuropathy (nerve damage).
A list of the fluroquinolone antibiotics currently available in the U.S. appears at the end of this article.
December 2004
People now taking Bextra should contact their doctors to discuss heart risks of this drug.
November 2004
Vioxx is the ninth prescription drug to be taken off the market in the past seven years that Worst Pills, Best Pills News readers were previously warned DO NOT USE. The average time between warning readers not to use these drugs and their removal from the market was one year and eight months.
November 2004
You should not take erythromycin in combination with one of the interacting drugs listed in this article. If you are, you should contact your physician immediately. As mentioned above, erythromycin is an important antibiotic when used appropriately. Therefore, we do not recommend against its use when it is not used with one of these interacting drugs.
November 2004
The use of lactobacillus in post-antibiotic vulvovaginitis is an example of a treatment that has widespread use despite lack of a biologically plausible basis or evidence of effectiveness.
November 2004
Trospium appears to offer no advantage over long-acting anticholinergics for treatment of overactive bladder, and its poor absorption from the gastrointestinal tract could be problematic.
October 2004
If you are now using ipratropium for breathing problems as a result of COPD, you may wish to switch to tiotropium. This would reduce the number of times per day you must use a drug from four to one, although there is a substantial cost associated.
October 2004
Novartis Pharma announced on August 24, 2004 that its drug tegaserod (ZELNORM) had been approved by the Food and Drug Administration (FDA) to treat chronic constipation in both males and females less than 65 years old.
October 2004
A high frequency of drug intake to manage headache pain may mean that you have a condition known as medication overuse headache (MOH). According to the International Headache Society, MOH may exist when the following criteria are fulfilled: (1) there is headache on 15 or more days a month; (2) pain characteristics are dull, and of light to moderate intensity on both sides of the head; (3) drug intake includes ergots, triptans and opioids (these drugs are discussed below) for 10 or more days per month, simple painkillers 15 days or more for a minimum of 3 months; and (4) the headache disappears after withdrawal.
October 2004
The Canadian equivalent of the Food and Drug Administration (FDA), Health Canada, issued a public advisory on August 9, 2004 warning that newborns may be adversely affected when their mothers take one of the family of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) and other newer anti-depressants during the third trimester of pregnancy.
September 2004
Public Citizen filed suit in the District Court for the District of Columbia on February 25, 2004 against the Food and Drug Administration (FDA) asking that they make public complete copies of the agency’s scientific reviews of the nonsteroidal anti-inflammatory drug (NSAID) valdecoxib (BEXTRA).
September 2004
There is a lack of evidence that this drug provides any meaningful benefit to Alzheimer’s disease patients.
September 2004
You should consider that all fluoroquinolone antibiotics have the potential to interact with warfarin and your physician should be ordering blood tests to monitor the status of your blood clotting if one of these antibiotics is needed and you are using warfarin. This is the safest thing to do.
September 2004
Whereas Germany has rejected the idea that the pharmaceutical industry, with its extraordinarily high profit margin, does not have enough money to develop drugs even with controls on prices, we are far behind in the U.S. One crucial difference is the power of the drug lobby in Washington: There are more pharmaceutical industry lobbyists in Washington than there are members of congress.
August 2004
At the request of the Food and Drug Administration (FDA), eight out of ten manufacturers of newer antidepressants have agreed to add a warning about the possibility of an increased risk of suicide associated with the use of these drugs. The warning will appear in the professional product labeling, or package insert, for these drugs.(listed in the article)
August 2004
The FDA recognizes the immense health benefits that breast milk provides for a nursing infant and is taking these actions today not to discourage women from breastfeeding but rather to warn them not to use this particular drug while they are breastfeeding.
August 2004
We can think of no medical reason why you should be taking Caduet unless you are being treated satisfactorily with doses of amlodipine and atorvastatin that are available as Caduet. If you have not been tried on more effective drugs for high blood pressure such as diuretics or beta-blockers, amlodipine is a poor choice.
August 2004
Neither dextromethorphan or diphenhydramine is effective and each has its own risks.
August 2004
In May 2004, the Food and Drug Administration (FDA) announced that new drug interaction warnings are now required in the professional product labeling or package insert for the antidepressant trazodone (DESYREL). Health Canada, the Canadian drug regulatory authority, announced similar warnings for the drug on July 9, 2004. This article lists those drugs that interact with trazodone.
August 2004
Back in the industry’s salad days in 1997, a full 79% of those surveyed professed a favorable attitude toward the drug companies. But since then the industry has experienced a downward spiral, losing support every year but one. The 35% drop in its favorable rating between 1997 and 2004 is a larger drop than every other industry, although the managed care (-21%) and health insurance industries (-19%) were in hot pursuit.
July 2004
Although, according to the New York Times, “a million Americans take them, at an overall cost of $1.2 billion a year.”, a professor at Johns Hopkins University School of Medicine who is an expert in Alzheimer’s disease was quoted in the article and placed the value of the current crop of Alzheimer’s drugs in perspective when he said, “You can name 11 fruits in a minute instead of 10. Is that worth 120 bucks a month?”
July 2004
Memantine (NAMENDA) is the first drug approved by the Food and Drug Administration (FDA) for the treatment of moderate to severe Alzheimer’s disease dementia.
July 2004
A new study shows that there is no direct evidence that sibutramine reduces obesity-associated morbidity or mortality and that there is insufficient evidence to accurately determine the risk-benefit profile for sibutramine.
July 2004
Instead of patients being prescribed the safest, most effective, least expensive drugs, the prescribing decision is distorted by golf, money, and other kinds of inducements by those doctors who are willing to be bribed. If the prescription involves a patient whose prescription is being paid for by Medicaid or Medicare, it is illegal for doctors to accept anything of value in exchange for prescribing a particular drug.
July 2004
FDA scientists reviewed 80 patients who developed nerve damage, mostly involving sensation but, in some cases, involving motor function (weakness) in the arms or legs after using ARAVA.
July 2004
The U.S. government, at least, seems to suspect that illegal activity is rife in this industry. Fourteen of the 68 pharmacies (nine U.S., one Canadian and four other foreign countries) were under investigation by either the U.S. FDA or the Drug Enforcement Administration for allegations of selling controlled substances without a prescription, lack of a doctor-patient relationship, selling adulterated or counterfeit drugs, smuggling, mail fraud, etc.
June 2004
In a recent study of more than 13,000 women going to a doctor because of a bladder infection, more than 95% of whom had an acute bladder infection (not a recurrent one), only 37% were prescribed the preferred treatment for this condition:
June 2004
In a current campaign to educate doctors and the public about the seriousness of the problem of antibacterial resistance, the Federal Centers for Disease Control, part of the Department of Health and Human Services, has published these worrisome statistics: Each year nearly 2 million patients in the United States get an infection in a hospital. Of those patients, about 90,000 die as a result of their infection. They recommend avoiding unnecessary use of antibiotics or the wrong antibiotic and list, for patients, principles to follow.
June 2004
Telithromycin (KETEK) has shown to be no more effective than other antibiotics: amoxicillin, cefuroxime, clarithromycin, and trovafloxacin.
June 2004
In March, 2003 Public Citizen’s Health Research Group first petitioned the FDA to ban this uniquely dangerous antidepressant because of liver toxicity (see Worst Pills, Best Pills News March 2003). As the toll of liver damage and death continued to rise, we amended our petition (see Worst Pills, Best Pills News December 2003) and in March of this year we filed a lawsuit in U.S. District Court for the District of Columbia against the FDA because they had failed to act on our petition.
June 2004
On April 15th of this year, the CBS Evening News asked Dr. Sidney Wolfe of Public Citizen "Is there any legitimate reason this drug should still be sold in the U.S. when it’s been taken off the market in other places for the same dangers?" Dr. Wolfe replied, "From a financial perspective, the only reason is to make money for Bristol Myers Squibb. But from a health perspective there is no justification for this drug being on the market."
June 2004
Tegaserod (ZELNORM) is a potentially dangerous drug of minimal efficacy used in the treatment of a non-life threatening condition.
May 2004
Aspirin is the preferred preventive treatment for those who have already had a heart attack (secondary prevention), at least for the majority of people who are not intolerant to aspirin. However, the lack of evidence of an aspirin benefit in the primary prevention of heart attack is clearly outweighed by the increased risk of bleeding from aspirin, and you should not use aspirin for the primary prevention of heart attacks.
May 2004
A randomized controlled clinical trial, the “gold standard” for scientific research, published in the November 26, 2003 Journal of the American Medical Association (JAMA) compared the newer top selling atypical antipsychotic drug olanzapine (ZYPREXA) to the much older antipsychotic agent haloperidol (HALDOL) and concluded that this trial: "...found no statistically or clinically significant advantages of olanzapine for schizophrenia on measures of compliance, symptoms, or overall quality of life, nor did it find evidence of reduced inpatient use or total cost."
May 2004
Fourteen years ago, in May 1991, the Health Research Group petitioned the Food and Drug Administration (FDA) to require a warning in the professional product labeling, or package insert, of fluoxetine (PROZAC) concerning the risk of suicidal impulses in patients using the drug. Fluoxetine belongs to the family of antidepressants known as selective serotonin re-uptake inhibitors, or SSRIs. Read the warning we asked for back then.
May 2004
As spring approaches, it brings with it flowers, pollen, and allergies. While there are a plethora of over-the-counter and prescription medications for symptomatic relief of allergic symptoms, sometimes the simplest solutions are the most effective. Discusses "recipe" for making saline nasal spray.
May 2004
After successful criminal prosecution of drug companies for bribing doctors, rhepharmaceutical industry has strengthened its voluntary guidelines on gifts to doctors, which now are not supposed to exceed $100 in value. Dr. Sidney Wolfe of the Public Citizen Health Research Group in Washington told ABC News that despite these guidelines, “We have evidence since those guidelines went into effect of doctors being offered $1,500 to be a ‘consultant’— translated into English, so that the company can convince that doctor to prescribe their drug.”
May 2004
Largely because there are more pharmaceutical industry lobbyists in Washington than there are members of congress, the idea of having price controls in the Medicare prescription drug benefit law that just was passed—-so that the drugs could actually be affordable—-was quickly killed. Details about other countries are discussed.
April 2004
There has been an extraordinary amount of news attention focused on recent studies concerning statins and heart disease, presented at the American College of Cardiology meetings in March and, in one case, published in the April 8, 2004 New England Journal of Medicine.This article discusses several specific ways in which industry-spun news coverage has misrepresented the facts about this issue.
April 2004
Public Citizen’s Health Research Group has been warning the FDA about the risks of birth defects and mental retardation for fetuses exposed to isotretinoin (ACCUTANE) for over 20 years. This article contains the history of these efforts and warns that you or your children should use isotretinoin only in the case of severe recalcitrant nodular acne after other safer acne treatments have been tried and failed. Exposure of an unborn fetus to isotretinoin is a serious adverse event and should be reported directly to the FDA Med Watch Program along with other adverse reactions.
April 2004
This article discusses why there is no medical reason that you or a family member should be taking either rosuvastatin or the anti-depressant nefazodone.
April 2004
A recent study of patients and doctors has found that most people in both groups have very negative views about the impact of prescription drug direct-to-consumer (DTC) advertising campaigns, now costing the public — which ultimately pays for the campaigns — about $3 billion a year. The study, published in the Archives of Internal Medicine in February, examined the attitudes of 784 doctors, in Colorado and nationally, and 500 Colorado households about many issues concerning DTC advertising.
April 2004
According to a supplement put out by Advertising Age in March entitled Fact Pack 2004 Edition, with additional information taken from Ad Age’s web site, the pharmaceutical industry continues to be quite adept at maintaining its place among the leading advertisers. Four of the top 25 U.S. advertisers, in terms of spending in this country during 2002, were drug companies. The article urges that you do not waste your time looking at or listening to prescription (or over-the-counter) drug ads.
March 2004
We have obtained new information about serious post-marketing adverse reactions — rhabdomyolysis and kidney failure — caused by the recently-approved cholesterol-lowering “statin” drug rosuvastatin (Crestor-AstraZeneca) and have also become aware of decisions by major U.S.health insurors not to reimburse for it.
March 2004
A highly misleading advertisement for ARICEPT, implying the drug could keep patients with Alzheimers Disease from having to go into a nursing home for two years, was allowed to run for a very long time without being stopped by the FDA.
March 2004
Aventis, manufacturer of the widely prescribed arthritis drug leflunomide (ARAVA) said that five Japanese patients have died from a drug-induced lung condition after taking its drug to treat arthritis and that it has asked doctors to take further precautions before prescribing the medication.
March 2004
In a 1991 book, Women's Health Alert, we warned that "Female replacement hormones may someday be remembered as the most recklessly prescribed and dangerous drugs of this century." Now, a new study shows that that women using Prempro, a combination of estrogen and progesterone as hormone replacement therapy, were twice as likely to suffer from demetia as women getting a placebo.
February 2004
Once again, Worst Pills, Best Pills readers were warned about the dangers of a drug well before — in this case two and one-half years before — the government got around to a ban.
February 2004
The January 5th issue of the Medical Letter, a widely respected source of independent information about pharmaceuticals and dietary supplements, has a review of the increasingly researched problem of the interaction between grapefruit juice and many prescription and over-the-counter drugs. Like most interactions between chemicals in the body, this one involves the impairment, by grapefruit juice, of the body’s ability to metabolize many drugs, leading to higher than expected — and sometimes dangerous — levels of these drugs.This article lists the drugs.
February 2004
Internet advertisements are heavily promoting the use of topiramate (TOPAMAX), a prescription drug approved by the FDA only for the treatment of seizures, as a weight reduction agent, a purpose for which it has not been shown to be safe and effective.
February 2004
On December 22nd, FDA and Lilly modified the label for pergolid mesylate (PERMAX), a drug used in the treatment of Parkinson’s disease, and informed healthcare professionals of the possibility of patients falling asleep while performing daily activities, including operation of motor vehicles, while receiving treatment with pergolid mesylate. Although the patient information in the revised label does not mention auto accidents, the professional information, printed below, does.
February 2004
The Editor of the British Medical Journal writes about how the acronym for the above title, HARLOT, means what it says.
February 2004
We have all seen pictures on the news of people waiting in long lines to get their flu shots this year; many of us were not able to get one before the supply ran out. Because the Canadians have taught us a thing or two about how to run a national health insurance system, we decided to look to our neighbors north of the border to see how they handle their flu shots.
January 2004
You should wait at least seven years from the date of release to take any new drug unless it is one of those rare “breakthrough” drugs that offers you a documented therapeutic advantage over older proven drugs.
January 2004
The maker of the arthritis drug leflunomide (ARAVA), Aventis Pharmaceuticals of Bridgewater, NJ, notified health professionals in October 2003 that new safety warnings concerning life-threatening liver toxicity and infections have been required on the professional product labeling or package insert for the drug.
December 2003
This statement appears in the professional product labeling, or package insert, for eplerenone: “The principal risk of INSPRA is hyperkalemia. Hyperkalemia can cause serious, sometimes fatal, arrhythmias (heart rhythm disturbances).”
December 2003
The Food and Drug Administration (FDA) issued a Public Health Advisory on October 27, 2003 about reports of suicidal thinking and suicide attempts in clinical trials of eight drugs in pediatric patients with major depressive disorder (MDD).
December 2003
Nefazodone (SERZONE), a dangerous antidepressant long linked to liver toxicity and deaths, was withdrawn from the Canadian market effective November 27, 2003. The drug is produced by Bristol-Myers Squibb in both Canada and the U.S.
December 2003
Consumers can play an important public health role by reporting any adverse experiences with drugs, devices, or dietary and herbal supplements to the Food and Drug Administration (FDA). This can be done through the MedWatch program, the FDA’s medical products reporting system. The article gives information on reporting these adverse reactions.
November 2003
The Food and Drug Administration (FDA), on January 23, 2003, approved the asthma drug montelukast (SINGULAIR) for the relief of symptoms of seasonal allergic rhinitis (hay fever) in adults and children two years of age and older. Montelukast is a member of a family of drugs known as leukotriene inhibitors.You should not use montelukast for the treatment of hay fever symptoms because of its meager effectiveness and exorbitant cost.
November 2003
Ten cases of life-threatening heart rhythm disturbances associated with the use of levomethadyl have been reported to European authorities since July 1, 1997.
November 2003
DO NOT STOP ANY ASTHMA MEDICATION WITHOUT FIRST CONSULTING YOUR PHYSICIAN. ABRUPTLY STOPPING A MEDICATION MAY RESULT IN ACUTELY DETERIORATING ASTHMA CONTROL.
In the March 2003 Worst Pills, Best Pills News we listed the asthma drug salmeterol (SEREVENT) as a DO NOT USE drug after the Food and Drug Administration (FDA) announced on January 23, 2003 that a large safety study involving the drug had been halted prematurely because an interim analysis of outcomes suggested that the drug may be associated with an increased risk of life-threatening asthma episodes or asthma-related deaths.
November 2003
Warnings: Reye’s syndrome: Children and teenagers should not use this medicine for chicken pox or flu symptoms before a doctor is consulted about Reye’s syndrome, a rare but serious illness reported to be associated with aspirin.
November 2003
Research published in the September 2003 issue of the Annals of Internal Medicine provides more supportive evidence that the high blood pressure-lowering thiazide diuretics, or water pills, may protect against hip fractures.
November 2003
In retrospect, it all seems so predictable. Put an unregulated industry hawking largely ineffective or unproven products on a free-wheeling medium, and false claims are sure to proliferate.
November 2003
FDA’s announcement on September 9 of a “Collaborative Campaign to Inform Women About Menopausal Hormone Therapy” sounded as though it might hold some promise; that is, until
you actually went to the Collaborative Campaign web site Instead of the dry, fact-filled explanation of the risks and benefits of HRT one might expect from the FDA, the opening page on the site contained no substantive information whatsoever.
October 2003
Rosuvastatin (CRESTOR) became the sixth cholesterol lowering "statin" drug on the U.S. There is no medical reason for you to be taking rosuvastatin when there are three safer and more effective statins, in terms of reducing cardiovascular events, on the market.
October 2003
Parents whose children are taking venlafaxine should consult the prescribing physician immediately.
DO NOT stop venlafaxine treatment immediately. Discontinuation of this drug requires medical supervision.
October 2003
You should try the non-pharmacologic interventions listed in the box below before trying antacids, histamine-2 blockers, or, as a last resort, proton pump inhibitors.
If you classify yourself as a person with frequent heartburn, that is heartburn more than two days per week, and the interventions recommended above have failed, you should be under the care of a physician
October 2003
Against the better judgment of both the physicians who reviewed the data for the Food and Drug Administration (FDA) and the FDA’s external Advisory Committee, the weight loss drug Meridia (sibutramine) has been on the market for over five years. Both the agency’s own doctors and its advisors are on record as saying that the benefits (loss of a few pounds in weight) do not outweigh the risks (increased blood pressure and thus increased risk for heart attack and stroke).
October 2003
This article, by Health Letter Editor Sidney Wolfe, appeared on September 10, 2003 on the editorial page of the Washington Post. With gusto, Food and Drug Administration Commissioner Mark McClellan has promoted, in speeches and press releases, one of his priorities: increasing the amount of accurate information conveyed to consumers about FDA-regulated products. “I consider it a public health hazard when people are misled by false claims,” he said recently.
October 2003
Children and teenagers should not use aspirin when they have the flu.
September 2003
Tell your physician not to prescribe mefloquine if you or someone you know has a history of psychiatric disturbances or convulsions. If mefloquine is prescribed, care should be exercised with regard to driving and operating machines since dizziness, a disturbed sense of balance, and other neuropsychiatric effects have been associated with this drug.
September 2003
Government-sponsored research published in the July 2, 2003 Journal of the American Medical Association found that the diabetes drugs metformin (GLUCOPHAGE), rosiglitazone (AVANDIA), and pioglitazone (ACTOS) were being prescribed inappropriately to patients with heart failure and that the inappropriate prescribing of these drugs has been increasing over time.
September 2003
Canadian drug regulatory authorities reviewed reported cases of serotonin syndrome in the July 2003 issue of the Canadian Adverse Reaction Newsletter. The serotonin syndrome is a potentially life-threatening adverse drug reaction involving an excess of serotonin, a naturally occurring nerve transmitter.
September 2003
DO NOT stop taking any of the drugs listed in the table without first consulting your physician.
You should report any alteration in your sense of taste to your physician if you are taking a drug.
September 2003
A warning was issued in June 2003 about the possibility of potentially serious decreased sweating (oligohidrosis) and elevated body temperature (hyperthermia) with the use of the seizure medication topiramate (TOPAMAX). Topiramate is approved by the Food and Drug Administration (FDA) for adult and child patients ages two to 16 years with certain types of seizures, and in patients two years of age and older with seizures associated with Lennox-Gastaut syndrome.
August 2003
The results of the study were mixed, with the increased risk of high-grade cancer caused by the drug outweighing the decreased risk of cancers that may be of little clinical significance.
August 2003
On June 19, 2003, the Food and Drug Administration (FDA) issued a public advisory concerning the safety of paroxetine (PAXIL), a member of the selective serotonin re-uptake inhibitor (SSRI) family of antidepressants, in children or adolescents less than 18 years of age. The advisory is based on reports of a possible increased risk of suicidal thinking and suicide attempts in children and adolescents under the age of 18 taking paroxetine for major depressive disorder (MDD). This was based on reports of a possible increased risk of suicidal thinking and suicide attempts in children and adolescents under the age of 18 taking paroxetine for major depressive disorder (MDD).
August 2003
GlaxoSmithKline of Research Triangle Park, NC announced in June 2003 that their seizure medication lamotrigine (LAMICTAL) had been approved by the Food and Drug Administration (FDA) for the maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes such as depression, mania (periods of severe highs), hypomania, or mixed episodes in patients also being treated with standard therapy. If you make the decision to use lamotrigine for bipolar I disorder and if a rash appears, report it to your physician immediately and the drug should be discontinued.
August 2003
The European Agency for the Evaluation of Medicinal Products (EMEA) issued a public warning on May 21, 2003 not to use the combination of repaglinide (PRANDIN), a drug for lowering blood sugar in type-2 diabetics, and the cholesterol drug gemfibrozil (LOPID). The warning was based on a recent publication in the March 2003 issue of the medical journal Diabetologia that found the use of these two drugs in combination can enhance the blood sugar lowering effects of repaglinide and can thereby result in severe blood sugar lowering (hypoglycemia).
August 2003
On April 10, 2003, the Food and Drug Administration (FDA) announced that it was beginning legal procedures to remove the marketing authorizations for combination drug products containing estrogen and androgen, female and male hormones respectively. Estrogen and androgen combination products had been approved for the treatment of moderate to severe “hot flashes” (vasomotor symptoms) associated with the menopause in women whose symptoms were not improved by estrogen alone. We agree with the FDA’s decision to remove the marketing authorizations for combination drug products containing estrogen and androgen; however, the issue over the effectiveness of these combinations goes back for decades and this action by the FDA is long overdue.
August 2003
A recent article in Medical Marketing and Media (May 2003), aimed at the marketing departments of the pharmaceutical industry, provides an extraordinary view of this industry of which the public, unfortunately, remains unaware. Vince Parry, the “Chief Branding Officer” for a company called “InChord,” tells his pharmaceutical company readers — and potential clients — how to increase sales by combining the “creation” of a disease with a drug to treat it.
August 2003
It is fair to say that without the NIH there would have been no Taxol. The agency identified a component of the Pacific Yew as having anti-tumor activity as long ago as 1963 and identified the chemical responsible for this activity back in 1971. In 1983, the NIH began the first of several clinical trials of Taxol; BMS was essentially absent from the scene until it signed a CRADA with the NIH in 1991.
July 2003
You should check the list of drugs that can cause loss of bladder control before starting drug treatment for this condition. You may be able to change from a drug that causes loss of bladder control to a drug that does not or alter the dose. This may be enough to solve the problem.
July 2003
Staff from the Food and Drug Administration (FDA) and the Duke Clinical Research Institute reviewed 47 cases of heart failure, reported the FDA’s adverse drug reaction reporting system associated with the use of the drugs etanercept (ENBREL) and infliximab (REMICADE), and the results were published in the May 20, 2003 issue of Annals of Internal Medicine.
July 2003
In this study, the researchers evaluated 100 consecutive patients who went to the emergency room and received a prescription for a fluoroquinolone antibiotic. Of the 100 patients, 81 (81%) received a fluoroquinolone antibiotic for an inappropriate use. In 43 (53%) of these patients, a fluoroquinolone was found inappropriate because another antibiotic was considered first-line treatment, and in 27 (33%) patients there was no evidence of an infection and therefore no indication for the use of any antibiotic.
June 2003
You should follow the Health Research Group’s Seven Year Rule with aripiprazole. There is no evidence to suggest that aripiprazole is a “breakthrough” drug.
June 2003
The manufacturer of the antipsychotic drug risperidone (RISPERDAL), announced on April 16, 2003, that an important new warning had been added to the professional product labeling, or package insert, for the drug concerning cerebrovascular adverse effects, including stroke and transient ischemic attack (temporary reduction of blood flow to the head), when the drug is used to treat elderly patients for dementia. In some of these cases the result was death.
June 2003
This study does provide additional support to what the National Institutes of Health and the Health Research Group have been saying for years: low-dose hydrochlorothiazide should be the first drug used in the treatment of mild to moderate high blood pressure.
June 2003
The new FDA regulations embody the principles we wrote about 14 years ago in the first edition of Worst Pills, Best Pills on how you can avoid the unnecessary use of antibiotics:
May 2003
The jackals selling unregulated dietary and herbal supplements have been hard at it bombarding the public with preposterous, unsubstantiated claims about the superiority of their particular miracle natural calcium products. Some disreputable companies have gone beyond just claiming a better calcium product and are now declaring that “coral calcium,” for example if it is from Okinawa, is the secret to good health and a long life.
May 2003
We wrote in the first edition of Worst Pills, Best Pills, published in 1988, that natural or desiccated (dried) thyroid extract products, such as ARMOUR THYROID, should not be used except by those who have successfully taken it for years to control their symptoms of low thyroid hormone production (hypothyroidism).
May 2003
You should not use Yasmin for the reasons we stated in the April 2002 newsletter. Some physicians may believe that Yasmin is less likely to cause blood clots than older oral contraceptives; however, there is no research to support such a belief.
May 2003
Benign intracranial hypertension is, in fact, not benign at all. It is also known as pseudotumor cerebri and involves a persistent rise in cerebrospinal fluid pressure. This reaction is characterized by headache, nausea, vomiting and papilledema (a sign of increased pressure within the central nervous system) with partial paralysis of a nerve that controls eye movement and some facial muscles (sixth cranial nerve palsy). If you are taking minocycline or another tetracycline and develop a persistent unexplained headache, this should be reported to the prescribing physician immediately.
May 2003
Stronger warnings have been added to the professional product label, or “package insert,” for the fluoroquinolone antibiotic gatifloxacin (TEQUIN) about possible heart rhythm disturbances and problems with blood sugar control. This drug was approved by the Food and Drug Administration (FDA) in October 2001 and its marketing brought to nine the number of fluoroquinolone antibiotics on the market.
April 2003
Teriparatide should not be used by men. Clearly, without evidence that teriparatide reduces fracture, the possibility of osteosarcoma outweighs any theoretical benefit of the drug.
Our recommendation for women is the same, but for different reasons. There is evidence of reduced fracture risk in both vertebral and non-vertebral locations; however, the absolute risk of vertebral fracture reductions is not large and many vertebral fractures are asymptomatic. Finally, alendronate appears to offer a comparable level of protection without the concerns of osteosarcoma.
April 2003
Older adults should not use nitrofurantoin long term for the treatment of urinary tract infections.
If you develop the symptoms of acute lung toxicity listed above, contact your physician immediately.
April 2003
The new FDA regulations embody the principles we wrote about 14 years ago in the first edition of Worst Pills, Best Pills on how you can avoid the unnecessary use of antibiotics:
April 2003
On February 24, 2003, Eli Lilly and Company of Indianapolis informed healthcare professionals that the professional product labeling, or “package insert,” for pergolide (PERMAX) was being updated to include a warning about the possibility of heart valve damage with the drug.
March 2003
You should avoid these "new" single mirror images of old drugs, not out of concern about their safety or effectiveness, but because they are the same as the old drugs. In the long run, they cause economic harm both to individuals and to the health care system because they have come on the market with extended monopoly protection. Article lists some examples.
March 2003
Bristol-Myers Squibb of Princeton, NJ announced on January 8, 2003 that it will pull the antidepressant nefazodone (SERZONE) in all European countries where it is marketed. The drug was withdrawn from the Swedish market in early 2002 and from Denmark in December 2002 after concerns about liver toxicity. If you or a family member are currently taking nefazodone, discuss with the prescribing physician switching to one of the numerous other, safer antidepressant drugs now on the market.
March 2003
DO NOT STOP ANY ASTHMA MEDICATION WITHOUT FIRST CONSULTING YOUR PHYSICIAN. ABRUPTLY STOPPING A MEDICATION MAY RESULT IN ACUTELY DETERIORATING ASTHMA CONTROL. An interim analysis of a company study of outcomes suggested that the drug may be associated with an increased risk of life-threatening asthma episodes or asthma-related deaths.
March 2003
The Institute for Safe Medication Practices (ISMP), with the knowledge of the FDA, issued an alert about methotrexate overdoses that occur when the drug is incorrectly prescribed or used daily rather than weekly.
February 2003
On December 5, 2002, the Food and Drug Administration (FDA) announced that a new warning statement would be required on the labels of all over-the-counter (OTC) antihistamine, anti-nausea, anti-cough and nighttime sleep-aid drug products containing diphenhydramine citrate or diphenhydramine hydrochloride. The statement advises consumers not to use oral OTC diphenhydramine products with any other product also containing diphenhydramine, including products used on the skin (topically).Article lists products.
February 2003
If you’re between 50 and 64, get vaccinated if you are in a high-risk group. In any event, get vaccinated with the old, proven inactivated flu vaccine, rather than one with so much murky science behind it as FLUMIST.
February 2003
Beta-blockers, a family of drugs frequently prescribed for high-blood pressure, are also very useful (as eye drops) in controlling elevated pressure in the eye (glaucoma). Because beta-blocking drugs, including the topical products, affect both the heart and the lungs these drugs should not be used in patients with bronchial asthma or a history of that disease
February 2003
The results of a very large clinical trial designed to give a definitive answer to the decades-old question of which of four commonly used families of high blood pressure medications should be prescribed first was published in the December 18, 2002 issue of the Journal of the American Medical Association. The answer is that the oldest drugs — known as the thiazide diuretics, or water pills — are superior in preventing one or more major forms of cardiovascular disease to the other families of drugs.
DO NOT STOP TAKING ANY HIGH BLOOD PRESSURE MEDICATION WITHOUT FIRST CONSULTING YOUR PHYSICIAN.
February 2003
In this issue of the Health Letter, we reprint those graphics in their entirety, along with some rather technical footnotes that accompany the charts. You should show this information to your doctor, in case he or she hasn’t seen it.
February 2003
In order that they suffer the least harm, women need to be fully informed about the results coming from these tamoxifen “prevention” trials. They need to realize that the current poor risk assessment tool coupled with the increase in possible serious illnesses or death is a poor foundation on which to base their hopes by taking tamoxifen for many years.
January 2003
The August 2002 issue of the Australian Adverse Drug Reactions Bulletin reviewed reports of low blood levels of sodium (hyponatremia) induced by the water pill, or diuretic, indapamide (LOZOL). The main symptoms of hyponatremia involve the central nervous system and include lethargy, confusion, stupor, or coma. If you are taking indapamide for high blood pressure, you should ask your doctor why you have not been prescribed hydrochlorothiazide.
January 2003
The editors of the highly respected Medical Letter On Drugs and Therapeutics, an independent source of drug information written for physicians and pharmacists, reviewed the use of the antiviral drug valacyclovir (VALTREX) for the treatment of cold sores (herpes labialis) in their November 11, 2002 issue. This prompted us to evaluate two other Food and Drug Administration (FDA) approved drugs, penciclovir (DENAVIR) and docosanol (ABREVA), together with valacyclovir for cold sore treatment. If you decide not to spend the money for one of these drugs every time a cold sore appears, there are things you can do to control discomfort, allowing healing and avoid complications. The cold sore should....
January 2003
There is an additional similarity (aside from our listing both as DO NOT USE drugs) between valdecoxib and celecoxib, both are sulfa drugs and individuals who are allergic to sulfa drugs should not use them. Although celecoxib came on the market with a warning about sulfa drug allergy, valdecoxib did not. We previously wrote “It may be a dangerous oversight on the part of the FDA not to have required the same warning for valdecoxib.” Unfortunately, because uninformed patients have been needlessly harmed, our prediction has come to pass.
January 2003
Escitalopram (LEXAPRO) was approved by the Food and Drug Administration (FDA) in August 2002 and brings to six the number of selective serotonin reuptake inhibitor (SSRI) antidepressants now on the market in the U.S. The primary purpose for developing escitalopram appears to be nothing more than a strategy to protect sales as citalopram nears the end of its patent protection. In the long run, escitalopram will cause economic harm to individuals and the healthcare system.
December 2002
Ephedra, or ma huang, the natural form of the stimulant ephedrine, the most infamous and dangerous drug found in dietary supplements sold for weight loss, is at last beginning to receive the negative notoriety it deserves. Ephedra causes heart attacks and strokes because of its ability to raise blood pressure and heart rate. Article discusses the risk of other dietary supplements.
December 2002
Investigators from Vanderbilt University in Nashville TN, in a study published in the October 5, 2002 issue of The Lancet, found that patients taking 50 milligrams per day of the arthritis and painkilling drug rofecoxib (VIOXX) for longer than five days are 70 percent more likely to develop coronary heart disease (CHD) than nonusers of the drug.
December 2002
Consumers can play an important public health role by reporting any adverse experiences with drugs, devices, or dietary and herbal supplements to the Food and Drug Administration (FDA). This can be done through the MedWatch program, the FDA’s medical products reporting system. Article shows how to file a report.
December 2002
The following editorial, by Health Letter Editor Dr. Sidney Wolfe, appeared in the December issue of Pharmacoepidemiology and Drug Safety. Ultimately, the cost for such notification should be borne by the pharmaceutical company making the dangerous drug. Pharmacists and/or physicians, if the latter have record access, should be reimbursed for doing the company’s work. In addition, the FDA should be given new legislative authority to impose mandatory drug recalls with an enforceable withdrawal schedule governing the level and rapidity of recall and patient notification.
December 2002
The past decade has seen a ballooning in private industry support for biomedical research. While the federal government was once the major funder of medical research, corporations are now the primary sponsors.
November 2002
This is the second of a two-part series on drug-induced psychiatric symptoms that began in last month’s Worst Pills, Best Pills News. The information is based on the July 8, 2002 issue of The Medical Letter on Drugs and Therapeutics. Article lists drugs and adverse effects.
November 2002
On July 31, 2002, the strongest type of drug safety warning that the Food and Drug Administration (FDA) can require, a black box warning, was added to the professional product labeling, or “package insert,” for the migraine headache drug dihydroergotamine (DHE 45 INJECTION, MIGRANAL NASAL SPRAY). The new warning involved numerous drug interactions between dihydroergotamine and other drugs that can raise the blood levels of dihydroergotamine leading to a life-threatening contraction of blood vessels (vasospasm) that can block the flow of blood to the brain and other areas of the body.
November 2002
Most of us remember the 1982 debacle in which Tylenol capsules laced with cyanide were held responsible for seven deaths. These tragic events led to a reimagining of tamper-resistant drug packages. This article discusses overdoses.
November 2002
Most of us remember the 1982 debacle in which Tylenol capsules laced with cyanide were held responsible for seven deaths. These tragic events led to a reimagining of tamper-resistant drug packages. Yet a far greater Tylenol-related tragedy has been unfolding before and since 1982—preventable deaths due to overdoses from acetaminophen (the active ingredient in Tylenol and many other prescription and over-the-counter drugs) and the resultant liver damage. In fact, acetaminophen is the leading cause of toxic drug ingestions in the U.S.
November 2002
A report from the General Accounting Office (GAO), an investigative branch of Congress, shows that since the Prescription Drug User Fee Act (PDUFA) was implemented in 1992, a higher percentage of newly approved drugs has been withdrawn than before. In the period 1993-1996, as PDUFA was being fully implemented, the drug withdrawal rate was 1.56 percent, compared to 5.34 percent in the period 1997-2000.
October 2002
This is the first of a two part series on drug induced psychiatric symptoms that is based on the July 8, 2002 issue of The Medical Letter on Drugs and Therapeutics. Regular readers of Worst Pills, Best Pills News will recognize The Medical Letter as a reference source written for physicians and pharmacists that we often use because of its reputation as an objective and independent source of drug information. The article lists the drugs and their psychiatric adverse effects.
October 2002
A June 20, 2002 press release from the Council for Responsible Nutrition (CRN) proclaimed: “Harvard Researchers Publish JAMA [Journal of the American Medical Association] Articles Recommending Vitamin Supplements For All Adults.” The studies concerned vitamins for chronic disease prevention. However, if you are a well-nourished elderly person living at home, taking vitamin E may actually increase the number of times you must see your doctor.
October 2002
On August 13, 2002, the Food and Drug Administration warned the public about the Chinese weight loss products CHASU (JIANFEI) DIET CAPSULES and CHASU GEMPI because they pose a potential public health risk. The alert followed illnesses reported in several people in Japan, some of whom died, after consuming these products.
October 2002
On September 4, 2002, Public Citizen sent a letter to Health and Human Services (HHS) Secretary Tommy Thompson asking that an Alzheimer’s Disease (AD) prevention trial be immediately stopped and that the patients be provided with information on the risks to which they may already have been exposed.
October 2002
Canada joined the growing list of countries that have banned the herbal supplement kava-kava because of liver toxicity that in some cases has resulted in liver transplants and death (see the May 2002 issue of Worst Pills, Best Pills News). An immediate ban and a recall at all levels of the market was announced by Canadian health authorities on August 21, 2002.
October 2002
Will a vitamin a day keep the doctor away? If you are malnourished or a strict vegetarian trying to prevent chronic disease due to a vitamin deficiency maybe, but there is also the possibility of harm. If you are a well-nourished elderly person living at home, taking vitamin E may actually increase the number of times you must see your doctor.
September 2002
We hope that by now women have heard that one part of a large, long term, government sponsored clinical trial, the Women’s Health Initiative, evaluating hormone replacement therapy (HRT) was halted prematurely. The bottom line from this trial is that long term HRT’s risks outweigh its benefits. You should not be using hormone replacement therapy for any reason other than its very short term use to control the symptoms of menopause.
September 2002
A new warning was added in May 2002 to the professional product labeling, or “package insert,” for the type-2 diabetes drug chlorpropamide (DIABINESE) concerning its use in the elderly. The new warning cites increased risks of low blood sugar (hypoglycemia), low blood sodium levels (hyponatremia), or both in patients aged 65 and over.
September 2002
Court documents revealed that senior officials at Parke-Davis determined that it was not sufficiently profitable for Parke-Davis to obtain FDA approval for gabapentin’s alternative uses mentioned above by doing the types of studies necessary for approval. Instead, company officials developed a strategy that would allow Parke-Davis to avoid the costs of proving gabapentin’s safety and effectiveness for these other uses, while allowing the company to enter the lucrative off-label markets.
September 2002
On June 28, 2002, Nature’s Way Products, Inc. of Springville, Utah, recalled four lots of its 100-count Nature’s Way brand Nettle capsules because these lots were found to contain excessive amounts of lead.
September 2002
Several new safety labeling changes have been required by the Food and Drug Administration (FDA) for the widely used anticoagulant drug warfarin (COUMADIN). These changes to the drug’s professional product labeling, or “package insert,” were made in May 2002. The article discusses the changes.
August 2002
The Food and Drug Administration (FDA) announced on June 18, 2002, the results of a national study to determine the extent of distribution and the quality of unregulated written drug information, known as “patient information leaflets” (PILs), produced by commercial information vendors to be disseminated by pharmacists to drug consumers when prescriptions are filled. The study’s results were appalling.
August 2002
The strongest cautionary language that the Food and Drug Administration (FDA) can require, a so-called “black box warning,” was added to the professional product labeling, or “package insert,” for the cancer drug tamoxifen (NOLVADEX) in June 2002. The warning concerns increased risk of sometimes fatal uterine cancers, stroke and blood clots in the lungs (pulmonary embolism) in women at high risk of breast cancer who use the drug to reduce the incidence of breast cancer and in women with a form of breast cancer called ductal carcinoma in situ (DCIS).
August 2002
The British equivalent of our Food and Drug Administration (FDA), in the April 2002 issue of its newsletter Current Problems in Pharmacovigilance, published a ranking of the relative gastrointestinal (GI) toxicity of some of the widely used older nonsteroidal anti-inflammatory drugs (NSAIDs). These drugs are commonly used for acute pain and the treatment of the symptoms of osteo- and rheumatoid arthritis.
August 2002
Dexmethylphenidate (FOCALIN), approved by the Food and Drug Administration (FDA) in November 2001 for attention-deficit/hyperactivity disorder (ADHD), joins a growing list of Do Not Use drugs, so called because they primarily result in economic harm to both individuals and the health care system. These drugs exist solely to extend a manufacturer’s brand name monopoly position in a lucrative market but offer nothing better than the drugs they replace.
August 2002
Germany’s Federal Institute for Drugs and Medical Devices, the counterpart of our Food and Drug Administration (FDA), announced on June 17, 2002 a ban on the sale of the herbal dietary supplement kava-kava, to take effect immediately, because of reports of liver toxicity.
August 2002
In a 1995 U.S. survey, approximately 90 percent of patients thought they should be told who paid for the study, 80 percent wanted to be told if the researcher owned stock in the company, and 85 percent wanted similar disclosure if the investigator was paid for each patient enrolled. For each of these questions, doctors recommended disclosure at somewhat lower rates. Similar disparities are apparent when doctors and patients are asked about the appropriateness of accepting knickknacks, free meals and trips to exotic locations from the pharmaceutical industry. When will the doctors catch up with their patients?
August 2002
For the 12th consecutive year, Johns Hopkins Hospital has come in first in the U.S. News & World Report ranking of American hospitals. Ironically, one day before receiving this honor, Hopkins came within a hair’s breadth of disgracing itself by sponsoring a “Botox Night”, in which healthy people would have received on-the-spot treatments at reduced prices in a social setting.
July 2002
Since publication of the 1999 edition of our book Worst Pills, Best Pills, a large number of drugs have come on the market. Because of many requests for an update from people who have the 1999 edition, we are publishing the Companion, which must be used in conjunction with the older book because the drugs in the Companion listed as Do Not Use refer to safer alternatives that are discussed in the 1999 edition.
July 2002
We are becoming increasingly concerned about reports of elevated blood sugar levels (hyperglycemia) and diabetes with the newer “atypical antipsychotic” drugs clozapine (CLOZARIL) and olanzapine (ZYPREXA).
July 2002
The approval of gatifloxacin(TEQUIN) in October 2001 brought to nine the number of fluoroquinolone antibiotics on the market, and this drug joins sparfloxacin (ZAGAM) and moxifloxacin (AVELOX) as fluoroquinolones that can cause a dangerous abnormality in the heart’s electrical conduction known as QT prolongation that can lead to fatal heart rhythm disturbances such as torsade de pointes.
July 2002
The Health Research Group wrote Department of Health and Human Services secretary Tommy Thompson on May 21, 2002, strongly urging the criminal prosecution of Abbott Laboratories for illegally withholding from the Food and Drug Administration (FDA) important information concerning eight deaths and other adverse effects related to its diet drug sibutramine (MERIDIA). Two months earlier we had petitioned to have this dangerous drug withdrawn from the market (see the May 2002 issue of Worst Pills, Best Pills News).
July 2002
A letter written by Rep.Henry A.Waxman: Although I support innovative strategies for smoking cessation, there were three problems with nicotine lollipops. First, these products pose serious risks to children. Nicotine lollipops are new, so there are no studies that examine the use of these products by children.
July 2002
The following is a statement by Health Letter Editor, Dr. Sidney Wolfe in response to this decision: Today's announcement by the Department of Health and Human Services (HHS), which not only fails to ban ephedra dietary supplements but also fails to seriously warn against the use of these products, should result in the firing of all officials in HHS and the Food and Drug Administration (FDA) who are responsible for this dangerous cowardice. The idea that more studies are needed and that the more than 100 deaths and hundreds of other cases of serious damage to users of these products, many of which are extremely well-documented and have occurred at recommended doses, is not enough for a ban is in sharp contrast to what has usually occurred with the removal of dangerous prescription drugs from the market.
June 2002
A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group’s drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug’s professional product labeling or its outright removal from the market. You should wait at least seven years from the date of release to take any new drug unless it is one of those rare “therapeutic advances” that offers you a documented therapeutic advantage over older, proven drugs.
June 2002
Grapefruit juice can interact with a number of therapeutically important drugs that could lead to the possibility of toxicity. These drugs are listed in the article.
June 2002
Leflunomide (ARAVA) was approved by the Food and Drug Administration (FDA) in September 1998 for the treatment of active rheumatoid arthritis in adults. On March 28, 2002, we petitioned Health and Human Services Secretary Tommy Thompson to remove leflunomide from the market immediately.
June 2002
Rofecoxib (VIOXX), the heavily promoted and overpriced nonsteroidal anti-inflammatory drug (NSAID), now carries a warning in its professional product labeling, or “package insert,” about its use by people with a history of heart disease....If you require treatment with an NSAID you should not be taking rofecoxib.
June 2002
A study published in the May 1, 2002 Journal of the American Medical Association (JAMA) has resulted in a major change in the Health Research Group's drug safety policy. The study, in association with physicians from the Harvard Medical School, examined the frequency and timing of the identification of new adverse drug reactions resulting in the addition of a black box warning in the drug's professional product labeling or its outright removal from the market.
Three of the authors have close identification with the Health Research Group: its director, Sidney M. Wolfe, and former HRG staffers Drs. Steffi Woolhandler and David Himmelstein. The other co-authors are affiliated with the Harvard Medical School.
May 2002
On March 19, 2002, Public Citizen’s Health Research Group petitioned Department of Health and Human Services (DHHS) Secretary Tommy Thompson to immediately ban the dangerous diet drug sibutramine (MERIDIA). As long ago as April 1998, we listed sibutramine as a Do Not Use drug in Worst Pills, Best Pills News.
May 2002
A March 14, 2002, New York Times article revealed that the manufacturer of the seizure medication gabapentin (NEURONTIN) illegally promoted the drug to prescribing physicians for at least 11 “off-label” (unapproved) medical conditions, using their own employees, euphemistically called “medical liaisons.” Many of the bases for the safety and effectiveness of gabapentin for these 11 unapproved uses appears to have been fabrications by the corporation.
May 2002
On March 25, 2002, the Food and Drug Administration (FDA) finally issued a consumer alert about the possibility of liver toxicity with the dietary supplement drug kava kava. This action came four months after German authorities issued a similar warning to their citizens.
May 2002
Physicians and pharmacists from the Food and Drug Administration (FDA), in the March 19, 2002, issue of the medical journal The Lancet reviewed the regulatory history of calcitonin (CALCIMAR, MIACALCIN) in the treatment of postmenopausal osteoporosis. Over six years ago, in the December 1995 issue of Worst Pills, Best Pills News, we listed calcitonin nasal spray as a Do Not Use drug because there was no credible evidence that the drug reduced the risk of fractures in postmenopausal women with osteoporosis.
May 2002
In an article in the March 23, 2002 issue of the British Medical Journal, journalist Jeanne Lenzer lays bare the evidence that the biotech firm Genentech inordinately skewed the American Heart Association's (AHA's) guidelines on the use of "clot-busters" like Genentech's tPA (also known as alteplase or Activase), the only Food and Drug Administration-approved treatment for acute stroke.
April 2002
On February 7, 2002, California health authorities warned consumers to stop immediately the use of two dietary supplement drug products, PC SPES and SPES, because they contain prescription drugs not listed on their labels that could cause serious health problems. These unregulated drug supplements are produced by BotanicLab of Brea, California. TEST
April 2002
The combination birth control pill of ethinyl estradiol with drospirenone (YASMIN) was approved by the Food and Drug Administration (FDA) in April 2001. Combination birth control pills contain the hormones estrogen and progestin. There is no medical reason that you should be using Yasmin rather than one of the older pills containing the progestins norgestrel, levonorgestrel or norethindrone.
April 2002
In December 2001 the Food and Drug Administration (FDA) strengthened the warnings and precautions sections of the professional product labeling, or “package insert,” for droperidol (INAPSINE), an injectable tranquilizer frequently used as premedication for anesthesia, as treatment for nausea after anesthesia, and for sedation of agitated patients. Droperidol alters the heart’s electrical conductivity, known as QT prolongation, which has led to a type of fatal heart rhythm disturbances known as torsades de pointes.
April 2002
The black box warning in the professional product labeling or “package insert” for the atypical antipsychotic drug clozapine (CLOZARIL) has been expanded to warn about an increased risk of fatal heart inflammation (myocarditis). A black box warning is the strongest type of warning that the Food and Drug Administration (FDA) can require in a drug’s labeling.
April 2002
The Food and Drug Administration (FDA) approved nateglinide (STARLIX) in December 2000 to lower blood sugar levels in patients with type-2 diabetes, also referred to as adult onset or non-insulin-dependent diabetes mellitus. It is now the 13th drug approved for type-2 diabetes in this country and the second member of a new class of diabetes drugs known as meglitinides. The respected Medical Letter concluded that “Nateglinide is a short-acting hypoglycemic agent that is less convenient and less effective than sulfonylureas and much more expensive. Its long term safety remains to be established.”
March 2002
This article by Worst Pills, Best Pills News Editor, Dr. Sidney Wolfe is reprinted from the New England Journal of Medicine 2002;346:524-526.
March 2002
By the time you read this, desloratadine (CLARINEX)—the Schering-Plough Corporation’s replacement for their $3 billion a year antihistamine loratadine (CLARITIN)—will be on pharmacy shelves. An army of sales people will be bribing your doctor with expensive meals, gifts, and vacations to switch your prescription from loratadine to desloratadine. There is no medical reason for you to be switched from loratadine to desloratadine. However, if you use desloratadine in the short term before generic loratadine is available you will save money. If you use desloratadine after generic loratadine is marketed you will be ripped-off.
March 2002
Astrongly worded letter from the Health Research Group, dated January 31, 2002, admonished Department of Health and Human Services secretary Tommy Thompson that his “… Department has been grossly negligent in protecting Americans from what is clearly the most dangerous drug that masquerades as a food supplement, Ephedra. At least 10 products made by nine dietary supplement producers are now being sold on the Internet—products that illegally contain dangerous synthetic derivatives of ephedra.
March 2002
Australian drug regulatory authorities have received 171 reports of suspected adverse reactions with the pain drugs tramadol (ULTRAM) or tramadol in combination with acetaminophen (ULTRACET) since Ultram began being marketed in Australia in late 1998. In six of these reports, a very serious adverse reaction known as the serotonin syndrome was listed as the adverse reaction.
March 2002
Cefditoren (SPECTRACEF) was approved for sale by the Food and Drug Administration (FDA) in November 2001 making it the 23rd member of the cephalosporin family of antibiotics (semisynthetic relations of penicillin) and the 11th member of the sub-group known as third generation cephalosporins. The drug has been available in Japan since 1994.
February 2002
“Inappropriate medication use is a major patient safety concern, especially for the elderly population.” This is the first sentence of a study published in the December 12, 2001 issue of the Journal of the American Medical Association. The majority of the 33 drugs in this study have been on the market for years........
February 2002
The Food and Drug Administration (FDA) informed pharmaceutical giant Bristol-Myers Squibb Co. on December 10, 2001 that it must add a black box warning to the professional product label, or “package insert,” for the antidepressant nefazodone (SERZONE), informing doctors and pharmacists that life-threatening liver damage can occur with this drug.
February 2002
Medical officers from the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research, along with a physician from the Duke University Medical Center, have reported a possible link between the use of the new antipsychotic drugs clozapine (CLOZARIL) and olanzapine (ZYPREXA) in adolescents and elevations in blood sugar levels (hyperglycemia) in 20 of these children. The report was published as a letter to the editor in the November 28, 2001 issue of the Journal of the American Medical Association.
February 2002
In the August 2000 issue of Worst Pills, Best Pills News we wrote about reports of dispensing errors involving the drugs lamotrigine (LAMICTAL) and terbinafine (LAMISIL). Lamotrigine is approved by the Food and Drug Administration (FDA) for certain types of seizure disorders and terbinafine for the treatment of toenail and fingernail fungal infections.
February 2002
Researchers from the United Kingdom reported in the October 6, 2001 issue of the British Medical Journal that published medical evidence does not support the use of progesterone in the treatment of premenstrual syndrome (PMS) and that it is unlikely that progestogens are effective in this disorder.
February 2002
On January 9, 2002, Canadian regulatory authorities announced the initiation of a voluntary recall of certain products containing the drug supplement Ephedra and one of its pure chemical constituents, ephedrine. Ephedra and ephedrine are mostly found in dietary supplements promoted for weight loss and energy enhancement.
February 2002
Forty-three percent of those people without prescription drug coverage who are of minority ethnicity, have annual incomes of less than $10,000 and have out-of-pocket prescription drug costs of more than $100 per month reported restricting their use of prescribed medicines.
January 2002
Editor’s Note: We are reprinting our first review of zanamivir (RELENZA) that appeared in the November 1999 issue of Worst Pills, Best Pills News. Over the past two years no credible evidence has been published that would alter our view that this drug lacks meaningful therapeutic value in the treatment of influenza.
January 2002
According to a story from Reuters Health News on November 20, 2001, German authorities are considering a ban on the sale of products containing more than tiny amounts of the herb Kava-Kava after reports of 24 cases of liver damage linked to the “drug” in Germany. We verified this report with colleagues who provided us with additional references linking Kava-Kava to liver damage.
January 2002
LIPOKINETIX is a concoction of five drugs of doubtful or no therapeutic value in reducing the morbidity and mortality associated with obesity and lack of exercise: 1) nor-ephedrine (also known as phenylpropanolamine or PPA); 2) caffeine; 3) yohimbine; 4) diiodothyronine; and 5) sodium usniate. Each of the drugs is discussed below.
December 2001
A study published in the October 3, 2001, Journal of the American Medical Association reveals the extent of inappropriate prescribing by physicians and the equally inappropriate dispensing by pharmacists of cisapride (PROPULSID), a dangerous nighttime heartburn drug that was removed from the market in March 2000 because of fatal heart rhythm disturbances (see the March 2000 issue of Worst Pills, Best Pills News). Before using a new prescription drug, ask your pharmacist for the drug’s professional product labeling or “package insert.” This is not the same as the automatically-dispensed, information-deficient sheet you usually get.
December 2001
Leflunomide (ARAVA) was approved by the Food and Drug Administration (FDA) on September 10, 1998 to reduce signs and symptoms of active rheumatoid arthritis in adults and to retard structural damage as evidenced by X-ray erosion and joint space narrowing. The drug is sold by Aventis Pharmaceuticals Inc. If you are now taking leflunomide you should discuss with your doctor the European recommendations for liver testing and strongly consider switching to a less dangerous drug.
December 2001
Physicians at Texas Tech University’s Health Sciences Center in Lubbock reported, in the August issue of the journal Pediatrics, the case of a five-year-old boy who received a massive overdose of the high blood pressure lowering drug clonidine (CATAPRES) that was being used to treat Attention Deficit/Hyperactivity Disorder (ADHD). Thankfully, he survived.
December 2001
Two new warnings about increased risk of tuberculosis and heart failure were issued for the arthritis drug infliximab (REMICADE) on October 23, 2001. Infliximab is approved by the Food and Drug Administration (FDA) for use in combination with methotrexate (RHEUMATREX), also an arthritis drug, for treating moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to methotrexate alone.
December 2001
The Food and Drug Administration (FDA) announced a “new” program on November 1, 2001 to prevent pregnancies and eliminate fetal exposure in women taking the acne drug isotretinoin (ACCUTANE) produced by Roche Laboratories of Nutley, New Jersey. The stated goals of the program are that: 1) no woman should begin isotretinoin treatment if she is pregnant; and 2) no pregnancies should occur while a woman is on the drug. You or your children should only use isotretinoin in the case of severe recalcitrant nodular acne after other safer acne treatments have been tried and failed.
December 2001
Consumers can play an important public health role by reporting to the Food and Drug Administration (FDA) any adverse experience with drugs and medical devices, including dietary and herbal supplements. This can be done through MedWatch, the FDA’s medical products reporting program. Article included an adverese reaction reporting form.
November 2001
The Food and Drug Administration (FDA) approved esomeprazole (NEXIUM) on February 20, 2001 as the fifth member of the “proton pump inhibitor,” or PPI, family of drugs. These drugs work by blocking the final step in the secretion of stomach acid for the treatment of various forms of ulcer and gastroesophageal reflux disease (GERD) often manifested as nighttime heartburn. If you are currently taking omeprazole and your symptoms are being adequately controlled, there is no medical reason for you to switch to esomeprazole. Keep an eye out for the release of generic omeprazole, it may save you from 40 to 60 percent at the pharmacy.
November 2001
With each new day come new reports of exposures, possible exposures and what turn out to be fake exposures to anthrax. Originally coming from Florida, reports are now emanating from other states including New York, Nevada and the District of Columbia.
November 2001
The Food and Drug Administration (FDA) on September 17, 2001 made public a Warning Letter it had issued to Merck & Co. about a false and misleading promotional campaign that the pharmaceutical giant had been conducting on behalf of its blockbuster arthritis drug rofecoxib (VIOXX).The FDA said, "Specifically, your promotional campaign discounts the fact that in the VIGOR study, patients on Vioxx were observed to have a four to five fold increase in myocardial infarctions (MIs) compared to patients on the comparator nonsteroidal anti-inflammatory drug (NSAID), Naprosyn (naproxen)."
November 2001
Health care professionals were notified on September 26, 2001 about an eye disorder in some patients taking the seizure drug topiramate (TOPAMAX). This condition is characterized by acute myopia (nearsightedness) and secondary-angle closure glaucoma.
November 2001
Just in case the bilking of hundreds of cancer patients wasn't enough to induce doctors to prescribe Lupron, the company also offered a doctor $65,000 in an "educational grant" if he would reverse his decision to recommend only Zoladex at his HMO. And it feted doctors with junkets to expensive golf and ski resorts and by picking up cocktail party bar tabs.
October 2001
This Is a Dangerous Substance and Should Be Taken off the Market.
September 2001
Recently, outside the Public Citizen offices in Dupont Circle, a fluorescent yellow flyer appeared heralding the arrival of an "Immunity Breakthrough!! Biochoice". This "clinically proven" product was said to be "effective against viruses and bacteria" and "directed against microorganisms of human concern.
April 2001
Once again, U.S. researchers are proposing a study in developing countries in which poor people would receive placebos instead of proven, lifesaving therapies. And this time, the U.S. government, in the form of the Food and Drug Administration (FDA), is playing a leading role.
March 2001
The Food and Drug Administration (FDA) on January 25, 2001, issued an urgent recall of 38 injectable drugs marketed by Phyne Pharmaceuticals of Scottsdale, Arizona. Another company, AMRAM Incorporated, of Rathdrum, Idaho, manufactured these products for Phyne, which was AMRAM’s sole customer.
March 2001
In the January 2001 issue of Worst Pills, Best Pills News we recommended that the new Alzheimer’s disease drug rivastigmine (EXELON), the third such drug on the market, should not be used for at least five years. This would be April 2005.
March 2001
An excellent Belgian study appearing in the January 27, 2001 issue of the highly respected British medical journal The Lancet found that glucosamine (XICIL) was more effective than an inactive dummy pill, or placebo, in relieving the symptoms of osteoarthritis. Glucosamine may also have a positive effect in modifying the course of osteoarthritis compared to no treatment at all. But until the results of a large NIH study are finished, avoid using this supplement.
March 2001
You may be able to prevent on your own or treat your high blood pressure, in consultation with your doctor, by instituting the type of dietary lifestyle changes tested in these two clinical trials.
March 2001
The editors of the highly respected Medical Letter on Drugs and Therapeutics, for doctors and pharmacists, reviewed evidence from controlled clinical trials of anti-seizure drugs for psychiatric disorders in the December 11, 2000 issue. Controlled clinical trials are the “gold standard” for testing the effectiveness of drugs.
March 2001
In light of the above discussion, we continue to advise the patient-protective five-year-rule for these drugs, as we do for all other new drugs that are not breakthroughs. Do Not Use.
January 2001
Glaxo Wellcome, the producer of the dangerous irritable bowel syndrome (IBS) drug alosetron (LOTRONEX), announced on November 28, 2000 that, at the request of the Food and Drug Administration (FDA), the drug would be withdrawn from the market. Alosetron caused numerous cases of ischemic colitis, a decrease of blood flow to the GI tract that can lead to inflammation, bleeding, and perforation of the GI tract resulting in infection of the abdominal cavity.
January 2001
The Food and Drug Administration (FDA) approved a third drug, rivastigmine (EXELON), in April 2000 for the treatment of mild to moderate dementia of the Alzheimer’s type. Rivastigmine was preceded by tacrine (COGNEX) approved in September 1993 and donepezil (ARICEPT) cleared by the FDA in November 1996.
January 2001
“You, or at least many of your colleagues, have failed to provide optimal care to your patients with high blood pressure.” This stinging critique of physician prescribing practices starts off an editorial in the Journal of General Internal Medicine for October 2000 that commented on a Harvard Medical School study of high blood pressure in older adults that appeared in the same issue.
January 2001
The Food and Drug Administration’s (FDA) Office of Postmarketing Drug Risk Assessment (OPDRA) recommended in a memorandum dated May 1, 2000, that liver failure be included as an adverse reaction in the professional product labeling, or “package insert” for the family of cholesterol-lowering drugs known as “statins.” The statins now being marketed in the U.S. are .....
Login
Subscribe